日本臨牀　78/増刊5　肉腫

出版社： 日本臨牀社
発行日： 2020-10-31
分野： 臨床医学：一般  >  雑誌
ISSN： 00471852
雑誌名：
特集： 肉腫―基礎・臨床の最新知見
電子書籍版： 2020-10-31 （初版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

22,000 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

22,000 円(税込)

購入する

目次

  • 特集　肉腫
    　　　―基礎・臨床の最新知見

    I．総　論
    　1．歴史と展望
    　　（1）肉腫治療の歴史と展望
    　　（2）肉腫基礎研究の歴史と展望
    　　（3）保険診療からみた肉腫
    　　（4）希少がん対策の中での肉腫診療
    　2．肉腫の疫学
    　　（1）肉腫の疫学
    　　（2）全国骨・軟部腫瘍登録
    　　（3）肉腫の危険因子
    　　（4）遺伝性・家族性肉腫
    　　（5）肉腫の患者会・advocate
    　3．肉腫の発生メカニズムと基礎研究
    　　（1）染色体転座を有する肉腫
    　　（2）染色体転座を有さない肉腫
    　　（3）肉腫の研究最前線
    　　　　1）骨軟部腫瘍ゲノムコンソーシアム
    　　　　2）iPS細胞技術を用いた肉腫研究
    　　　　3）肉腫のプロテオゲノミクス研究
    　　　　4）エピジェネティクス
    　　　　5）肉腫に対する抗腫瘍薬開発の基礎的側面
    　　　　6）SWI/SNF複合体
    　　　　7）microRNA
    　　　 ８)　免疫療法
    　　　 ９)　患者由来がんモデル：肉腫研究の視点からの考察
    　　　10）脂肪肉腫
    　　　11）粘液線維肉腫
    　4．肉腫のゲノム医療
    　　（1）わが国のがんゲノム医療と肉腫
    　　（2）肉腫のがんクリニカルシークエンス
    　5．肉腫の病理診断
    　　（1）WHO診断基準（2020）
    　　（2）骨の肉腫
    　　（3）軟部肉腫
    　　（4）診断に有用な免疫染色・FISH
    　6．肉腫の画像診断
    　　（1）MRI
    　　（2）PET-CT
    　　（3）IVR
    　7．肉腫の病期とアウトカムの評価
    　　（1）TNM分類（AJCC第8版）
    　　（2）Surgical staging system
    　　（3）ガイドライン
    　　（4）悪性骨軟部腫瘍のノモグラム開発における最近の動向
    　　（5）機能評価（MSTS）
    　　（6）ADL評価（TESS）
    　　（7）QOL評価（SF36, COMMON）
    　8．肉腫の年齢的特徴
    　　（1）小児の肉腫
    　　（2）AYA世代の肉腫
    　　（3）高齢者の肉腫
    　9．肉腫の臨床試験
    　　（1）JCOG0304
    　　（2）骨肉腫に対する補助化学療法についての臨床試験
    　　（3）JCOG1306
    　10．肉腫の外科的治療
    　　（1）切除
    　　　　1）骨軟部肉腫の切除縁
    　　　　2）浸潤型軟部肉腫
    　　　　3）In situ preparation
    　　　　4）ナビゲーションサージェリー
    　　（2）骨の再建
    　　　　1）腫瘍用人工関節―下肢―　
    　　　　2）腫瘍用人工関節―上肢―
    　　　　3）自家処理骨―パスツール処理骨―
    　　　　4）自家処理骨―凍結処理骨―
    　　　　5） 遊離血管柄付き骨移植の適応と評価法
    　　　　6）仮骨延長法を用いた骨再建
    　　　　7）回転形成術
    　　　　8）腫瘍脊椎骨全摘術
    　　（3）軟部組織の再建
    　　　　1）局所皮弁　　
    　　　　2）Pedicle flapによる軟部肉腫広範切除後の皮膚軟部組織再建
    　　　　3）遊離皮弁
    　　　　4）四肢の軟部組織再建
    　　　　5）体幹（胸壁・腹壁）の軟部組織再建
    　　　　6）血行再建
    　　（4）その他
    　　　　1）神経移植・再建
    　　　　2）術後リハビリテーション
    　11．肉腫の薬物療法
    　　（1）骨の肉腫
    　　　　1）周術期化学療法
    　　　　2）進行・再発例に対する薬物療法：概論
    　　　　3）開発中の薬物療法
    　　（2）軟部肉腫
    　　　　1）周術期化学療法
    　　　　2）進行・再発例に対する薬物療法：概論
    　　　　3）パゾパニブ
    　　　　4）トラベクテジン
    　　　　5）軟部肉腫に対するエリブリン
    　　　　6）オララツマブ
    　　　　7）NY-ESO-1抗原に対する特異的リンパ球輸注療法
    　　　　8）開発中の薬物療法
    　　（3）その他
    　　　　1）MASTER KEY Project: a platform study for rare cancers
    　　　　2）Cardio-oncology ：肉腫医療の進歩と腫瘍循環器学
    　12．肉腫の放射線療法
    　　（1）肉腫の放射線療法：概論
    　　（2）粒子線治療
    　　　　1）重粒子線治療
    　　　　2）肉腫に対する陽子線治療
    II．各　論
    　1．肉腫の部位別治療と成績
    　　（1）骨の肉腫
    　　　　1） 上　肢
    　　　　2） 下　肢
    　　　　3）体幹、頭蓋、顔面骨
    　　　　4）脊　椎
    　　　　5）骨盤悪性骨腫瘍の治療成績
    　　（2）軟部肉腫
    　　　　1）上肢に発生した軟部肉腫に対する治療とその成績
    　　　　2）下　肢
    　　　　3）体幹の軟部肉腫
    　　　　4）後腹膜
    　　　　5）頭頸部
    　　　　6）内　臓
    　　　　7）子宮肉腫の薬物療法と最新の開発動向
    　　　　8）皮　膚
    　2．肉腫の組織型別治療と成績
    　　（1）骨肉腫
    　　（2）ユーイング肉腫
    　　（3）軟骨肉腫
    　　（4）脊索腫
    　　（5）その他の骨の肉腫
    　　（6）脂肪肉腫
    　　（7）粘液線維肉腫の臨床病理学的解析に基づく治療成績と今後の展望
    　　（8）平滑筋肉腫
    　　（9）滑膜肉腫
    　　(10) 悪性末梢神経鞘腫瘍
    　　(11) 血管肉腫
    　　(12) 横紋筋肉腫
    　　(13) 類上皮肉腫
    　　(14) デスモイド型線維腫症
    　　(15) その他の軟部肉腫

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

I 総論

P.9 掲載の参考文献
1) Mankin HJ : The history of musculoskeletal tumors. Orthop J Harvard Med School 11 : 129-135, 2010.
 
2) Suzuki T : Paleopathological study on a case of osteosarcoma. Am J Phys Anthropol 74 : 309-318, 1987.
 
3) 図録日本医事文化史料集成 [第一巻] (日本医史学会編), p129-130, 三一書房, 1978.
 
4) 本間棗軒 : 瘍科秘録 [第十巻], 玉巌堂 (早稲田大学図書館所蔵), 1847.
 
5) Huvos AG, Bone Tumors : Diagnosis, Treatment and Prognosis, 2nd ed, p431, WB Saunders, Philadelphia, 1991.
 
6) Coley WB : The treatment of malignant tumors by repeated inoculations of erysipelas : with a report of ten original cases. Am J Med Sci 105 : 485-511, 1893.
 
7) Codman EA : The registry of cases of bone sarcoma. Surg Gynecol Obstet 34 : 335-343, 1922.
 
8) Linberg BE : Interscapulo-thoracic resection for malignant tumours of the shoulder joint region. J Bone Joint Surg 10 : 344-349, 1928.
 
9) Moore AT, Bohlman HR : Metal hip joint. A case report. J Bone Joint Surg Am 25 : 688-692, 1943.
 
10) Van Nes CP : Rotation-plasty for congenital defects of the femur. J Bone Joint Surg Br 32 : 12-16, 1950.
 
11) Windhager R, et al : Resection-replantation for primary malignant tumours of the arm. An alternative to fore-quarter amputation. J Bone Joint Surg Br 77 : 176-184, 1995.
PubMed
12) Meyers PA, et al : Intensification of preoperative chemotherapy for osteogenic sarcoma : results of the Memorial Sloan-Kettering (T12) protocol. J Clin Oncol 16 : 2452-2458, 1998.
PubMed
13) Iwamoto Y, et al : Multiinstitutional phase II study of neoadjuvant chemotherapy for osteosarcoma (NECO study) in Japan : NECO-93J and NECO-95J. J Orthop Sci 14 : 397-404, 2009.
PubMed
14) Enneking WF, et al : A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop Relat Res (153) : 106-120, 1980.
PubMed
15) Kawaguchi N, et al : The concept of curative margin in surgery for bone and soft tissue sarcoma. Clin Orthop Relat Res (419) : 165-172, 2004.
 
P.15 掲載の参考文献
1) Jin Y, et al : Absence of oncogenic mutations of RAS family genes in soft tissue sarcomas of 100 Japanese patients. Anticancer Res 30 : 245-251, 2010.
PubMed
2) Toguchida J, Nakayama T : Molecular genetics of sarcomas : applications to diagnoses and therapy. Cancer Sci 100 : 1573-1580, 2009.
PubMed
3) Gorthi A, et al : EWS-FLI1 increases transcription to cause R-loops and block BRCA1 repair in Ewing sarcoma. Nature 555 : 387-391, 2018.
 
4) Ye Y, et al : TRE17/USP6 oncogene translocated in aneurysmal bone cyst induces matrix metallo-proteinase production via activation of NF-kappaB. Oncogene 29 : 3619-3629, 2010.
 
5) Giraudet AL, et al : A first-in-human study investigating biodistribution, safety and recommended dose of a new radiolabeled MAb targeting FZD10 in metastatic synovial sarcoma patients. BMC Cancer 18 : 646, 2018.
PubMed
6) Johnson JE, Broccoli D : Telomere maintenance in sarcomas. Curr Opin Oncol 19 : 377-382, 2007.
 
7) Karow JK, et al : RecQ family helicases : roles in cancer and aging. Curr Opin Genet Dev 10 : 32-38,2000.
PubMed
8) Solomon DA, et al : Mutational inactivation of STAG2 causes aneuploidy in human cancer. Science 333 : 1039-1043, 2011.
PubMed
9) Yan H, et al : IDH1 and IDH2 mutations in gliomas. N Engl J Med 360 : 765-773, 2009.
PubMed
P.22 掲載の参考文献
1) 尾形裕也 : 我が国の社会保障政策と国民皆保険制度. THE LUNG perspectives 25 : 17-20, 2017.
 
2) 日医総研ワーキングペーパー 医療関連データの国際比較 2018. [www.jmari.med.or.jp/research/research/wr_655.html] (2019年11月閲覧)
 
3) 川渕孝一 : 医師の技術料の国際比較. 医学のあゆみ 248 : 163-169, 2014.
Medical*Online
4) (一般社団法人外科系学会社会保険委員会連合編) 外保連試案 2020 : 手術・処置・生体検査・麻酔・内視鏡試案, 医学通信社, 2019.
 
5) 土谷一晃 : 外科系学会社会保険委員会連合について. MB Orthopaedics 32 : 35-41, 2019.
Medical*Online
P.27 掲載の参考文献
1) 厚生労働省 : がん対策推進基本計画 (第2期, 平成24年6月), 2012. [https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000183313.html] (2019年8月閲覧)
 
2) 厚生労働省 : 希少がん医療・支援のあり方に関する検討会報告書, 2015. [https://www.mhlw.go.jp/stf/shingi2/0000095430.html] (2019年8月閲覧)
 
3) 国立がん研究センターがん対策情報センターがん臨床情報部 : 希少がん対策ワークショップ報告書, 2014. [https://www.ncc.go.jp/jp/cis/divisions/health_s/health_s/050/06health_s_work.pdf] (2019年8月閲覧)
 
4) RARECAREnet : Cancer List, 2015. [http://www.rarecarenet.eu/rarecarenet/index.php/cancerlist] (2019年8月閲覧)
 
5) 内閣府 : がん対策に関する世論調査, 2014. [https://survey.gov-online.go.jp/h28/h28-gantaisaku/index.html] (2019年8月閲覧)
 
6) 国立がん研究センターがん対策情報センター : がん情報サービス・希少がん情報公開専門施設の要件. [https://hospdb.ganjoho.jp/kyotendb.nsf/xpAboutRareCancer.xsp?documentId=4CB715552B6AA5414925831500044371&action=openDocument] (2019年9月閲覧)
 
P.34 掲載の参考文献
1) SEER Data & Software, National Cancer Institute. [https://seer.cancer.gov/data-software/] (2019年6月閲覧)
 
2) RARECARE, Surveillance of Rare Cancers in Europe. [http://www.rarecare.eu/] (2019年6月閲覧)
 
3) Stiller CA, et al : Descriptive epidemiology of sarcomas in Europe : report from the RARECARE project. Eur J Cancer 49 : 684-695, 2013.
PubMed
4) 全国骨腫瘍登録一覧表 [平成27年度] (日本整形外科学会骨軟部腫瘍委員会編), 国立がんセンター, 2015.
 
5) 全国軟部腫瘍登録一覧表 [平成27年度] (日本整形外科学会骨軟部腫瘍委員会編), 国立がんセンター, 2015.
 
6) Ogura K, et al : Statistics of bone sarcoma in Japan : Report from the Bone and Soft Tissue Tumor Registry in Japan. J Orthop Sci 22 : 133-143, 2017.
PubMed
7) Mirabello L, et al : Osteosarcoma incidence and survival rates from 1973 to 2004 : data from the Surveillance, Epidemiology, and End Results Program. Cancer 115 : 1531-1543, 2009.
PubMed
8) Damron TA, et al : Osteosarcoma, chondrosarcoma, and Ewing's sarcoma : National Cancer Data Base Report. Clin Orthop Relat Res 459 : 40-47, 2007.
PubMed
9) Toro JR, et al : Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978-2001 : An analysis of 26. 758 cases. Int J Cancer 119 : 2922-2930, 2006.
PubMed
10) SEER Cancer Statistics Review 1975-2015. National Cancer Institute. [https://seer.cancer.gov/csr/1975_2015/results_merged/sect_34_soft_tissue_sarcomas.pdf] (2019年6月閲覧)
 
11) Cancer Stat Facts : Soft Tissue including Heart Cancer, National Cancer Institute. [https://seer.cancer.gov/statfacts/html/soft.html] (2019年6月閲覧)
 
12) Corey RM, et al : Epidemiology and survivorship of soft tissue sarcomas in adults : a national cancer database report. Cancer Med 3 : 1404-1415, 2014.
PubMed
13) Kalra S, et al : Radiation-induced sarcomas of bone : factors that affect outcome. J Bone Joint Surg Br 89 : 808-813, 2007.
PubMed
14) Unni KK, Inwards CY : Chapter 11 : Osteosarcoma. In : Dahlin's Bone Tumors : General Aspects and Data on 10,165 Cases, 6th ed, p139-141, Wolters Kluwer/Lippincott Williams & Wilkins, Philadelphia, 2010.
 
15) Sonne-Holm E, et al : Multiple cartilaginous exostoses and development of chondrosarcomas-a systematic review. Dan Med J 61 : A4895, 2014.
PubMed
16) Herget GW, et al : Insights into Enchondroma, Enchondromatosis and the risk of secondary Chondrosarcoma. Review of the literature with an emphasis on the clinical behaviour, radiology, malignant transformation and the follow up. Neoplasma 61 : 365-378, 2014.
PubMed
17) James AW, et al : Malignant Peripheral Nerve Sheath Tumor. Surg Oncol Clin N Am 25 : 789-802, 2016.
PubMed
P.42 掲載の参考文献
1) 国立がん研究センター : 希少がんにおける専門施設のリストと情報公開を開始, 2017. [https://www.ncc.go.jp/jp/information/pr_release/2017/1225/index.html]
 
2) Cancer Stat Facts : Bone and Joint Cancer. [https://seer.cancer.gov/statfacts/html/bones.html]
 
3) Cancer Stat Facts : Soft Tissue including Heart Cancer. [https://seer.cancer.gov/statfacts/html/soft.html]
 
4) 全国骨腫瘍登録一覧表 2015年 (平成27年).
 
5) 全国軟部腫瘍登録一覧表 2015年 (平成27年).
 
6) Ogura K, et al : Statistics of bone sarcoma in Japan : Report from the Bone and Soft Tissue Tumor Registry in Japan. J Orthop Sci 22 : 133-143, 2017.
PubMed
7) Ogura K, et al : Statistics of soft-tissue sarcoma in Japan : Report from the Bone and Soft Tissue Tumor Registry in Japan. J Orthop Sci 22 : 755-764, 2017.
PubMed
8) Nagano A, et al : Primary bone sarcomas in patients over 40 years of age : A retrospective study using data from the Bone Tumor Registry of Japan. J Orthop Sci 22 : 749-754, 2017.
PubMed
9) Nakamura T, et al : Analysis of the patients with soft tissue sarcoma who received additional excision after unplanned excision : report from the Bone and Soft Tissue Tumor Registry in Japan. Jpn J Clin Oncol 47 : 1055-1059, 2017.
 
10) Nishida Y, et al : Clinical features and treatment outcome of desmoid-type fibromatosis : based on a bone and soft tissue tumor registry in Japan. Int J Clin Oncol 24 : 1498-1505, 2019.
PubMed
11) Sekimizu M, et al : Development of nomograms for prognostication of patients with primary soft tissue sarcomas of the trunk and extremity : report from the Bone and Soft Tissue Tumor Registry in Japan. BMC Cancer 19 : 657, 2019.
 
12) Mirabello L, et al : International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons. Int J Cancer 125 : 229-234, 2009.
PubMed
13) Ray-Coquard I, et al : Sarcoma : concordance between initial diagnosis and centralized expert review in a population-based study within three European regions. Ann Oncol 23 : 2442-2449, 2012.
 
P.46 掲載の参考文献
1) Gelberg KH, et al : Growth and development and other risk factors for osteosarcoma in children and young adults. Int J Epidemiol 26 : 272-278, 1997.
 
2) Samartzis D, et al : Ionizing radiation exposure and the development of soft-tissue sarcomas in atomic-bomb survivors. J Bone Joint Surg Am 95 : 222-229, 2013.
PubMed
3) Samartzis D, et al : Exposure to ionizing radiation and development of bone sarcoma : new insights based on atomic-bomb survivors of Hiroshima and Nagasaki. J Bone Joint Surg Am 93 : 1008-1015, 2011.
 
4) Brady MS, et al : Radiation-associated sarcoma of bone and soft tissue. Arch Surg 127 : 1379-1385, 1992.
PubMed
5) Rosenberg AE, et al : Conventional osteosarcoma. In : WHO Classification of Tomours of Soft Tissue and Bone, p282-288, IARC Press, Lyon, 2013.
 
6) Penel N, et al : Frequency of certain established risk factors in soft tissue sarcomas in adults : a prospective descriptive study of 658 cases. Sarcoma 2008 : 459386, 2008.
PubMed
7) Katano H, et al : Identification of antigenic proteins encoded by human herpesvirus 8 and seroprevalence in the general population and among patients with and without Kaposi's sarcoma. J Virol 74 : 3478-3485, 2000.
PubMed
8) Valery PC, et al : Hernias and Ewing's sarcoma family of tumours : a pooled analysis and metaanalysis. Lancet Oncol 6 : 485-490, 2005.
PubMed
9) Waxweiler RJ, et al : Neoplastic risk among workers exposed to vinyl chloride. Ann N Y Acad Sci 271 : 40-48, 1976.
PubMed
10) Hampras SS, et al : Socioeconomic factors and the risk for sarcoma. Eur J Cancer Prev 23 : 560-565, 2014.
PubMed
11) Serraino D, et al : Non-occupational risk factors for adult soft-tissue sarcoma in northern Italy. Cancer Causes Control 2 : 157-164, 1991.
PubMed
12) Matsukuma S, et al : Paget sarcoma of the cervical vertebrae : an autopsy case report and review of the literature. Pathol Int 45 : 885-889, 1995.
PubMed
13) Gonzalez KD, et al : High frequency of de novo mutations in Li-Fraumeni syndrome. J Med Genet 46 : 689-693, 2009.
 
14) Wong FL, et al : Cancer incidence after retinoblastoma. Radiation dose and sarcoma risk. JAMA 278 : 1262-1267, 1997.
PubMed
15) McCaughan JA, et al : Further evidence of the increased risk for malignant peripheral nerve sheath tumour from a Scottish cohort of patients with neurofibromatosis type 1. J Med Genet 44 : 463-466, 2007.
PubMed
16) Sonne-Holm E, et al : Multiple cartilaginous exostoses and development of chondrosarcomas-a systematic review. Dan Med J 61 : A4895, 2014.
PubMed
17) Hicks MJ, et al : Clinicopathologic features of osteosarcoma in patients with Rothmund-Thomson syndrome. J Clin Oncol 25 : 370-375, 2007.
PubMed
18) German J : Bloom's syndrome. XX. The first 100 cancers. Cancer Genet Cytogenet 93 : 100-106, 1997.
PubMed
19) Goto M, et al : Excess of rare cancers in Werner syndrome (adult progeria). Cancer Epidemiol Biomarkers Prev 5 : 239-246, 1996.
PubMed
P.50 掲載の参考文献
1) Li FP, et al : A cancer family syndrome in twenty-four kindreds. Cancer Res 48 : 5358-5362, 1988.
PubMed
2) Malkin D, et al : Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250 : 1233-1238, 1990.
 
3) Gonzalez KD, et al : Beyond Li Fraumeni Syndrome : clinical characteristics of families with p53 germline mutations. J Clin Oncol 27 : 1250-1256, 2009.
PubMed
4) Ognjanovic S, et al : Sarcomas in TP53 germline mutation carriers : a review of the IARC TP53 database. Cancer 118 : 1387-1396, 2012.
PubMed
5) Chompret A, et al : Sensitivity and predictive value of criteria for p53 germline mutation screening. J Med Genet 38 : 43-47, 2001.
PubMed
6) Toguchida J, et al : Prevalence and spectrum of germline mutations of the p53 gene among patients with sarcoma. N Engl J Med 326 : 1301-1308, 1992.
PubMed
7) Villani A, et al : Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome : 11 year follow-up of a prospective observational study. Lancet Oncol 17 : 1295-1305, 2016.
PubMed
8) Weinberg RA : The retinoblastoma tumor provides a solution to the genetic puzzle of tumor suppressor genes. In : The Biology of Cancer, p235-238, Garland Science, Taylor & Francis Group, New York, 2014.
 
9) Dimaras H, et al : Retinoblastoma. Nat Rev Dis Primers 1 : 15021, 2015.
PubMed
10) Kleinerman RA, et al : Risk of new cancers after radiotherapy in long-term survivors of retinoblastoma : an extended follow-up. J Clin Oncol 23 : 2272-2279, 2005.
PubMed
11) Nemes K, et al : Rhabdoid Tumor Predisposition Syndrome. GeneReviews(R) [Internet], University of Washington, Seattle, 2017.
 
12) Sredni ST, Tomita T : Rhabdoid tumor predisposition syndrome. Pediatr Dev Pathol 18 : 49-58, 2015.
PubMed
13) Lammert M, et al : Prevalence of neurofibromatosis 1 in German children at elementary school enrollment. Arch Dermatol 141 : 71-74, 2005.
PubMed
14) Oshima J, et al : Werner syndrome : Clinical features, pathogenesis and potential therapeutic interventions. Ageing Res Rev 33 : 105-114, 2017.
PubMed
15) Unni KK, Inwards CY : Osteochondroma. In : Dahlin's Bone Tumors 6th ed, p9-21, Lippincott Williams & Wilkins, Philadelphia, 2010.
 
P.57 掲載の参考文献
1) Sarcoma Alliance. [https://sarcomaalliance.org] (2019年12月1月閲覧).
 
2) Sarcoma UK. [https://sarcoma.org.uk] (2019年12月閲覧).
 
3) Sarcoma Patients EuroNet. [https://www.sarcoma-patients.eu/en/] (2019年12月閲覧).
 
P.67 掲載の参考文献
1) Kawai A, et al : SYT-SSX gene fusion as a determinant of morphology and prognosis in synovial sarcoma. N Engl J Med 338 : 153-160, 1998.
PubMed
2) Nielsen TO, et al : Synovial sarcoma : recent discoveries as a roadmap to new avenues for therapy. Cancer Discov 5 : 124-134, 2015.
PubMed
3) Kimura T, et al : Identification and analysis of CXCR4-positive synovial sarcoma-initiating cells. Oncogene 35 : 3932-3943, 2016.
PubMed
4) Minami Y, et al : SS18-SSX-regulated miR-17 promotes tumor growth of synovial sarcoma by inhibiting p21WAF1/CIP1. Cancer Sci 105 : 1152-1159, 2014.
PubMed
5) Kondo T, et al : Current status of proteomics in Ewing's sarcoma. Proteomics Clin Appl 13 : e1700130, 2019.
PubMed
6) Arvand A, et al : Biology of EWS/ETS fusions in Ewing's family tumors. Oncogene 20 : 5747-5754, 2001.
 
7) Grunewald TG, et al : Chimeric EWSR1-FLI1 regulates the Ewing sarcoma susceptibility gene EGR2 via a GGAA microsatellite. Nat Genet 47 : 1073-1078, 2015.
 
8) Loganathan SN, et al : BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma. Oncotarget 7 : 43504-43517, 2016.
PubMed
9) Ferreira EN, et al : A genomic case study of desmoplastic small round cell tumor : comprehensive analysis reveals insights into potential therapeutic targets and development of a monitoring tool for a rare and aggressive disease. Hum Genomics 10 : 36, 2016.
PubMed
10) Hocar O, et al : Clear cell sarcoma (malignant melanoma) of soft parts : a clinicopathologic study of 52 cases. Dermatol Res Pract 2012 : 984096, 2012.
PubMed
11) Antonescu CR, et al : EWSR1-POU5F1 fusion in soft tissue myoepithelial tumors. A molecular analysis of sixty-six cases, including soft tissue, bone, and visceral lesions, showing common involvement of the EWSR1 gene. Genes Chromosomes Cancer 49 : 1114-1124, 2010.
PubMed
12) Brenca M, et al : NR4A3 fusion proteins trigger an axon guidance switch that marks the difference between EWSR1 and TAF15 translocated extraskeletal myxoid chondrosarcomas. J Pathol 249 : 90-101, 2019.
PubMed
13) Panagopoulos I, et al : Chromosome aberrations and HEY1-NCOA2 fusion gene in a mesenchymal chondrosarcoma. Oncol Rep 32 : 40-44, 2014.
 
14) Oliveira AM, et al : USP6-induced neoplasms : the biologic spectrum of aneurysmal bone cyst and nodular fasciitis. Hum Pathol 45 : 1-11, 2014.
PubMed
15) Oliveira AM, Chou MM : The TRE17/USP6 oncogene : a riddle wrapped in a mystery inside an enigma. Front Biosci (Schol Ed) 4 : 321-334, 2012.
 
16) Horn L, et al : EML4-ALK : honing in on a new target in non-small-cell lung cancer. J Clin Oncol 27 : 4232-4235, 2009.
 
17) Iwasaki T, et al : Current Update on the Molecular Biology of Cutaneous Sarcoma : Dermatofibrosarcoma Protuberans. Curr Treat Options Oncol 20 : 29, 2019.
PubMed
18) Vogels R, et al : Prognostic significance of NAB2-STAT6 fusion variants and TERT promotor mutations in solitary fibrous tumors/hemangiopericytomas of the CNS : not (yet) clear. Acta Neuropathol 137 : 679-682, 2019.
 
19) Chmielecki J, et al : Whole-exome sequencing identifies a recurrent NAB2-STAT6 fusion in solitary fibrous tumors. Nat Genet 45 : 131-132, 2013.
PubMed
20) Schmitt-Ney M, et al : The PAX3-FOXO1 fusion protein present in rhabdomyosarcoma interferes with normal FOXO activity and the TGF-β pathway. PLoS ONE 10 : e0121474, 2015.
 
21) Bharathy N, et al : The HDAC3-SMARCA4-miR-27a axis promotes expression of the PAX3 : FOXO1 fusion oncogene in rhabdomyosarcoma. Sci Signal 11. pii : eaau7632, 2018.
 
22) Shibuya R, et al : CAMTA1 is a useful immunohistochemical marker for diagnosing epithelioid haemangioendothelioma. Histopathology 67 : 827-835, 2015,
PubMed
23) Panagopoulos I, et al : Fusion of the Genes WWTR1 and FOSB in Pseudomyogenic Hemangioendothelioma. Cancer Genomics Proteomics 16 : 293-298, 2019.
PubMed
24) Tsuda M, et al : TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition. Cancer Res 67 : 919-929, 2007.
PubMed
25) Ishiguro N, et al : ASPL-TFE3 Oncoprotein Regulates Cell Cycle Progression and Induces Cellular Senescence by Up-Regulating p21. Neoplasia 18 : 626-635, 2016.
PubMed
26) Wu CC, et al : Fusion Pathway : Prediction of pathways and therapeutic targets associated with gene fusions in cancer. PLoS Comput Biol 14 : e1006266, 2018.
PubMed
27) Church AJ, et al : Recurrent EML4-NTRK3 fusions in infantile fibrosarcoma and congenital mesoblastic nephroma suggest a revised testing strategy. Mod Pathol 31 : 463-473, 2018.
PubMed
28) Panagopoulos I, et al : Novel CSF1-S100A10 fusion gene and CSF1 transcript identified by RNA sequencing in tenosynovial giant cell tumors. Int J Oncol 44 : 1425-1432, 2014.
PubMed
P.76 掲載の参考文献
1) Anisimov VN, et al : Cancer in rodents : does it tell us about cancer in humans? Nat Rev Cancer 5 : 807-819, 2005.
PubMed
2) Rickel K, et al : Molecular genetics of osteosarcoma. Bone 102 : 69-79, 2017.
PubMed
3) Savage SA, Mirabello L : Using epidemiology and genomics to understand osteosarcoma etiology. Sarcoma 2011 : 548151, 2011.
PubMed
4) Kovac M, et al : Exome sequencing of osteosarcoma reveals mutation signatures reminiscent of BRCA deficiency. Nat Commun 6 : 8940, 2015.
PubMed
5) Perry JA, et al : Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma. Proc Natl Acad Sci USA 111 : E5564-5573, 2014.
PubMed
6) Chen X, et al : Recurrent somatic structural variations contribute to tumorigenesis in pediatric osteosarcoma. Cell Rep 7 : 104-112, 2014.
PubMed
7) Landuzzi L, et al : Genetic prevention of lymphoma in p53 knockout mice allows the early development of p53-related sarcomas. Oncotarget 5 : 11924-11938, 2014.
PubMed
8) Berman SD, et al : Metastatic osteosarcoma induced by inactivation of Rb and p53 in the osteoblast lineage. Proc Natl Acad Sci USA 105 : 11851-11856, 2008.
PubMed
9) Moriarity BS, et al : A Sleeping Beauty forward genetic screen identifies new genes and pathways driving osteosarcoma development and metastasis. Nat Genet 47 : 615-624, 2015.
PubMed
10) Schoenebeck JJ, Ostrander EA : Insights into morphology and disease from the dog genome project. Annu Rev Cell Dev Biol 30 : 535-560, 2014.
 
11) Jacques C, et al : Small animal models for the study of bone sarcoma pathogenesis : characteristics, therapeutic interests and limitations. J Bone Oncol 12 : 7-13, 2018.
 
12) Grobner SN, et al : The landscape of genomic alterations across childhood cancers. Nature 555 : 321-327, 2018.
PubMed
13) Amary MF, et al : IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. J Pathol 224 : 334-343, 2011.
 
14) Lu C, et al : Induction of sarcomas by mutant IDH2. Genes Dev 27 : 1986-1998, 2013.
PubMed
15) de Andrea CE, et al : Cell cycle deregulation and mosaic loss of Ext1 drive peripheral chondrosar-comagenesis in the mouse and reveal an intrinsic cilia deficiency. J Pathol 236 : 210-218, 2015.
 
16) Behjati S, et al : Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone. Nat Genet 45 : 1479-1482, 2013.
PubMed
17) Branstetter DG, et al : Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone. Clin Cancer Res 18 : 4415-4424, 2012.
PubMed
18) Shimizu T, et al : c-MYC overexpression with loss of Ink4a/Arf transforms bone marrow stromal cells into osteosarcoma accompanied by loss of adipogenesis. Oncogene 29 : 5687-5699, 2010.
PubMed
19) Cancer Genome Atlas Research Network. Electronic address : elizabeth.demicco@sinaihealthsystem.ca ; Cancer Genome Atlas Research Network : Comprehensive and Integrated Genomic Characterlzation of Adult Soft Tissue Sarcomas. Cell 171 : 950-965. e28, 2017.
 
20) Hayashi T, et al : Mice-lacking LMP2, immuno-proteasome subunit, as an animal model of spontaneous uterine leiomyosarcoma. Protein Cell 1 : 711-717, 2010.
PubMed
21) Dodd RD, et al : Animal models of soft-tissue sarcoma. Dis Model Mech 3 : 557-566, 2010.
PubMed
22) Kikuchi K, et al : Developmental origins of fusion-negative rhabdomyosarcomas. Curr Top Dev Biol 96 : 33-56, 2011.
PubMed
23) Zanola A, et al : Rhabdomyosarcomas : an overview on the experimental animal models, J Cell Mol Med 16 : 1377-1391, 2012.
PubMed
24) Rubin BP, et al : Evidence for an unanticipated relationship between undifferentiated pleomorphic sarcoma and embryonal rhabdomyosarcoma. Cancer Cell 19 : 177-191, 2011.
 
25) Shimozono N, et al : NUP160-SLC43A3 is a novel recurrent fusion oncogene in angiosarcoma. Cancer Res 75 : 4458-4465, 2015.
PubMed
26) Behjati S, et al : Recurrent PTPRB and PLCG1 mutations in angiosarcoma. Nat Genet 46 : 376-379, 2014.
PubMed
27) Thibodeau BJ, et al : Mutational landscape of radiation-associated angiosarcoma of the breast. Oncotarget 9 : 10042-10053, 2018.
PubMed
28) Hanna JA, et al : Biallelic Dicerl Loss Mediated by aP2-Cre Drives Angiosarcoma. Cancer Res 77 : 6109-6118, 2017.
 
29) Sun S, et al : Constitutive Activation of mTORC1 in Endothelial Cells Leads to the Development and Progression of Lymphangiosarcoma through VEGF Autocrine Signaling. Cancer Cell 28 : 758-772, 2015.
 
30) Mito JK et al : Oncogene-dependent control of miRNA biogenesis and metastatic progression in a model of undifferentiated pleomorphic sarcoma. J Pathol 229 : 132-140, 2013.
 
31) LaFemina J, et al : Oncologic outcomes of sporadic, neurofibromatosis-associated, and radiation-induced malignant peripheral nerve sheath tumors. Ann Surg Oncol 20 : 66-72, 2013.
PubMed
32) Lee W, et al : PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors. Nat Genet 46 : 1227-1232, 2014.
PubMed
33) Sohier P, et al : Confirmation of mutation landscape of NF1-associated malignant peripheral nerve sheath tumors. Genes Chromosomes Cancer 56 : 421-426, 2017.
PubMed
34) Keng VW, et al : PTEN and NF1 inactivation in Schwann cells produces a severe phenotype in the peripheral nervous system that promotes the development and malignant progressionof peripheral nerve sheath tumors. Cancer Res 72 : 3405-3413, 2012.
 
35) Rhodes SD, et al : Cdkn2a (Arf) loss drives NF1-associated atypical neurofibroma and malignant transformation. Hum Mol Genet 28 : 2752-2762, 2019.
PubMed
36) Crago AM, et al : Near universal detection of alterations in CTNNB1 and Wnt pathway regulators in desmoid-type fibromatosis by whole-exome sequencing and genomic analysis. Genes Chromosomes Cancer 54 : 606-615, 2015.
PubMed
37) Cheon SS, et al : beta-Catenin stabilization dysregulates mesenchymal cell proliferation, motility, and invasiveness and causes aggressive fibromatosis and hyperplastic cutaneous wounds. Proc Natl Acad Sci USA 99 : 6973-6978, 2002.
PubMed
38) Huizinga JD, et al : W/kit gene required for interstitial cells of Cajal and for intestinal pacemaker activity, Nature 373 : 347-349, 1995.
PubMed
39) Hirota S, et al : Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279 : 577-580, 1998.
PubMed
40) Vitiello GA, et al : Differential immune profiles distinguish the mutational subtypes of gastrointestinal stromal tumor. J Clin Invest 129 : 1863-1877, 2019.
PubMed
41) Ran L, et al : FOXF1 Defines the Core-Regulatory Circuitry in Gastrointestinal Stromal Tumor. Cancer Discov 8 : 234-251, 2018.
PubMed
42) Sommer G, et al : Gastrointestinal stromal tumors in a mouse model by targeted mutation of the Kit receptor tyrosine kinase. Proc Natl Acad Sci USA 100 : 6706-6711, 2003.
 
43) Ran L, et al : Combined inhibition of MAP kinase and KIT signaling synergistically destabilizeg. ETV1 and suppresses GIST tumor growth. Cancer Discov 5 : 304-315, 2015.
PubMed
44) Sharifnia T, et al : Small-molecule targeting of brachyury transcription factor addiction in chordoma. Nat Med 25 : 292-300, 2019.
PubMed
45) Johann PD, et al : Atypical Teratoid/Rhabdoid Tumors Are Comprised of Three Epigenetic Subgroups with Distinct Enhancer Landscapes. Cancer Cell 29 : 379-393, 2016.
PubMed
46) Torchia J, et al : Integrated (epi) -Genomic Analyses Identify Subgroup-Specific Therapeutic Targets in CNS Rhabdoid Tumors. Cancer Cell 30 : 891-908, 2016.
PubMed
47) Isakoff MS, et al : Inactivation of the Snf5 tumor suppressor stimulates cell cycle progression and cooperates with p53 loss in oncogenic transformation. Proc Natl Acad Sci USA 102 : 17745-17750, 2005.
PubMed
48) Howard TP, et al : MDM2 and MDM4 Are Therapeutic Vulnerabilities in Malignant Rhabdoid Tumors. Cancer Res 79 : 2404-2414, 2019.
PubMed
49) Modena P, et al : SMARCB1/INI1 tumor suppressor gene is frequently inactivated in epithelioid sarcomas. Cancer Res 65 : 4012-4019, 2005.
PubMed
P.83 掲載の参考文献
1) Mano H : ALKoma : a cancer subtype with a shared target. Cancer Discov 2 : 495-502, 2012.
PubMed
2) Iglehart JD, Silver DP : Synthetic lethality-a new direction in cancer-drug development. N Engl J Med 361 : 189-19L 2009.
PubMed
3) Rizvi NA, et al : Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348 : 124-128, 2015.
 
4) Crowley E, et al : Liquid biopsy : monitoring cancer-genetics in the blood. Nat Rev Clin Oncol 10 : 472-484, 2013.
PubMed
5) Jo VY, Fletcher CD : WHO classification of soft tissue tumours : an update based on the 2013 (4th) edition. Pathology 46 : 95-104, 2014.
PubMed
6) Tamaki T, et al : The burden of rare cancer in Japan : application of the RARECARE definition. Cancer Epidemiol 38 : 490-495, 2014.
PubMed
7) Matsuda T, Matsuda A : Time trends in total cancer mortality (All Sites) between 1950 and 2008 in Japan, USA and Europe based on the WHO mortality database. Jpn J Clin Oncol 41 : 833-834, 2011.
PubMed
8) West RB, et al : A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells. Proc Natl Acad Sci USA 103 : 690-695, 2006.
 
9) Tsuda, Y, et al : Massively parallel sequencing of tenosynovial giant cell tumors reveals novel CSF1 fusion transcripts and novel somatic CBL mutations. Int J Cancer 145 : 3276-3284, 2019.
PubMed
P.88 掲載の参考文献
1) Mak IW, et al : Lost in translation : animal models and clinical trials in cancer treatment. Am J Transl Res 6 : 114-118, 2014.
PubMed
2) Kawai A, et al : Current state of therapeutic development for rare cancers in Japan, and proposals for improvement. Cancer Sci 109 : 1731-1737, 2018.
PubMed
3) Takahashi K, et al : Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131 : 861-872, 2007.
PubMed
4) Carette JE, et al : Generation of iPSCs from cultured human malignant cells. Blood 115 : 4039-4042, 2010.
PubMed
5) Moore JB, et al : Epigenetic reprogramming and re-differentiation of a Ewing sarcoma cell line. Front Cell Dev Biol 3 : 15, 2015.
 
6) Le LQ, et al : Susceptible stages in Schwann cells for NF1-associated plexiform neurofibroma development. Cancer Res 71 : 4686-4695, 2011.
PubMed
7) Carrio M, et al : Reprogramming Captures the Genetic and Tumorigenic Properties of Neurofibromatosis Type 1 Plexiform Neurofibromas. Stem Cell Reports 12 : 639-641, 2019.
PubMed
8) Zhang X, et al : Terminal differentiation and loss of tumorigenicity of human cancers via pluripotency-based reprogramming. Oncogene 32 : 2249-2260, 2260. e1-21, 2013.
 
9) Lee DF, et al : Modeling Familiai Cancer with Induced Pluripotent Stem Cells. Cell 161 : 240-254, 2015.
PubMed
10) Komura S, et al : An EWS-FLI1-Induced Osteosarcoma Model Unveiled a Crucial Role of Impaired Osteogenic Differentiation on Osteosarcoma Development. Stem Cell Reports 6 : 592-606, 2016.
PubMed
11) Hayakawa K, et al : Identification of target genes of synovial sarcoma-associated fusion oncoprotein using human pluripotent stem cells. Biochem Biophys Res Commun 432 : 713-719, 2013.
PubMed
12) Fukuta M, et al : Derivation of mesenchymal stromal cells from pluripotent stem cells through a neural crest lineage using small molecule compounds with defined media. PLoS ONE 9 : e112291, 2014.
PubMed
13) Tamaki S, et al : SS18-SSX, the Oncogenic Fusion Protein in Synovial Sarcoma, Is a Cellular Context-Dependent Epigenetic Modifier. PLoS ONE 10 : e0142991, 2015.
PubMed
14) Mali P, et al : RNA-guided human genome engineering via Cas9. Science 339 : 823-826, 2013.
PubMed
15) Torres-Ruiz R, et al : Efficient Recreation of t (11 ; 22) EWSR1-FLI1+ in Human Stem Cells Using CRISPR/Cas9. Stem Cell Reports 8 : 1408-1420, 2017.
PubMed
P.94 掲載の参考文献
1) Hattori E, Kondo T : Current status of cancer proteogenomics : a brief introduction. J Electrophoresis 63 : 33-37, 2019.
 
2) Woo S, et al : Proteogenomic strategies for identification of aberrant cancer peptides using large-scale next-generation sequencing data. Proteomics 14 : 2719-2730, 2014.
PubMed
3) Sheynkman GM, et al : Using Galaxy-P to leverage RNA-Seq for the discovery of novel protein variations. BMC Genomics 15 : 703, 2014.
PubMed
4) Park H, et al : Compact variant-rich customized sequence database and a fast and sensitive database search for efficient proteogenomic analyses. Proteomics 14 : 2742-2749, 2014.
 
5) Wen B, et al : sapFinder : an R/Bioconductor package for detection of variant peptides in shotgun proteomics experirnents. Bioinformatics 30 : 3136-3138, 2014.
 
6) Wang X, et al : customProDB : an R package to generate customized protein databases from RNA-Seq data for proteomics search. Bioinformatics 29 : 3235-3237, 2013.
 
7) Zickmann F, Renard BY : MSProGene : integrative proteogenomics beyond six-frames and single nucleotide polymorphisms. Bioinformatics 31 : i106-115, 2015.
PubMed
8) Nagaraj SH, et al : PGTools : A Software Suite for Proteogenomic Data Analysis and Visualization. J Proteome Res 14 : 2255-2266, 2015.
PubMed
9) Krasnov GS, et al : PPLine : An Automated Pipeline for SNP, SAP, and Splice Variant Detection in the Context of Proteogenomics. J Proteome Res 14 : 3729-3737, 2015.
PubMed
10) Crappe J, et al : PROTEOFORMER : deep proteome coverage through ribosome profiling and MS integration. Nucleic Acids Res 43 : e29, 2015.
PubMed
11) Ruggles KV, et al : An Analysis of the Sensitivity of Proteogenomic Mapping of Somatic Mutations and Novel Splicing Events in Cancer. Mol Cell Proteomics 15 : 1060-1071, 2016.
PubMed
12) Li Y, et al : JUMPg : An Integrative Proteogenomics Pipeline Identifying Unannotated Proteins in Human Brain and Cancer Cells. J Proteome Res 15 : 2309-2320, 2016.
PubMed
13) Wen B, et al : PGA : an R/Bioconductor package for identification of novel peptides using a customized database derived from RNA-Seq. BMC Bioinformatics 17 : 244, 2016.
 
14) Zhu Y, et al : Proteogenomics produces comprehensive and highly accurate protein-coding gene annotation in a complete genome assembly of Malassezia sympodialis. Nucleic Acids Res 45 : 2629-2643, 2017.
 
15) National Cancer Institute : International Cancer Proteogenomics Consortium. [https://proteomics.cancer.gov/programs/international-cancer-proteogenome-consortium]
 
P.101 掲載の参考文献
1) Feinberg AP, et al : Epigenetic modulators, modifiers and mediators in cancer aetiology and progression. Nat Rev Genet 17 : 284-299, 2016.
PubMed
2) Jones PA, et al : Targeting the cancer epigenome for therapy. Nat Rev Genet 17 : 630-641, 2016.
PubMed
3) Jenuwein T, Allis CD : Translating the histone code. Science 293 : 1074-1080, 2001.
PubMed
4) Soini Y : Epigenetic and genetic changes in soft tissue sarcomas : a review. APMIS 124 : 925-934, 2016.
PubMed
5) Bhat AV, et al : Epigenetic Regulation of the PTEN-AKT-RAC1 Axis by G9a Is Critical for Tumor Growth in Alveolar Rhabdomyosarcoma. Cancer Res 79 : 2232-2243, 2019.
PubMed
6) Gryder BE, et al : PAX3-FOXO1 Establishes Myogenic Super Enhancers and Confers BET Bromodomain Vulnerability. Cancer Discov 7 : 884-899, 2017.
PubMed
7) Seki M, et al : Integrated genetic and epigenetic analysis defines novel molecular subgroups in rhabdomyosarcoma. Nat Commun 6 : 7557, 2015.
PubMed
8) Su L, et al : Deconstruction of the SS18-SSX fusion oncoprotein complex : insights into disease etiology and therapeutics. Cancer Cell 21 : 333-347, 2012.
PubMed
9) Banito A, et al : The SS18-SSX Oncoprotein Hijacks KDM2B-PRC1.1 to Drive Synovial Sarcoma. Cancer Cell 34 : 346-348, 2018.
PubMed
10) Richter GH, et al : EZH2 is a mediator of EWS/FLI1 driven tumor growth and metastasis blocking endothelial and neuro-ectodermal differentiation. Proc Natl Acad Sci USA 106 : 5324-5329, 2009.
PubMed
11) Tomazou EM, et al : Epigenome mapping reveals distinct modes of gene regulation and widespread enhancer reprogramming by the oncogenic fusion protein EWS-FLI1. Cell Rep 10 : 1082-1095, 2015.
PubMed
12) Morrow JJ, Khanna C : Osteosarcoma Genetics and Epigenetics : Emerging Biology and Candidate Therapies. Crit Rev Oncog 20 : 173-197, 2015.
PubMed
13) Liu P, et al : Aberrant DNA methylations in chondrosarcoma. Epigenomics 8 : 1519-1525, 2016.
PubMed
14) Lee W, et al : PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors. Nat Genet 46 : 1227-1232, 2014.
PubMed
15) Lu C, et al : Histone H3K36 mutations promote sarcomagenesis through altered histone methylation landscape. Science 352 : 844-849, 2016.
PubMed
P.108 掲載の参考文献
1) Swinney DC, Anthony J : How were new medicines discovered? Nat Rev Drug Discov 10 : 507-519, 2011.
PubMed
2) Potter JW, et al : Sarcoma-The standard-bearer in cancer discovery. Crit Rev Oncol Hematol 126 : 1-5, 2018.
PubMed
3) Balachandran VP, DeMatteo RP : Gastrointestinal stromal tumors : who should get imatinib and for how long? Adv Surg 48 : 165-183, 2014.
PubMed
4) Amatu A, et al : NTRK gene fusions as novel targets of cancer therapy across multiple tumour types. ESMO Open 1 : e000023, 2016.
PubMed
5) Schoffski P, et al : Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE) : a multicentre, single-drug, prospective, non-randomised phase 2 trial. Lancet Respir Med 6 : 431-441, 2018.
PubMed
6) Cancer Genome Atlas Research Network. Electronic address : elizabeth.demicco@sinaihealthsystem.ca ; Cancer Genome Atlas Research Network : Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas. Cell 171 : 950-965. e28, 2017.
 
7) Lawrence MS, et al : Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499 : 214-218, 2013.
PubMed
8) Ciriello G, et al : Emerging landscape of oncogenic signatures across human cancers. Nat Genet 45 : 1127-1133, 2013.
PubMed
9) Dickson MA, et al : Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma. J Clin Oncol 31 : 2024-2028, 2013.
PubMed
10) Sayles LC, et al : Genome-Informed Targeted Therapy for Osteosarcoma. Cancer Discov 9 : 46-63, 2019.
PubMed
11) Maleki Vareki S : High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors. J Immunother Cancer 6 : 157, 2018.
PubMed
12) Dudley JC, et al : Microsatellite Instability as a Biomarker for PD-1 Blockade. Clin Cancer Res 22 : 813-820, 2016.
PubMed
13) Tawbi HA, et al : Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028) : a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol 18 : 1493-1501, 2017.
PubMed
14) Kawaguchi S, et al : SYT-SSX breakpoint peptide vaccines in patients with synovial sarcoma : a study from the Japanese Musculoskeletal Oncology Group. Cancer Sci 103 : 1625-1630, 2012.
PubMed
15) Burgess M, Tawbi H : Immunotherapeutic approaches to sarcoma. Curr Treat Options Oncol 16 : 26, 2015.
PubMed
P.116 掲載の参考文献
1) Mashtalir N, et al : Modular Organization and Assembly of SWI/SNF Family Chromatin Remodeling Complexes. Cell 175 : 1272-1288. e20, 2018.
 
2) Staahl BT, et al : Kinetic analysis of npBAF to nBAF switching reveals exchange of SS18 with CREST and integration with neural developmental pathways. J Neurosci 33 : 10348-10361, 2013.
PubMed
3) Kadoch C, et al : Dynamics of BAF-Polycomb complex opposition on heterochromatin in normal and oncogenic states. Nat Genet 49 : 213-222, 2017.
PubMed
4) Kosho T, et al : Coffin-Siris syndrome and related disorders involving components of the BAF (mSWI/SNF) complex : historical review and recent advances using next generation sequencing. Am J Med Genet C Semin Med Genet 166C : 241-251, 2014.
PubMed
5) Kadoch C, et al : Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy. Nat Genet 45 : 592-601, 2013.
PubMed
6) Biegel JA, et al : Monosomy 22 in rhabdoid or atypical tumors of the brain. J Neurosurg 73 : 710-714, 1990.
 
7) Versteege I, et al : Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature 394 : 203-206, 1998.
PubMed
8) Jackson EM, et al : Genomic analysis using high-density single nucleotide polymorphism-based oligonucleotide arrays and multiplex ligation-dependent probe amplification provides a comprehensive analysis of INI1/SMARCB1 in malignant rhabdoid tumors. Clin Cancer Res 15 : 1923-1930, 2009.
PubMed
9) Hollmann TJ, et al : INI1-deficient tumors : diagnostic features and molecular genetics. Am J Surg Pathol 35 : e47-63, 2011.
PubMed
10) Roberts CW, et al : Highly penetrant, rapid tumorigenesis through conditional inversion of the tumor suppressor gene Snf5. Cancer Cell 2 : 415-425, 2002.
PubMed
11) Nakayama RT, et al : SMARCB1 is required for widespread BAF complex-mediated activation of enhancers and bivalent promoters. Nat Genet 49 : 1613-1623, 2017.
PubMed
12) Kadoch C, et al : Reversible disruption of mSWI/SNF (BAF) complexes by the SS18-SSX oncogenic fusion in synovial sarcoma. Cell 153 : 71-85, 2013.
PubMed
13) Kohashi K, et al : Reduced expression of SMARCB1/INI1 protein in synovial sarcoma. Mod Pathol 23 : 981-990, 2010.
PubMed
14) McBride MJ, et al : The SS18-SSX Fusion Oncoprotein Hijacks BAF Complex Targeting and Function to Drive Synovial Sarcoma. Cancer Cell 33 : 1128-1141. e7, 2018.
 
P.123 掲載の参考文献
1) Friedman RC. et al : Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 19 : 92-105, 2009.
 
2) Lim LP, et al : Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 433 : 769-773, 2005.
PubMed
3) Croce CM : Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 10 : 704-714, 2009.
PubMed
4) Kobayashi E, et al : MicroRNA Involvement in Osteosarcoma. Sarcoma 2012 : 359739, 2012.
PubMed
5) Palmini G, et al : What Is New in the miRNA World Regarding Osteosarcoma and Chondrosarcoma? Molecules 22. pii : E417, 2017.
 
6) Zhu Z, et al : MicroRNA-100 resensitizes resistant chondrosarcoma cells to cisplatin through direct targeting of mTOR. Asian Pac J Cancer Prev 15 : 917-923, 2014.
PubMed
7) McKinsey EL, et al : A novel oncogenic mechanism in Ewing sarcoma involving IGF pathway targeting by EWS/Fli1-regulated microRNAs. Oncogene 30 : 4910-4920, 2011.
PubMed
8) Nezu Y, et al : miR-135b, a key regulator of malignancy, is linked to poor prognosis in human myxoid liposarcoma. Oncogene 35 : 6177-6188, 2016.
PubMed
9) Hanna JA, et al : PAX3-FOXO1 drives miR-486-5p and represses miR-221 contributing to pathogenesis of alveolar rhabdomyosarcoma. Oncogene 37 : 1991-2007, 2018.
PubMed
10) Sarver AL, et al : MicroRNA miR-183 functions as an oncogene by targeting the transcription factor EGR1 and promoting tumor cell migration. Cancer Res 70 : 9570-9580, 2010.
PubMed
11) Subramanian S, et al : Genome-wide transcriptome analyses reveal p53 inactivation mediated loss of miR-34a expression in malignant peripheral nerve sheath tumours. J Pathol 220 : 58-70, 2010.
PubMed
12) Uotani K, et al : Circulating MicroRNA-92b-3p as a Novel Biomarker for Monitoring of Synovial Sarcoma. Sci Rep 7 : 14634, 2017.
PubMed
13) Weng Y, et al : Identification of serum microRNAs in genome-wide serum microRNA expression profiles as novel noninvasive biomarkers for malignant peripheral nerve sheath tumor diagnosis. Med Oncol 30 : 531, 2013.
PubMed
14) Osaki M, et al : MicroRNA-143 regulates human osteosarcoma metastasis by regulating matrix metalloprotease-13 expression. Mol Ther 19 : 1123-1130, 2011.
 
15) Fujiwara T, et al : Clinical relevance and therapeutic significance of microRNA-133a expression profiles and functions in malignant osteosarcoma-initiating cells. Stem Cells 32 : 959-973, 2014.
PubMed
P.130 掲載の参考文献
1) van der Bruggen P, et al : A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254 : 1643-1647, 1991.
PubMed
2) Rosenberg SA, et al : Cancer immunotherapy : moving beyond current vaccines. Nat Med 10 : 909-915, 2004.
PubMed
3) Sato Y, et al : Detection and induction of CTLs specific for SYT-SSX-derived peptides in HLA-A24+ patients with synovial sarcoma. J Immunol 169 : 1611-1618, 2002.
PubMed
4) Tsukahara T, et al : Identification of human autologous cytotoxic T-lymphocyte-defined osteosarcoma gene that encodes a transcriptional regulator, papillomavirus binding factor. Cancer Res 64 : 5442-5448, 2004.
PubMed
5) Ishikura H, et al : Identification of CLUAP1 as a human osteosarcoma tumor-associated antigen recognized by the humoral immune system. Int J Oncol 30 : 461-467, 2007.
PubMed
6) Tsukahara T, et al : Prognostic impact and immunogenicity of a novel osteosarcoma antigen, papillomavirus binding factor, in patients with osteosarcoma. Cancer Sci 99 : 368-375, 2008.
PubMed
7) Tsukahara T, et al : Prognostic significance of HLA class I expression in osteosarcoma defined by anti-pan HLA class I monoclonal antibody, EMR8-5. Cancer Sci 97 : 1374-1380, 2006.
 
8) Yabe H, et al : Prognostic significance of HLA class I expression in Ewing's sarcoma family of tumors. J Surg Oncol 103 : 380-385, 2011.
 
9) Kawaguchi S, et al : Phase I vaccination trial of SYT-SSX junction peptide in patients with disseminated synovial sarcoma. J Transl Med 3 : 1, 2005.
PubMed
10) Kawaguchi S, et al : SYT-SSX breakpoint peptide vaccines in patients with synovial sarcoma : a study from the Japanese Musculoskeletal Oncology Group. Cancer Sci 103 : 1625-1630, 2012.
PubMed
11) Robbins PF, et al : Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 29 : 917-924, 2011.
PubMed
12) Robbins PF, et al : A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor : long-term follow-up and correlates with response. Clin Cancer Res 21 : 1019-1027, 2015.
 
13) Rapoport AP, et al : NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nat Med 21 : 914-921, 2015.
PubMed
14) Lai Jp, et al : NY-ESO-1 expression in synovial sarcoma and other mesenchymal tumors : significance for NY-ESO-1-based targeted therapy and differential diagnosis. Mod Pathol 25 : 854-858, 2012.
PubMed
15) Topalian SL, et al : Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366 : 2443-2454, 2012.
PubMed
16) Wolchok JD, et al : Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369 : 122-133, 2013.
PubMed
17) D'Angelo SP, et al : Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment. Hum Pathol 46 : 357-365, 2015.
PubMed
18) Koirala P, et al : Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma. Sci Rep 6 : 30093, 2016.
PubMed
P.136 掲載の参考文献
1) Boehm JS, Golub TR : An ecosystem of cancer cell line factories to support a cancer dependency map. Nat Rev Genet 16 : 373-374, 2015.
PubMed
2) Tuveson D, Clevers H : Cancer modeling meets human organoid technology. Science 364 : 952-955, 2019.
PubMed
3) Furukawa T, et al : Clinical applications of the histoculture drug response assay. Clin Cancer Res 1 : 305-311, 1995.
PubMed
4) Jiang X, et al : Establishment of Slice Cultures as a Tool to Study the Cancer Immune Microenvironment. Methods Mol Biol 1884 : 283-295, 2019.
 
5) Aparicio S, et al : Examining the utility of patient-derived xenograft mouse models. Nat Rev Cancer 15 : 311-316, 2015.
PubMed
6) Komatsu A, et al : Patient Derived Chicken Egg Tumor Model (PDcE Model) : Current Status and Critical Issues. Cells 8. pii : E440, 2019.
 
7) Bentley VL, et al : Focused chemical genomics using zebrafish xenotransplantation as a pre-clinical therapeutic platform for T-cell acute lymphoblastic leukemia. Haematologica 100 : 70-76, 2015.
 
8) Hoffman RM : Patient-derived orthotopic xenografts : better mimic of metastasis than subcutaneous xenografts. Nat Rev Cancer 15 : 451-452, 2015.
PubMed
9) Sharpless NE, Depinho RA : The mighty mouse : geneticaHy engineered mous e models in cancer drug development. Nat Rev Drug Discov 5 : 741-754, 2006.
 
10) Gao H, et al : High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response. Nat Med 21 : 1318-1325, 2015.
PubMed
11) Izumchenko E, et al : Patient-derived xenografts effectively capture responses to oncology therapy in a heterogeneous cohort of patients with solid tumors. Ann Oncol 28 : 2595-2605, 2017.
 
12) Burstein HJ, et al : American Society of Clinical Oncology clinical practice guideline update on the use of chemotherapy sensitivity and resistance assays. J Clin Oncol 29 : 3328-3330, 2011.
 
13) Ben-David U, et al : Patient-derived xenografts undergo mouse-specific tumor evolution. Nat Genet 49 : 1567-1575. 2017.
PubMed
14) Hattori E, et al : Systematic Review of the Current Status of Human Sarcoma Cell Lines. Cells 8. pii : E157, 2019.
 
15) Oyama R, et al : Generation of novel patient-derived CIC-DUX4 sarcoma xenografts and cell lines. Sci Rep 7 : 4712, 2017.
PubMed
P.143 掲載の参考文献
1) Mariani O, et al : JUN oncogene amplification and overexpression block adipocytic differentiation in highly aggressive sarcomas. Cancer Cell 11 : 361-374, 2007.
PubMed
2) Crago AM, et al : Copy number losses define subgroups of dedifferentiated liposarcoma with poor prognosis and genomic instability. Clin Cancer Res 18 : 1334-1340, 2012.
PubMed
3) Erickson-Johnson MR, et al : Carboxypeptidase M : a biomarker for the discrimination of well-differentiated liposarcoma from lipoma. Mod Pathol 22 : 1541-1547, 2009.
PubMed
4) Louis-Brennetot C, et al : The CDKN2A/CDKN2B/CDK4/CCND1 pathway is pivotal in well-differentiated and dedifferentiated liposarcoma oncogenesis : an analysis of 104 tumors. Genes Chromosomes Cancer 50 : 896-907, 2011.
PubMed
5) Snyder EL, et al : c-Jun amplification and overexpression are oncogenic in liposarcoma but not always sufficient to inhibit the adipocytic differentiation programme. J Pathol 218 : 292-300, 2009.
PubMed
6) Italiano A, et al : Clinical and biological significance of CDK4 amplification in well-differentiated and dedifferentiated liposarcomas. Clin Cancer Res 15 : 5696-5703, 2009.
PubMed
7) Tap WD, et al : Evaluation of well-differentiated/de-differentiated liposarcomas by high-resolution oligonucleotide array-based comparative genomic hybridization. Genes Chromosomes Cancer 50 : 95-112, 2011.
PubMed
8) Italiano A, et al : HMGA2 is the partner of MDM2 in well-differentiated and dedifferentiated liposarcomas whereas CDK4 belongs to a distinct inconsistent amplicon. Int J Cancer 122 : 2233-2241, 2008.
PubMed
9) Cantile M, et al : Hyperexpression of HOXC13, located in the 12q13 chromosomal region, in well-differentiated and dedifferentiated human liposarcomas. Oncol Rep 30 : 2579-2586, 2013.
PubMed
10) Cancer Genome Atlas Research Network. Electronic address : elizabeth.demicco@sinaihealthsystem.ca ; Cancer Genome Atlas Research Network : Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas. Cell 171 : 950-965. e28, 2017.
 
11) Dalal KM, et al : Subtype specific prognostic nomogram for patients with primary liposarcoma of the retroperitoneum, extremity, or trunk. Ann Surg 244 : 381-391, 2006.
PubMed
12) Barretina J, et al : Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet 42 : 715-721, 2010.
PubMed
13) Kanojia D, et al : Genomic landscape of liposarcoma. Oncotarget 6 : 42429-42444, 2015.
PubMed
14) Borjigin N, et al : TLS-CHOP represses miR-486 expression, inducing upregulation of a metastasis regulator PAI-l in human myxoid liposarcoma. Biochem Biophys Res Commun 427 : 355-360, 2012.
 
15) Goransson M, et al : The myxoid liposarcoma FUS-DDIT3 fusion oncoprotein deregulates NF-kappaB target genes by interaction with NFKBIZ. Oncogene 28 : 270-278, 2009.
PubMed
16) Goransson M, et al : Myxoid liposarcoma FUS-DDIT3 fusion oncogene induces C/EBP betamediated interleukin 6 expression. Int J Cancer 115 : 556-560, 2005.
PubMed
17) Nezu Y, et al : miR-135b, a key regulator of malignancy, is linked to poor prognosis in human myxoid liposarcoma. Oncogene 35 : 6177-6188, 2016.
PubMed
18) Rieker RJ, et al : Distinct chromosomal imbalances in pleomorphic and in high-grade dedifferentiated liposarcomas. Int J Cancer 99 : 68-73, 2002.
PubMed
P.151 掲載の参考文献
1) Vogelstein B, et al : Cancer genome landscapes. Science 339 : 1546-1558, 2013.
PubMed
2) Druker BJ, et al : Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344 : 1031-1037, 2001.
PubMed
3) Cappuzzo F, et al : Gefitinib in pretreated non-small-cell lung cancer (NSCLC) : analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC. J Clin Oncol 21 : 2658-2663, 2003.
PubMed
4) Behjati S, et al : Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone. Nat Genet 45 : 1479-1482, 2013.
PubMed
5) Behjati S, et al : Recurrent PTPRB and PLCG1 mutations in angiosarcoma. Nat Genet 46 : 376-379, 2014.
PubMed
6) Tarpey PS, et al : Frequent mutation of the major cartilage collagen gene COL2A1 in chondrosarcoma. Nat Genet 45 : 923-926, 2013.
PubMed
7) Kohsaka S, et al : A recurrent neomorphic mutation in MYOD1 defines a clinically aggressive subset of embryonal rhabdomyosarcoma associated with PI3K-AKT pathway mutations. Nat Genet 46 : 595-600, 2014.
PubMed
8) Chmielecki J, et al : Whole-exome sequencing identifies a recurrent NAB2-STAT6 fusion in solitary fibrous tumors. Nat Genet 45 : 131-132, 2013.
PubMed
9) Lee W, et al : PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors. Nat Genet 46 : 1227-1232, 2014.
PubMed
10) Fletcher CD, et al : Clinicopathologic re-evaluation of 100 malignant fibrous histiocytomas : prognostic relevance of subclassification. J Clin Oncol 19 : 3045-3050, 2001.
 
11) Mertens F, et al : Cytogenetic analysis of 46 pleomorphic soft tissue sarcomas and correlation with morphologic and clinical features : a report of the CHAMP Study Group. Chromosomes and MorPhology. Genes Chromosomes Cancer 22 : 16-25, 1998.
 
12) Willems SM, et al : Local recurrence of myxofibrosarcoma is associated with increase in tumour grade and cytogenetic aberrations, suggesting a multistep tumour progression model. Mod Pathol 19 : 407-416, 2006.
 
13) Barretina J, et al : Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet 42 : 715-721, 2010.
PubMed
14) Cancer Genome Atlas Research Network, Electronic address : elizabeth.demicco@sinaihealthsystem.ca ; Cancer Genome Atlas Research Network : Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas. Cell 171 : 950-965. e28, 2017.
 
15) Ogura K, et al : Integrated genetic and epigenetic analysis of myxofibrosarcoma. Nat Commun 9 : 2765, 2018.
PubMed
P.159 掲載の参考文献
1) Tanabe Y, et al : Comprehensive screening of target molecules by next-generation sequencing in patients with malignant solid tumors : guiding entry into phase I clinical trials. Mol Cancer 15 : 73, 2016.
PubMed
2) Sunami K, et al : Feasibility and utility of a panel testing for 114 cancer-associated genes in a clinical setting : A hospital-based study. Cancer Sci 110 : 1480-1490, 2019.
 
3) Kato M, et al : A computational tool to detect DNA alterations tailored to formalin-fixed paraffin-embedded samples in cancer clinical sequencing. Genome Med 10 : 44, 2018.
 
4) Frampton GM, et al : Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol 31 : 1023-1031, 2013.
PubMed
5) Chalmers ZR, et al : Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med 9 : 34, 2017.
PubMed
6) Kohsaka S, et al : Comprehensive assay for the molecular profiling of cancer by target enrichment from formalin-fixed paraffin-embedded specimens. Cancer Sci 110 : 1464-1479, 2019.
PubMed
7) Sunami K, et al : Clinical practice guidance for next-generation sequencing in cancer diagnosis and treatment (Edition 1.0). Cancer Sci 109 : 2980-2985, 2018.
 
8) Zehir A, et al : Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med 23 : 703-713, 2017.
PubMed
9) Cancer Genome Atlas Research Network : Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas. Cell 171 : 950-965, 2017.
 
10) Yamazaki F, et al : Novel NTRK3 Fusions in Fibrosarcomas of Adults. Am J Surg Pathol 43 : 523-530, 2019.
PubMed
P.167 掲載の参考文献
1) Pao W, Hutchinson KE : Chipping away at the lung cancer genome. Nat Med 18 : 349-351, 2012.
PubMed
2) Drilon A, et al : Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas. Cancer Discov 3 : 630-635, 2013.
PubMed
3) Suehara Y, et al : Identification of KIF5B-RET and GOPC-ROS1 fusions in lung adenocarcinomas through a comprehensive mRNA-based screen for tyrosine kinase fusions. Clin Cancer Res 18 : 6599-6608, 2012.
PubMed
4) Zehir A, et al : Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med 23 : 703-713, 2017.
PubMed
5) Kato S, et al : Multicenter experience with large panel next-generation sequencing in patients with advanced solid cancers in Japan. Jpn J Clin Oncol 49 : 174-182, 2019.
PubMed
6) Drilon A, et al : Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med 378 : 731-739, 2018.
PubMed
7) Laetsch TW, et al : Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions : phase 1 results from a multicentre, open-label, phase 1/2 study. Lancet Oncol 19 : 705-714, 2018.
 
8) Drilon A, et al : Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib : Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1). Cancer Discov 7 : 400-409, 2017.
PubMed
9) Cocco E, et al : NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol 15 : 731-747, 2018.
PubMed
10) Frampton GM, et al : Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol 31 : 1023-1031, 2013.
PubMed
11) Cheng DT, et al : Memorial Sloan Kettering-lntegrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT) : A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology. J Mol Diagn 17 : 251-264, 2015.
 
12) Niu B, et al : MSIsensor : microsatellite instability detection using paired tumor-normal sequence data. Bioinformatics 30 : 1015-1016, 2014.
PubMed
13) Chakravarty D, et al : OncoKB : A Precision Oncology Knowledge Base. JCO Precis Oncol 2017. doi : 10.1200/PO.17.00011, 2017.
 
14) Benayed R, et al : High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden. Clin Cancer Res 25 : 4712-4722, 2019.
PubMed
15) Suehara Y, et al : Clinical genomic sequencing of pediatric and adult osteosarcoma reveals distinct molecular subsets with potentially targetable alterations. Clin Cancer Res, 2019. [Epub ahead of print]
 
P.182 掲載の参考文献
1) WHO Classification of Tumours, 5th ed, Vol 3, Soft Tissue and Bone Tumours (ed by WHO Classification of Tumours Editorial Board), IARC, Lyon, 2020.
 
2) Creytens D, et al : Atypical spindle cell lipoma : a clinicopathologic, immunohistochemical, and molecular study emphasizing its relationship to classical spindle cell lipoma. Virchows Arch 465 : 97-108, 2014.
PubMed
3) Alaggio R, et al : Liposarcomas in young patients : a study of 82 cases occurring in patients younger than 22 years of age. Am J Surg Pathol 33 : 645-658, 2009.
PubMed
4) Michal M, et al : EWSR1-SMAD3-rearranged Fibroblastic Tumor : An Emerging Entity in an Increasingly More Complex Group of Fibroblastic/Myofibroblastic Neoplasms. Am J Surg Pathol 42 : 1325-1333, 2018.
 
5) Marino-Enriquez A, Fletcher CD : Angiofibroma of soft tissue : clinicopathologic characterization of a distinctive benign fibrovascular neoplasm in a series of 37 cases. Am J Surg Pathol 36 : 500-508, 2012.
 
6) Bekers EM, et al : Soft tissue angiofibroma : Clinicopathologic, immunohistochemical and molecular analysis of 14 cases. Genes Chromosomes Cancer 56 : 750-757, 2017.
PubMed
7) Carter JM, et al : Superficial CD34-positive fibroblastic tumor : report of 18 cases of a distinctive low. grade mesenchymal neoplasm of intermediate (borderline) malignancy. Mod Pathol 27 : 294-302, 2014.
PubMed
8) Lappa E, Drakos E : Anastomosing Hemangioma : Short Review of a Benign Mimicker of Angiosarcoma. Arch Pathol Lab Med 144 : 240-244, 2020.
PubMed
9) Deyrup AT, et al : Epstein-Barr virus-associated smooth muscle tumors are distinctive mesenchymal tumors reflecting multiple infection events : a clinicopathologic and molecular analysis of 29 tumors from 19 patients. Am J Surg Pathol 30 : 75-82, 2006.
 
10) Cohen JI, et al : Association of GATA2 Deficiency With Severe Primary Epstein-Barr Virus (EBV) Infection and EBV-associated Cancers. Clin Infect Dis 63 : 41-47, 2016.
PubMed
11) Arbajian E, et al : Inflammatory leiomyosarcoma is a distinct tumor characterized by near-haploidization, few somatic mutations, and a primitive myogenic gene expression signature. Mod Pathol 31 : 93-100, 2018.
 
12) Suurmeijer AJH, et al : A novel group of spindle cell tumors defined by S100 and CD34 co-expression shows recurrent fusions involving RAF1, BRAF, and NTRK1/2 genes. Genes Chromosomes Cancer 57 : 611-621, 2018.
PubMed
13) Diaz-Perez JA, et al : EWSR1/FUS-NFATc2 rearranged round cell sarcoma : clinicopathological series of 4 cases and literature review. Hum Pathol 90 : 45-53, 2019.
PubMed
14) Antonescu CR, et al : Sarcomas With CIC-rearrangements Are a Distinct Pathologic Entity With Aggressive Outcome : A Clinicopathologic and Molecular Study of 115 Cases. Am J Surg Pathol 41 : 941-949, 2017.
PubMed
15) Matsuyama A, et al : Clinicopathologic Diversity of Undifferentiated Sarcoma With BCOR-CCNB3 Fusion : Analysis of 11 Cases With a Reappraisal of the Utility of Immunohistochemistry for BCOR and CCNB3. Am J Surg Pathol 41 : 1713-1721, 2017.
PubMed
P.190 掲載の参考文献
1) WHO Classification of Tumours, 5th ed, Vol 3, Soft Tissue and Bone Tumours (ed by WHO Classification of Tumours Editorial Board), IARC, Lyon, 2020.
 
2) WHO Classification of Tumours of Soft Tissue and Bone, 4th ed (ed by Fletcher CDM, et al), IARC, Lyon, 2013.
 
3) Jaffe HL : Tumors and Tumorous Conditions of the Bones and Joints, Lea & Febiger, Philadelphia, 1958.
 
4) Eefting D, et al : Assessment of interobserver variability and histologic parameters to improve reliability in classification and grading of central cartilaginous tumors. Am J Surg Pathol 33 : 50-57, 2009.
PubMed
5) Bovee JV, et al : EXT-mutation analysis and loss of heterozygosity in sporadic and hereditary osteochondromas and secondary chondrosarcomas. Am J Hum Genet 65 : 689-698, 1999.
PubMed
6) Shah ZK, et al : Sarcomatous transformation in diaphyseal aclasis. Australas Radiol 51 : 110-119, 2007.
PubMed
7) Behjati S, et al : Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone. Nat Genet 45 : 1479-1482, 2013.
PubMed
8) Yamazaki F, et al : Novel NTRK3 Fusiong. in Fibrosarcomas of Adults. Am J Surg Pathol 43 : 523-530, 2019.
 
9) Kato I, et al : Giant cell tumours of bone treated with denosumab : histological, immunohistochemical and H3F3A mutation analyses. Histopathology 72 : 914-9. 22, 2018.
 
10) Antonescu CR, et al : Sarcomas With CIC-rearrangements Are a Distinct Pathologic Entity With Aggressive Outcome : A Clinicopathologic and Molecular Study of 115 Cases. Am J Surg Pathol 41 : 941-949, 2017.
PubMed
11) Schoifield DW, et al : Does osteofibrous dysplasia progress to adamantinoma and how should they be treated? Bone Joint J 99-B : 409-416, 2017,
 
12) 骨軟部腫瘍の病理 II (特集編集 : 久岡正典, 小田義直). 病理と臨床 38 : 297-354, 2020.
 
P.197 掲載の参考文献
1) WHO Classification of Tumours, 5th ed, Vol 3, Soft Tissue and Bone Tumours (ed by WHO Classification of Tumours Editorial Board), IARC, Lyon, 2020.
 
2) 日本病理学会 : ゲノム診療用病理組織検体取扱い規程, 2018. [http://pathology.or.jp/genome_med/]
 
3) Hornick JL : Practical Soft Tissue Pathology : A Diagnostic Approach, 2nd ed, Elsevier, Philadelphia, 2018.
 
4) 松山篤二, 久岡正典 : 軟部. 病理と臨床 38 (臨時増刊号 : 免疫組織化学 実践的な診断・治療方針決定のために) : 255-262, 2020.
 
5) Baranov E, et al : A Novel SS18-SSX Fusion-specific Antibody for the Diagnosis of Synovial Sarcoma. Am J Surg Pathol 44 : 922-933, 2020.
 
6) Koelsche C, et al : Array-based DNA-methylation profiling in sarcomas with small blue round cell histology provides valuable diagnostic information. Mod Pathol 31 : 1246-1256, 2018.
PubMed
7) Alaggio R, et al : Liposarcomas in young patients : a study of 82 cases occurring in patients younger than 22 years of age. Am J Surg Pathol 33 : 645-658, 2009.
PubMed
8) Yoshida A, et al : CIC-rearranged Sarcomas : A Study of 20 Cases and Comparisons With Ewing Sarcomas. Am J Surg Pathol 40 : 313-323, 2016.
PubMed
9) Kao YC, et al : BCOR-CCNB3 Fusion Positive Sarcomas : A Clinicopathologic and Molecular Analysis of 36 Cases With Comparison to Morphologic Spectrum and Clinical Behavior of Other Round Cell Sarcomas. Am J Surg Pathol 42 : 604-615, 2018.
PubMed
P.201 掲載の参考文献
1) Yoshida A, et al : STAT6 immunohistochemistry is helpful in the diagnosis of solitary fibrous tumors. Am J Surg Pathol 38 : 552-559, 2014.
PubMed
2) Solomon Jp, et al : NTRK fusion detection across multiple assays and 33,997 cases : diagnostic implications and pitfalls. Mod Pathol 33 : 38-46, 2020.
PubMed
3) Baranov E, et al : A Novel SS18-SSX Fusion-specific Antibody for the Diagnosis of Synovial Sarcoma. Am J Surg Pathol 44 : 922-933, 2020.
 
4) Ito J, et al : The diagnostic utility of reduced immunohistochemical expression of SMARCB1 in synovial sarcomas : a validation study. Hum Pathol 47 : 32-37, 2016.
PubMed
5) Yoshida A, et al : NKX2.2 is a useful immunohistochemical marker for Ewing sarcoma. Am J Surg Pathol 36 : 993-999, 2012.
PubMed
6) Toki S, et al : PAX7 immunohistochemical evaluation of Ewing sarcoma and other small round cell tumours. Histopathology 73 : 645-652, 2018.
PubMed
7) Le Guellec S, et al : ETV4 is a useful marker for the diagnosis of CIC-rearranged undifferentiated round-cell sarcomas : a study of 127 cases including mimicking lesions. Mod Pathol 29 : 1523-1531, 2016.
PubMed
8) Binh MB, et al : MDM2 and CDK4 immunostainings are useful adjuncts in diagnosing well-differentiated and dedifferentiated liposarcoma subtypes : a comparative analysis of 559 soft tissue neoplasms with genetic data. Am J Surg Pathol 29 : 1340-1347, 2005.
PubMed
9) Yoshida A, et al : MDM2 and CDK4 immunohistochemical coexpression in high-grade osteosarcoma : correlation with a dedifferentiated subtype. Am J Surg Pathol 36 : 423-431, 2012.
PubMed
10) Yamamoto H, et al : Diagnostic utility of histone H3.3 G34W, G34R, and G34V mutant-specific antibodies for giant cell tumors of bone. Hum Pathol 73 : 41-50, 2018.
PubMed
11) Amary MF, et al : The H3F3 K36M mutant antibody is a sensitive and specific marker for the diagnosis of chondroblastoma. Histopathology 69 : 121-127, 2016.
PubMed
12) Yoshida A, et al : Clinicopathological and molecular characterization of SMARCA4-deficient thoracic sarcomas with comparison to potentially related entities. Mod Pathol 30 : 797-809, 2017.
PubMed
13) Asano N, et al : Immunohistochemistry for trimethylated H3K27 in the diagnosis of malignant peripheral nerve sheath tumours. Histopathology 70 : 385-393, 2017.
PubMed
14) Mentzel T, et al : Postradiation cutaneous angiosarcoma after treatment of breast carcinoma is characterized by MYC amplification in contrast to atypical vascular lesions after radiotherapy and control cases : clinicopathological, immunohistochemical and molecular analysis of 66 cases. Mod Pathol 25 : 75-85, 2012.
PubMed
15) Panagopoulos I, et al : Cytogenetics of Spindle Cell/Pleomorphic Lipomas : Karyotyping and FISH Analysis of 31 Tumors. Cancer Genomics Proteomics 15 : 193-200, 2018.
PubMed
P.207 掲載の参考文献
1) Moser RP, et al : Radiographic evaluation of soft tissue tumors. In : Enzinger and Weiss's Soft Tissue Tumors, 4th ed (ed by Weiss SW, Goldblum JR), p49-55, Mosby, St. Louis, 2001.
 
2) van der Woude HJ, et al : Musculoskeletal tumors : does fast dynamic contrast-enhanced subtraction MR imaging contribute to the characterization? Radiology 208 : 821-828, 1998.
 
3) May DA, et al : MR imaging of musculoskeletal tumors and tumor mimickers with intravenous gadolinium : experience with 242 patients. Skeietal Radiol 26 : 2-15, 1997.
PubMed
4) Wu JL et al : Imaging strategies in intramuscular haemangiomas : an analysis of 20 cases. Int Orthop 31 : 569-575, 2007.
PubMed
5) Knebel C, et al : Differentiating atypical lipomatous tumors from lipomas with magnetic resonance imaging : a comparison with MDM2 gene amplification status. BMC Cancer 19 : 309, 2019.
 
6) Nishida J, et al : Imaging characteristics of deep-seated lipomatous tumors : intramuscular lipoma, intermuscular lipoma, and lipoma-like liposarcoma. J Orthop Sci 12 : 533-541, 2007.
PubMed
7) O'Sullivan PJ, et al : Radiological features of synovial cell sarcoma. Br J Radiol 81 : 346-356, 2008.
PubMed
8) Manoso MW, et al : Infiltrative MRI pattern and incomplete initial surgery compromise local control of myxofibrosarcoma. Clin Orthop Relat Res 450 : 89-94, 2006.
PubMed
9) Kaya M, et al : MRI and histological evaluation of the infiltrative growth pattern of myxofibrosarcoma. Skeletal Radiol 37 : 1085-1090, 2008.
PubMed
10) Suh JS, et al : Alveolar soft part sarcoma : MR and angiographic findings. Skeletal Radiol 29 : 680-689, 2000.
PubMed
11) Burke M, et al : Assessment of response to induction therapy and its influence on 5-year failure-free survival in group III rhabdomyosarcoma : the Intergroup Rhabdomyosarcoma Study-IV experience-a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. J Clin Oncol 25 : 4909-4913, 2007.
 
12) Crombe A, et al : MRI assessment of surrounding tissues in soft-tissue sarcoma during neoadjuvant chemotherapy can help Predicting response and prognosis. Eur J Radiol 109 : 178-187, 2018.
PubMed
13) Wang X, et al : Therapeutic response in musculoskeletal soft tissue sarcomas : evaluation by MRI. NMR Biomed 24 : 750-763, 2011.
PubMed
14) Oka K, et al : The value of diffusion-weighted imaging for monitoring the chemotherapeutic response of osteosarcoma : a comparison between average apparent diffusion coefficient and minimum apparent diffusion coefficient. Skeletal Radiol 39 : 141-146, 2010.
PubMed
15) Sagiyama K, et al : Multiparametric voxel-based analyses of standardized uptake values and apparent diffusion coefficients of soft tissue tumours with a positron emission tomography/magnetic resonance system : Preliminary results. Eur Radiol 27 : 5024-5033, 2017.
PubMed
P.212 掲載の参考文献
1) Eary JF, et al : Quantitative [F-18] fluorodeoxyglucose positron emission tomography in pretreatment and grading of sarcoma. Clin Cancer Res 4 : 1215-1220, 1998.
PubMed
2) Even-Sapir E, et al : Assessment of malignant skeletal disease : initial experience with 18F-fluoride PET/CT and comparison between 18F-fluoride PET and 18F-fluoride PET/CT. J Nucl Med 45 : 272-278, 2004.
PubMed
3) Etchebehere EC, et al : Assessing the role of 18F-FDG PET and 18F-FDG PET/CT in the diagnosis of soft tissue musculoskeletal malignancies : a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging 43 : 860-870, 2016.
PubMed
4) Charest M, et al : FDG PET/CT imaging in primary osseous and soft tissue sarcomas : a retrospective review of 212 cases. Eur J Nucl Med Mol Imaging 36 : 1944-1951, 2009.
PubMed
5) Aoki J, et al : FDG-PET in differential diagnosis and grading of chondrosarcomas. J Comput Assist Tomogr 23 : 603-608, 1999.
PubMed
6) Nieweg OE, et al : Fluorine-18-fluorodeoxyglucose PET imaging of soft-tissue sarcoma. J Nucl Med 37 : 257-261, 1996.
PubMed
7) Macpherson RE, et al : Retrospective audit of 957 consecutive 18F-FDG PET-CT scans compared to CT and MRI in 493 patients with different histological subtypes of bone and soft tissue sarcoma. Clin Sarcoma Res 8 : 9, 2018.
 
8) Huang T, et al : Effectiveness of 18F-FDG PET/CT in the diagnosis, staging and recurrence monitoring of Ewing sarcoma family of tumors : A meta-analysis of 23 studies. Medicine (Baltimore) 97 : e13457, 2018.
PubMed
9) Fortes DL, et al : The sensitivity of 18F-fluorodeoxyglucose positron emission tomography in the evaluation of metastatic pulmonary nodules. Eur J Cardiothorac Surg 34 : 1223-1227, 2008.
PubMed
10) Harrison DJ, et al : The Role of 18F-FDG-PET/CT in Pediatric Sarcoma. Semin Nucl Med 47 : 229-241, 2017.
PubMed
11) Denecke T, et al : Assessment of histological response of paediatric bone sarcomas using FDG PET in comparison to morphological volume measurement and standardized MRI parameters. Eur J Nucl Med Mol Imaging 37 : 1842-1853, 2010.
PubMed
12) Cheon GJ, et al : Prediction model of chemotherapy response in osteosarcoma by 18F-FDG PET and MRI. J Nucl Med 50 : 1435-1440, 2009.
PubMed
13) Eary JF, et al : Sarcoma mid-therapy [F-18] fluorodeoxyglucose positron emission tomography (FDG PET) and patient outcome. J Bone Joint Surg Am 96 : 152-158, 2014.
PubMed
14) 須佐美知郎, ほか : 【小児整形外科疾患, 診断・治療の進歩】診断・評価の進歩 CT, PET-CT : 小児期の悪性骨・軟部腫瘍に対するPET-CTを用いた診断・治療の現状と今後の展望. 別冊整形外科 32 : 30-36, 2013.
 
15) Sharp SE, et al : FDG PET/CT appearance of local osteosarcoma recurrences in pediatric patients. Pediatr Radiol 47 : 1800-1808, 2017.
PubMed
P.220 掲載の参考文献
1) Serpell JW, et al : The diagnosis of soft tissue tumours. Ann R Coll Surg Engl 74 : 277-280, 1992.
PubMed
2) Verheijen P, et al : Current pathology work-up of extremity soft tissue sarcomas, evaluation of the validity of different techniques. Eur J Surg Oncol 36 : 95-99, 2010.
PubMed
3) Traina F, et al : Current concepts in the biopsy of musculoskeletal tumors : AAOS exhibit selection. J Bone Joint Surg Am 97 : e7, 2015.
PubMed
4) Kubo T, et al : A meta-analysis supports core needle biopsy by radiologists for better histological diagnosis in soft tissue and bone sarcomas. Medicine (Baltimore) 97 : e11567, 2018.
 
5) Puri A, et al : CT-guided percutaneous core needle biopsy in deep seated musculoskeletal lesions : a prospective study of 128 cases. Skeletal Radiol 35 : 138-143, 2006.
PubMed
6) Rougraff BT, et al : Biopsy of soft tissue masses : evidence-based medicine for the musculoskeletal tumor society. Clin Orthop Relat Res 467 : 2783-2791, 2009.
PubMed
7) Sone M, et al : Feasibility of genomic profiling with next-generation sequencing using specimens obtained by image-guided percutaneous needle biopsy. Ups J Med Sci 124 : 119-124, 2019.
PubMed
8) Nakamura T, et al : Lung radiofrequency ablation in patients with pulmonary metastases from musculoskeletal sarcomas [corrected]. Cancer 115 : 3774-3781, 2009.
PubMed
9) Palussiere J, et al : Sarcoma lung metastases treated with percutaneous radiofrequency ablation : results from 29 patients. Ann Surg Oncol 18 : 3771-3777, 2011.
PubMed
10) Koelblinger C, et al : Outcome after radiofrequency ablation of sarcoma lung metastases. Cardiovasc Intervent Radiol 37 : 147-153, 2014.
PubMed
11) de Baere T, et al : Radiofrequency ablation is a valid treatment option for lung metastases : experience in 566 patients with 1037 metastases. Ann Oncol 26 : 987-991, 2015.
PubMed
12) Sato T, et al : Radiofrequency ablation of pulmonary metastases from sarcoma : single-center retrospective evaluation of 46 patients. Jpn J Radiol 35 : 61-67, 2017.
PubMed
13) de Baere T, et al : Evaluating Cryoablation of Metastatic Lung Tumors in Patients--Safety and Efficacy : The ECLIPSE Trial-Interim Analysis at 1 Year. J Thorac Oncol 10 : 1468-1474, 2015,
PubMed
14) Jung JH, et al : Safety and Efficacy of Radiofrequency Ablation for Hepatic Metastases from Gastrointestinal Stromal Tumor. J Vasc Interv Radiol 26 : 1797-1802, 2015.
PubMed
15) Maluccio MA, et al : Treatment of metastatic sarcoma to the liver with bland embolization. Cancer 107 : 1617-1623, 2006.
 
16) Takaki H, et al : Hepatic artery embolization for liver metastasis of gastrointestinal stromal tumor following imatinib and sunitinib therapy. J Gastrointest Cancer 45 : 494-499, 2014.
PubMed
17) Chapiro J, et al : Transarterial chemoembolization in soft-tissue sarcoma metastases to the liver-the use of imaging biomarkers as predictors of patient survival. Eur J Radiol 84 : 424-430, 2015.
 
P.226 掲載の参考文献
1) International Union against Cancer (UICC) : TNM Classification of Malignant Tumours, 4th ed (ed by Hermanek P, Sobin LH), Springer-Verlag, Berlin, 1987.
 
2) AJCC Cancer Staging Manual, 8th ed (ed by Amin MB, et al), Springer, New York, 2017.
 
3) Tanaka K, Ozaki T : New TNM classification (AJCC eighth edition) of bone and soft tissue sarcomas : JCOG Bone and Soft Tissue Tumor Study Group. Jpn J Clin Oncol 49 : 103-107, 2019.
 
4) Steffner RJ, Jang ES : Staging of Bone and Soft-tissue Sarcomas. J Am Acad Orthop Surg 26 : e269-e278, 2018.
PubMed
5) Union for International Cancer Control (UICC) : TNM Classification of Malignant Tumours, 8th ed (ed by Brierley JD, et al), Wiley-Blackwell, Hoboken, 2017.
 
6) Fisher SB, et al : Comparative Performance of the 7th and 8th Editions of the American Joint Committee on Cancer Staging Systems for Soft Tissue Sarcoma of the Trunk and Extremities. Ann Surg Oncol 25 : 1126-1132, 2018.
PubMed
7) 川井章, ほか : 骨・軟部腫瘍. TNM悪性腫瘍の分類 [第8版] -日本語版 (UICC日本委員会TNM委員会訳), p124-126, 金原出版, 2017.
 
P.230 掲載の参考文献
1) Enneking WF : A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop Relat Res (153) : 106-120, 1980.
PubMed
2) Broders AC, et al : Pathological features of soft tissue fibrosarcoma with special reference to the grading of its malignancy. Surg Gynecol Obstet 69 : 267-280, 1939.
 
3) Wunder JS, et al : A comparison of staging systems for localized extremity soft tissue sarcoma. Cancer 88 : 2721-2730, 2000.
PubMed
4) Fleming ID, et al : AJCC Cancer Staging Manual, 5th ed, Lippincott-Raven, Philadelphia, 1997.
 
5) Saddegh MK, et al : Staging of soft-tissue sarcomas. Prognostic analysis of clinical and pathological features. J Bone Joint Surg Br 74 : 495-500, 1992.
PubMed
P.236 掲載の参考文献
1) Minds診療ガイドライン作成マニュアル 2017 (小島原典子, ほか編), 公益財団法人日本医療機能評価機構, 2017.
 
2) Graham R, et al : Clinical Practice Guidelines We Can Trust. The National Academies Press, Washington DC, 2011
 
3) 中山健夫 : 診療ガイドライン : 現状と今後の展望, 痛風と核酸代謝 33 : 137-147, 2009.
 
4) 軟部腫瘍診療ガイドライン 2012 (日本整形外科学会診療ガイドライン委員会, 軟部腫瘍診療ガイドライン策定委員会編), 南江堂, 2012.
 
5) EBM普及推進事業 (Minds) : Mindsからの提言 希少疾患など, エビデンスが少ない領域での診療ガイドライン作成, 公益財団法人日本医療機能評価機構, 2016.
 
6) 桑原博道, 浅野陽介 : ガイドラインと医療訴訟について-弁護士による211の裁判例の法的解析-. Minds診療ガイドライン作成マニュアル, 2015.
 
7) Eddy DM : Clinical decision making : from theory to practice. Designing a practice policy. Standards, guidelines, and options. JAMA 263 : 3077, 3081, 3084, 1990.
PubMed
P.242 掲載の参考文献
1) Kattan MW, et al : American Joint Committee on Cancer acceptance criteria for inclusion of risk models for individualized prognosis in the practice of precision medicine. CA Cancer J Clin 66 : 370-374, 2016.
PubMed
2) Shariat SF, et al : Comparison of nomograms with other methods for predicting outcomes in prostate cancer : a critical analysis of the literature. Clin Cancer Res 14 : 4400-4407, 2008.
PubMed
3) Iasonos A, et al : How to build and interpret a nomogram for cancer prognosis. J Clin Oncol 26 : 1364-1370, 2008.
PubMed
4) Kattan MW, et al : Postoperative nomogram for 12-year sarcoma-specific death. J Clin Oncol 20 : 791-796, 2002.
 
5) Eilber FC, et al : Validation of the postoperative nomogram for 12-year sarcoma-specific mortality. Cancer 101 : 2270-2275, 2004.
PubMed
6) Mariani L, et al : Validation and adaptation of a nomogram for predicting the survival of patients with extremity soft tissue sarcoma using a three-grade system. Cancer 103 : 402-408, 2005.
PubMed
7) Gronchi A, et al : Outcome prediction in primary resected retroperitoneal soft tissue sarcoma : histology-specific overall survival and disease-free survival nomograms built on major sarcoma center data sets. J Clin Oncol 31 : 1649-1655, 2013.
PubMed
8) Raut CP, et al : External validation of a multi-institutional retroperitoneal sarcoma nomogram. Cancer 122 : 1417-1424, 2016.
PubMed
9) Callegaro D, et al : Development and external validation of two nomograms to predict overall survival and occurrence of distant metastases in adults after surgical resection of localised soft-tissue sarcomas of the extremities : a retrospective analysis, Lancet Oncol 17 : 671-680, 2016.
PubMed
10) Pasquali S, et al : The impact of chemotherapy on survival of patients with extremity and trunk wall soft tissue sarcoma : revisiting the results of the EORTC-STBSG 62931 randomised trial. Eur J Cancer 109 : 51-60, 2019.
PubMed
11) Raut CP, et al : Predicting Survival in Patients Undergoing Resection for Locally Recurrent Retroperitoneal Sarcoma : A Study and Novel Nomogram from TARPSWG. Clin Cancer Res 25 : 2664-2671, 2019.
PubMed
12) Sekimizu M, et al : Development of nomograms for prognostication of patients with primary soft tissue sarcomas of the trunk and extremity : report from the Bone and Soft Tissue Tumor Registry in Japan. BMC Cancer 19 : 657, 2019.
 
13) Kim MS, et al : Prognostic nomogram for predicting the 5-year probability of developing metastasis after neo-adjuvant chemotherapy and definitive surgery for AJCC stage II extremity osteosarcoma. Ann Oncol 20 : 955-960, 2009.
PubMed
14) Kim SH, et al : Postoperative nomogram to predict the probability of metastasis in Enneking stage IIB extremity osteosarcoma. BMC Cancer 14 : 666, 2014.
PubMed
15) Ogura K, et al : Development and external validation of nomograms predicting distant metastases and overall survival after neoadjuvant chemotherapy and surgery for patients with nonmetastatic osteosarcoma : A multi-institutional study. Cancer 121 : 3844-3852, 2015.
PubMed
16) Song K, et al : Prognostic nomograms for predicting overall and cancer-specific survival of high-grade osteosarcoma patients. J Bone Oncol 13 : 106-113, 2018.
PubMed
17) Chen W, Lin Y : Nomograms predicting overall survival and cancer-specific survival in osteosarcoma patients (STROBE). Medicine (Baltimore) 98 : e16141, 2019.
PubMed
18) Zhang J, et al : Development and validation of a nomogram for osteosarcoma-specific survival : A population-based study. Medicine (Baltimore) 98 : e15988, 2019.
PubMed
19) Chibon F, et al : Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to genome complexity. Nat Med 16 : 781-787, 2010.
PubMed
P.249 掲載の参考文献
1) Suit HD, et al : Management of patients with sarcoma of soft tissue in an extremity. Cancer 31 : 1247-1255, 1973.
 
2) Jaffe N, et al : Adjuvant methotrexate and citrovorum-factor treatment of osteogenic sarcoma. N Engl J Med 291 : 994-997, 1974.
PubMed
3) Enneking WF, et al : A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop Relat Res (153) : 106-120, 1980.
PubMed
4) Potter DA, et al : High-grade soft tissue sarcomas of the extremities. Cancer 58 : 190-205, 1986.
PubMed
5) Williard WC, et al : Comparison of amputation with limb-sparing operations for adult soft tissue sarcoma of the extremity. Ann Surg 215 : 269-275, 1992.
PubMed
6) Alamanda VK, et al : Amputation for extremity soft tissue sarcoma does not increase overall survival : a retrospective cohort study. Eur J Surg Oncol 38 : 1178-1183, 2012.
 
7) Enneking WF : Modification of the system for functional evaluation of surgical management of musculoskeletal tumors. In : Limb Salvage in Musculoskeletal Oncology (ed by Enneking WF), p626-639, Churchill Livingstone, New York, 1987.
 
8) Enneking WF, et al : A system for the functional evaluation of reconstructive procedures after surgical treatment of tumors of the musculoskeletal system. Clin Orthop Relat Res (286) : 241-246, 1993.
PubMed
9) 悪性骨腫瘍取扱い規約 [第3版], (日本整形外科学会骨・軟部腫瘍委員会編) 金原出版, 2000.
 
10) 日本整形外科学会 : ISOLS (International Society of Limb Salvage) /MSTS (Musculoskeletal Tumor Society) 機能評価表 (日本整形外科学会訳), 2012. [日本整形外科学会ホームページ会員専用ページ掲載]
 
11) Iwata S, et al : Reliability and Validity of a Japanese-language and Culturally Adapted Version of the Musculoskeletal Tumor Society Scoring System for the Lower Extremity. Clin Orthop Relat Res 474 : 2044-2052, 2016.
PubMed
12) Uehara K, et al : Reliability and Validity of the Musculoskeletal Tumor Society Scoring System for the Upper Extremity in Japanese Patients. Clin Orthop Relat Res 475 : 2253-2259, 2017.
PubMed
13) 神奈川県福祉子どもみらい局福祉部障害福祉課, 神奈川県立総合療育相談センター : 身体障害者診断書作成の手引き, p163-180, 神奈川県, 2018.
 
14) 小倉浩一 : 骨軟部腫瘍領域の患者立脚型アウトカム評価. Bone Joint Nerve 7 : 491-499, 2017.
Medical*Online
P.254 掲載の参考文献
1) Davis AM, et al : Development of a measure of physical function for patients with bone and soft tissue sarcoma. Qual Life Res 5 : 508-516, 1996.
PubMed
2) Saraiva D, et al : Cultural adaptation, translation and validation of a functional outcome questionnaire (TESS) to Portuguese with application to patients with lower extremity osteosarcoma. Pediatr Blood Cancer 50 : 1039-1042, 2008.
PubMed
3) Seebye C, et al : Validation of a Danish version of the Toronto Extremity Salvage Score questionnaire for patients with sarcoma in the extremities. Dan Med J 61 : A4734, 2014.
PubMed
4) Ogura K, et al : Cross-cultural adaptation and validation of the Japanese version of the Toronto Extremity Salvage Score (TESS) for patients with malignant musculoskeletal tumors in the lower extremities. J Orthop Sci 20 : 1098-1105, 2015.
PubMed
5) Akiyama T, et al : Cross-cultural adaptation and validation of the Japanese version of the Toronto Extremity Salvage Score (TESS) for patients with malignant musculoskeletal tumors in the upper extremities. J Orthop Sci 22 : 127-132, 2017.
PubMed
6) 秋山達ほか : 日本語版Toronto Extremity Salvage Score (TESS) -上肢の開発 : 言語的妥当性を担保した翻訳版の作成. 整形外科 67 : 933-937, 2016.
 
7) 小倉浩一, ほか : 日本語版Toronto Extremity Salvage Score下肢の開発 : 言語的妥当性を担保した翻訳版の作成. 整形外科 67 : 223-227, 2016.
 
P.260 掲載の参考文献
1) EORTC : Quality of Life. [https://qol.eortc.org/questionnaires/]
 
2) 福原俊一, 鈴鴨よしみ : SF-36v2 (日本語版マニュアル) [2019年4月版], iHope International, 2019.
 
3) Ogura K, et al : Development of a patient-oriented disease specific outcome measure of health-related quality of life (HRQOL) for musculoskeletal oncology patients. J Orthop Sci 24 : 539-547, 2019.
PubMed
4) Cohen J : Statistical Power Analysis for the Behavioral Sciences, Academic Press, New York, 1977.
 
P.266 掲載の参考文献
1) Nakata K, et al : Childhood cancer incidence and survival in Japan and England : A population-based study (1993-2010). Cancer Sci 109 : 422-434, 2018.
 
2) Bisogno G, et al : Maintenance low-dose chemotherapy in patients with high-risk (HR) rhabdomyosarcoma (RMS) : A report from the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG). J Clin Oncol 36 (18 Suppl) : LBA2, 2018.
 
3) Ferrari A, et al : Defining and listing very rare cancers of paediatric age : consensus of the Joint Action on Rare Cancers in cooperation with the European Cooperative Study Group for Pediatric Rare Tumors. Eur J Cancer 110 : 120-126, 2019.
 
4) Spunt SL, et al : Risk-based treatment for nonrhabdomyosarcoma soft tissue sarcomas (NRSTS) in patients under 30 years of age : Children's Oncology Group study ARST0332 [abstract]. J Clin Oncol 32 (15 Suppl) : 10008, 2014.
 
5) Venkatramani R, et al : Risk-based treatment for synovial sarcoma in patients under 30 years of age : Children's Oncology Group study ARST0332. J Clin Oncol 33 (15 Suppl) : 10012, 2015.
 
6) Kreimer SR, et al : Risk group accurately predicts outcome in primary extremity non-rhabdomyosarcoma soft tissue sarcomas (NRSTS) in patients < 30 years of age : Findings from Children's Oncology Group study ARST0332. J Clin Oncol 36 (15 Suppl) : 10546, 2018.
 
7) Waxweiler TV, et al : Non-Rhabdomyosarcoma Soft Tissue Sarcomas in Children : A Surveillance, Epidemiology, and End Results Analysis Validating COG Risk Stratifications. Int J Radiat Oncol Biol Phys 92 : 339-348, 2015.
PubMed
8) Orbach D, et al : Conservative strategy in infantile fibrosarcoma is possible : The European paediatric Soft tissue sarcoma Study Group experience. Eur J Cancer 57 : 1-9, 2016.
 
9) Laetsch TW, et al : Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions : phase 1 results from a multicentre, open-label, phase 1/2 study. Lancet Oncol 19 : 705-714, 2018.
 
10) DuBois SG, et al : The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas, Cancer 124 : 4241-4247, 2018.
PubMed
11) Informed consent, parental permission, and assent in pediatric practice. Committee on Bioethics, American Academy of Pediatrics. Pediatrics 95 : 314-317, 1995.
 
P.271 掲載の参考文献
1) 国立がん研究センターがん情報サービス : 「がん登録・統計」.
 
2) 日本整形外科学会骨軟部腫瘍委員会 : 全国軟部腫瘍登録一覧表, 平成27年度.
 
3) 日本整形外科学会骨軟部腫瘍委員会 : 全国骨腫瘍登録一覧表, 平成27年度.
 
4) 三菱UFJリサーチ&コンサルティング : 「がん治療と仕事の両立に関する調査」, 2016.
 
5) 平成27-29年度厚生労働科学研究がん対策推進総合研究事業「総合的な思春期・若年成人 (AYA) 世代のがん対策のあり方に関する研究」, 2017.
 
P.276 掲載の参考文献
1) Younger E, et al : Outcomes of Elderly Patients with Advanced Soft Tissue Sarcoma Treated with First-Line Chemotherapy : A Pooled Analysis of 12 EORTC Soft Tissue and Bone Sarcoma Group Trials. Oncologist 23 : 1250-1259, 2018.
PubMed
2) Nagano A, et al : Primary bone sarcomas in patients over 40 years of age : A retrospective study using data from the Bone Tumor Registry of Japan. J Orthop Sci 22 : 749-754, 2017.
PubMed
3) Wildiers H, et al : International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer. J Clin Oncol 32 : 2595-2603, 2014.
 
4) Extermann M, et al : Use of comprehensive geriatric assessment in older cancer patients : recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). Crit Rev Oncol Hematol 55 : 241-252, 2005.
PubMed
5) Decoster L, et al : Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients : an update on SIOG recommendations t. Ann Oncol 26 : 288-300, 2015.
 
6) Iwata S, et al : Prognostic factors in elderly osteosarcoma patients : a multi-institutional retrospective study of 86 cases. Ann Surg Oncol 21 : 263-268, 2014.
PubMed
7) Pakos EE, et al : The 'other' bone sarcomas : prognostic factors and outcomes of spindle cell sarcomas of bone. J Bone Joint Surg Br 93 : 1271-1278, 2011.
 
8) Grimer RJ, et al : Osteosarcoma over the age of forty. Eur J Cancer 39 : 157-163, 2003.
PubMed
9) Ferrari S, et al : EURO-B. O. S. S. : A European study on chemotherapy in bone-sarcoma patients aged over 40 : Outcome in primary high-grade osteosarcoma. Tumori 104 : 30-36, 2018.
 
10) Tanaka K, et al : Perioperative chemotherapy with ifosfamide and doxorubicin for high-grade soft tissue sarcomas in the extremities (JCOG0304). Jpn J Clin Oncol 45 : 555-561, 2015.
PubMed
11) Ogura K, et al : Statistics of soft-tissue sarcoma in Japan : Report from the Bone and Soft Tissue Tumor Registry in Japan. J Orthop Sci 22 : 755-764, 2017.
PubMed
12) Wilkinson KH, et al : Outcomes of Elderly Patients Undergoing Curative Resection for Retroperitoneal Sarcomas : Analysis From the US Sarcoma Collaborative, J Surg Res 233 : 154-162, 2019.
PubMed
13) Yoneda Y, et al : Favorable outcome after complete resection in elderly soft tissue sarcoma patients : Japanese Musculoskeletal Oncology Group study. Eur J Surg Oncol 40 : 49-54, 2014.
 
14) Al-Refaie WB, et al : Extremity soft tissue sarcoma care in the elderly : insights into the generalizability of NCI Cancer Trials. Ann Surg Oncol 17 : 1732-1738, 2010.
PubMed
15) Tsuchie H, et al : The prognostic significance of surgical treatment for excessive elderly patients with soft tissue sarcoma. Int J Clin Oncol 23 : 775-782, 2018.
PubMed
P.282 掲載の参考文献
1) Tanaka K, et al : Perioperative chemotherapy with ifosfamide and doxorubicin for high-grade soft tissue sarcomas in the extremities (JCOG0304). Jpn J Clin Oncol 45 : 555-561, 2015.
PubMed
2) Tanaka K, et al : Preoperative and postoperative chemotherapy with ifosfamide and adriamycin for adult high-grade soft-tissue sarcomas in the extremities : Japan Clinical Oncology Group Study JCOG0304. Jpn J Clin Oncol 39 : 271-273, 2009.
 
3) Pisters PW, et al : Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities. J Clin Oncol 14 : 1679-1689, 1996.
PubMed
4) Ravaud A, et al : Prognostic variables for the selection of patients with operable soft tissue sarcomas to be considered in adjuvant chemotherapy trials. Br J Cancer 66 : 961-969, 1992.
PubMed
5) Frustaci S, et al : Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles : results of the Italian randomized cooperative trial. J Clin Oncol 19 : 1238-1247, 2001.
 
6) Woll PJ, et al : Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931) : a multicentre randomised controlled trial. Lancet Oncol 13 : 1045-1054, 2012.
PubMed
7) Gortzak E, et al : A randomised phase II study on neo-adjuvant chemotherapy for 'high-risk' adult soft-tissue sarcoma. Eur J Cancer 37 : 1096-1103, 2001.
PubMed
8) Pervaiz N, et al : A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer 113 : 573-581, 2008.
PubMed
9) Gronchi A, et al : Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001) : an international, open-label, randomised, controlled, phase 3, multicentre trial. Lancet Oncol 18 : 812-822, 2017.
PubMed
P.289 掲載の参考文献
1) Link MP, et al : Adj uvant chemotherapy of high-grade osteosarcoma of the extremity. Updated results of the Multi-Institutional Osteosarcoma Study. Clin Orthop Relat Res (270) : 8-14, 1991.
 
2) Eilber F, et al : Adjuvant chemotherapy for osteosarcoma : a randomized prospective trial. J Clin Oncol 5 : 21-26, 1987.
 
3) Goorin AM, et al : Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma : Pediatric Oncology Group Study POG-8651. J Clin Oncol 21 : 1574-1580, 2003.
 
4) Meyers PA, et al : Osteosarcoma : The Addition of Muramyl Tripeptide to Chemotherapy Improves Overall Survival-A Report From the Children's Oncology Group. J Clin Oncol 26 : 633-638, 2008.
 
5) Piperno-Neumann S, et al : Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006) : a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol 17 : 1070-1080, 2016.
PubMed
6) Bielack SS, et al : Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP : First Results of the EURAMOS-1 Good Response Randomized Controlled Trial. J Clin Oncol 33 : 2279-2287, 2015.
PubMed
7) Marina NM, et al : Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1) : an open-label, international, randomised controlled trial. Lancet Oncol 17 : 1396-1408, 2016.
PubMed
8) Iwamoto Y, et al : Multiinstitutional phase II study of neoadjuvant chemotherapy for osteosarcoma (NECO study) in Japan : NECO-93J and NECO-95J. J Orthop Sci 14 : 397-404, 2009.
PubMed
P.295 掲載の参考文献
1) Kataoka K, et al : A randomized phase II/III trial of perioperative chemotherapy with adriamycin plus ifosfamide versus gemcitabine plus docetaxel for high-grade soft tissue sarcoma : Japan Clinical Oncology Group Study JCOG1306. Jpn J Clin Oncol 44 : 765-769, 2014.
 
2) Frustaci S, et al : Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles : results of the Italian randomized cooperative trial. J Clin Oncol 19 : 1238-1247, 2001.
 
3) Pervaiz N, et al : A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer 113 : 573-581, 2008.
PubMed
4) Woll PJ, et al : Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931) : a multicentre randomised controlled trial. Lancet Oncol 13 : 1045-1054, 2012.
PubMed
5) Gronchi A, et al : Short, full-dose adjuvant chemotherapy in high-risk adult soft tissue sarcomas : a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group. J Clin Oncol 30 : 850-856, 2012.
 
6) Tanaka K, et al : Preoperative and postoperative chemotherapy with ifosfamide and adriamycin for adult high-grade soft-tissue sarcomas in the extremities : Japan Clinical Oncology Group Study JCOG0304. Jpn J Clin Oncol 39 : 271-273, 2009.
 
7) Tanaka K, et al : Perioperative chemotherapy with ifosfamide and doxorubicin for high-grade soft tissue sarcomas in the extremities (JCOG0304). Jpn J Clin Oncol 45 : 555-561, 2015.
PubMed
8) Maki RG, et al : Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas : results of sarcoma alliance for research through collaboration study 002 [corrected]. J Clin Oncol 25 : 2755-2763, 2007.
PubMed
9) Davis EJ, et al : A randomised, open-label, phase II study of neo/adjuvant doxorubicin and ifosfamide versus gemcitabine and docetaxel in patients with localised, high-risk, soft tissue sarcoma, Eur J Cancer 51 : 1794-1802, 2015.
PubMed
10) Frustaci S, et al : Ifosfamide in the adjuvant therapy of soft tissue sarcomas. Oncology 65 (Suppl 2) : 80-84, 2003.
 
11) Gronchi A, et al : Short, full-dose adjuvant chemotherapy (CT) in high-risk adult soft tissue sarcomas (STS) : long-term follow-up of a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group. Ann Oncol 27 : 2283-2288, 2016.
PubMed
12) Tanaka K, et al : Ten-year follow-up results of perioperative chemotherapy with doxorubicin and ifosfamide for high-grade soft-tissue sarcomas of the extremities : Japan Clinical Oncology Group study JCOG0304. BMC Cancer 19 : 890, 2019.
 
13) Gronchi A, et al : Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001) : an international, open-label, randomised, controlled, phase 3, multicentre trial. Lancet Oncol 18 : 812-822, 2017.
PubMed
P.302 掲載の参考文献
1) Wittekind C, et al : TNM residual tumor classification revisited. Cancer 94 : 2511-2516, 2002.
PubMed
2) 骨・軟部肉腫切除縁評価法 [第1版] (日本整形外科学会骨・軟部腫瘍委員会編), 金原出版, 1989.
 
3) 川口智義, ほか : 悪性軟部腫瘍の根治的広切法についての検討. 臨床整形外科 17 : 1192-1206, 1982.
 
4) Kawaguchi N, et al : The concept of Curative Margin in surgery for Bone and Soft Tissue Sarcoma. Clin Orthop Relat Res (419) : 165-172, 2004.
 
5) Modern Surgical Challenges for Musculoskeletal Sarcoma Vol 21, Proceeding from the 28th Annual Meeting of Surgical Treatment for Musculoskeletal Sarcoma, Surgical Society for Musculoskeletal Sarcoma, Cancer Institute Hospital, Japanese Foundation Cancer Research, 2019.
 
6) 整形外科・病理 悪性軟部腫瘍取扱い規約 [第2版] (日本整形外科学会骨・軟部腫瘍委員会編), 金原出版, 1989.
 
7) Gundle KR, et al : Analysis of Margin Classification Systems for Assessing the Risk of Local Recurrence After Soft Tissue Sarcoma Resection. J Clin Oncol 36 : 704-709, 2018.
PubMed
P.308 掲載の参考文献
1) Fanburg-Smith JC, et al : Infiltrative subcutaneous malignant fibrous histiocytoma : a comparative study with deep malignant fibrous histiocytoma and an observation of biologic behavior. Ann Diagn Pathol 3 : 1-10, 1999.
 
2) Song B, et al : Prognostic significance of microscopic tumor extension in local recurrence of myxofibrosarcoma and undifferentiated pleomorphic sarcoma. Pathol Int 68 : 509-516, 2018.
PubMed
3) 松本誠一 : 軟部悪性線維性組織球腫の診断と治療-浸潤性発育の定義に関する考察-. 日本整形外科学会雑誌 86 : 641-646, 2012.
 
4) Iwata S, et al : Optimal surgical margin for infiltrative soft tissue sarcomas : Assessing the efficacy of excising beyond the infiltration. J Surg Oncol 118 : 525-531, 2018.
PubMed
5) Iwata S, et al : Impact of infiltrative growth on the outcome of patients with undifferentiated pleomorphic sarcoma and myxofibrosarcoma. J Surg Oncol 110 : 707-711, 2014.
PubMed
6) Kikuta K, et al : An analysis of factors related to the tail-like pattern of myxofibrosarcoma seen on MRI. Skeletal Radiol 44 : 55-62, 2015.
 
7) Look Hong NJ, et al : Prognostic factors and outcomes of patients with myxofibrosarcoma. Ann Surg Oncol 20 : 80-86, 2013.
PubMed
8) Sambri A, et al : Does pre-operative MRI predict the risk of local recurrence in primary myxofibrosarcoma of the extremities? Asia Pac J Clin Oncol 15 : e181-e186, 2019.
PubMed
9) Sambri A, et al : Surgical margins do not affect prognosis in high grade myxofibrosarcoma. Eur J Surg Oncol 42 : 1042-1048, 2016.
 
10) Lin CN, et al : Prognostic factors of myxofibrosarcomas : implications of margin status, tumor necrosis, and mitotic rate on survival. J Surg Oncol 93 : 294-303, 2006.
PubMed
11) Dewan V, et al : Prognostic and survival factors in myxofibrosarcomas. Sarcoma 2012 : 830879, 2012.
PubMed
12) Haglund KE, et al : Recurrence patterns and survival for patients with intermediate- and high-grade myxofibrosarcoma. Int J Radiat Oncol Biol Phys 82 : 361-367, 2012.
PubMed
13) Matsumoto S, et al : Results of surgery for malignant fibrous histiocytomas of soft tissue. Int J Clin Oncol 8 : 104-109, 2003.
PubMed
14) Sanfilippo R, et al : Myxofibrosarcoma : prognostic factors and survival in a series of patients treated at a single institution. Ann Surg Oncol 18 : 720-725, 2011.
 
15) Mutter RW, et al : The enigma of myxofibrosarcoma of the extremity. Cancer 118 : 518-527, 2012.
PubMed
16) Waters B, et al : Low-grade myxofibrosarcoma : CT and MRI patterns in recurrent disease. AJR Am J Roentgenol 188 : W193-198, 2007.
PubMed
17) Kaya M, et al : MRI and histological evaluation of the infiltrative growth pattern of myxofibrosarcoma. Skeletal Radiol 37 : 1085-1090, 2008.
PubMed
18) Imanishi J, et al : Tail of Superficial Myxofibrosarcoma and Undifferentiated Pleomorphic Sarcoma After Preoperative Radiotherapy. Anticancer Res 36 : 2339-2344, 2016.
PubMed
19) White LM, et al : Histologic assessment of peritumoral edema in soft tissue sarcoma. Int J Radiat Oncol Biol Phys 61 : 1439-1445, 2005.
PubMed
20) Riouallon G, et al : Superficial myxofibrosarcoma : assessment of recurrence risk according to the surgicai margin following resection. A series of 21 patients. Orthop Traumatol Surg Res 99 : 473-477, 2013.
 
21) Boughzala-Bennadji R, et al : Localized Myxofibrosarcomas : Roles of Surgical Margins and Adjuvant Radiation Therapy. Int J Radiat Oncol Biol Phys 102 : 399-406, 2018.
PubMed
22) Kikuta K, et al : Discoidin, CUB and LCCL domain-containing protein 2 (DCBLD2) is a novel biomarker of myxofibrosarcoma invasion identified by global protein expression profiling. Biochim Biophys Acta Proteins Proteom 1865 : 1160-1166, 2017.
PubMed
23) Callegaro D, et al : Impact of perioperative chemotherapy and radiotherapy in patients with primary extremity soft tissue sarcoma : retrospective analysis across major histological subtypes and major reference centres. Eur J Cancer 105 : 19-27, 2018.
 
24) Manoso MW, et al : Infiltrative MRI pattern and incomplete initial surgery compromise local control of myxofibrosarcoma. Clin Orthop Relat Res 450 : 89-94, 2006.
PubMed
P.314 掲載の参考文献
1) Matsumoto S, et al : "In situ preparation" : new surgical procedure indicated for soft-tissue sarcoma of a lower limb in close proximity to major neurovascular structures. Int J Clin Oncol 7 : 51-56, 2002.
PubMed
2) 骨・軟部肉腫切除縁評価法 (第1版) (日本整形外科学会骨・軟部腫瘍委員会編), 金原出版, 1989.
 
3) 阿江啓介, ほか : In situ preparation法 (ISP法). 整形・災害外科 61 : 1091-1100, 2018.
 
P.320 掲載の参考文献
1) Krettek C, et al : Computer aided tumor resection in the pelvis. Injury 35 (Suppl 1) S-A79-83, 2004.
 
2) Wong KC, Kumta SM : Use of Computer Navigation in Orthopedic Oncology. Curr Surg Rep 2 : 47, 2014.
PubMed
3) Ieguchi M, et al : Navigation-assisted surgery for bone and soft tissue tumors with bony extension. Clin Orthop Relat Res 470 : 275-283, 2012.
PubMed
4) Cho HS, et al : Joint-preserving limb salvage surgery under navigation guidance. J Surg Oncol 100 : 227-232, 2009.
PubMed
5) Nandra R, et al : Long-term outcomes after an initial experience of computer-navigated resection of primary pelvic and sacral bone tumours : soft-tissue margins must be adequate to reduce local recurrences. Bone Joint J 101-B : 484-490, 2019.
PubMed
6) Young PS, et al : The evolving role of computer-assisted navigation in musculoskeletal oncology. Bone Joint J 97-B : 258-264, 2015.
 
7) 国定俊之, ほか : ナビゲーション : 四肢, 脊椎. スタンダード小児がん手術 : 臓器別アプローチと手技のポイント (田口智章, 黒田達夫編), p117-120, メジカルビュー社, 2017.
 
8) Fujiwara T, et al : Intraoperative O-arm-navigated resection in musculoskeletal tumors. J Orthop Sci 23 : 1045-1050, 2018.
PubMed
9) Zhang W, et al : Accuracy of pedicle screw insertion in posterior scoliosis surgery : a comparison between intraoperative navigation and preoperative navigation techniques. Eur Spine J 26 : 1756-1764, 2017.
PubMed
10) Kunisada T, et al : Temporary External Fixation Can Stabilize Hip Transposition Arthroplasty After Resection of Malignant Periacetabular Bone Tumors. Clin Orthop Relat Res 477 : 1892-1901, 2019.
PubMed
11) Sternheim A, et al : Navigated pelvic osteotomy and tumor resection : a study assessing the accuracy and reproducibility of resection planes in Sawbones and cadavers. J Bone Joint Surg Am 97 : 40-46, 2015.
PubMed
12) Farfalli GL, et al : What Is the Expected Learning Curve in Computer-assisted Navigation for Bone Tumor Resection? Clin Orthop Relat Res 475 : 668-675, 2017.
PubMed
13) Konieczny MR, Krauspe R : Navigation Versus Fluoroscopy in Multilevel MIS Pedicle Screw Insertion : Separate Analysis of Exposure to Radiation of the Surgeon and of the Patients. Clin Spine Surg 32 : E258-E265, 2019.
 
14) Cheng EY, et al : Radiation dosimetry of intraoperative cone-beam compared with conventional CT for radiofrequency ablation of osteoid osteoma. J Bone Joint Surg Am 96 : 735-742, 2014.
PubMed
15) Ieguchi M : CORR Insights : Can Navigation-assisted Surgery Help Achieve Negative Margins in Resection of Pelvic and Sacral Tumors? Clin Orthop Relat Res 476 : 509-510, 2018.
PubMed
P.324 掲載の参考文献
1) Yang Y, et al : Advances in limb salvage treatment of osteosarcoma. J Bone Oncol 10 : 36-40, 2018.
PubMed
2) Ferrari S, et al : Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in nonmetastatic osteosarcoma of the extremity : an Italian sarcoma group trial ISG/OS-1. J Clin Oncol 30 : 2112-2118, 2012.
 
3) Ogura K, et al : Statistics of bone sarcoma in Japan : Report from the Bone and Soft Tissue Tumor Registry in Japan. J Orthop Sci 22 : 133-143, 2017.
PubMed
4) Fukushima T, et al : Descriptive epidemiology and outcomes of bone sarcomas in adolescent and young adult patients in Japan. BMC Musculoskelet Disord 19 : 297, 2018.
 
5) Ogihara Y, et al : Current management, local management, and survival statistics of high-grade osteosarcoma. Experience in Japan. Clin Orthop Relat Res (270) : 72-78, 1991.
PubMed
6) Brown TS, et al : Reconstruction of the hip after resectionof periacetabular oncological lesions : a systematic review. Bone Joint J 100-B : 22-30, 2018.
 
7) Ogura K, et al : Reconstruction using a constrained-type hip tumor prosthesis after resection of malignant periacetabular tumors : A study by the Japanese Musculoskeletal Oncology Group (JMOG). J Surg Oncol 117 : 1455-1463, 2018.
PubMed
8) Calabro T, et al : Reconstruction of the proximal femur with a modular resection prosthesis. Eur J Orthop Surg Traumatol 26 : 415-421, 2016.
PubMed
9) Pala E, et al : Survival of modern knee tumor megaprostheses : failures, functional results, and a comparative statistical analysis. Clin Orthop Relat Res 473 : 891-899, 2015.
 
10) Nakamura T, et al : Clinical outcomes of Kyocera Modular Limb Salvage system after resection of bone sarcoma of the distal part of the femur : the Japanese Musculoskeletal Oncology Group study. Int Orthop 38 : 825-830, 2014.
 
11) Farfalli GL, et al : Early equivalence of uncemented press-fit and Compress femoral fixation. Clin Orthop Relat Res 467 : 2792-2799, 2009.
PubMed
12) Zhang C, et al : Survival, complications and functional outcomes of cemented megaprostheses for high-grade osteosarcoma around the knee. Int Orthop 42 : 927-938, 2018.
PubMed
13) Niimi R, et al : Prosthetic limb salvage surgery for bone and soft tissue tumors around the knee, Oncol Rep 28 : 1984-1990, 2012.
PubMed
14) Sevelda F, et al : Total Femur Replacement After Tumor Resection : Limb Salvage Usually Achieved But Complications and Failures are Common. Clin Orthop Relat Res 473 : 2079-2087, 2015.
PubMed
15) Kakimoto T, et al : The clinical outcomes of total femur prosthesis in patients with musculoskeletal tumors. SICOT J 5 : 23, 2019.
PubMed
16) 濱田健一郎, ほか : 下肢原発骨肉腫に対する外科的治療. 日本小児血液・がん学会雑誌 52 : 289-293, 2015.
Medical*Online
P.332 掲載の参考文献
1) 整形外科・病理悪性軟部腫瘍取扱い規約 [第3版] (日本整形外科学会 骨・南部腫瘍委員会編), 金原出版, 2002.
 
2) Schunke M, et al : Prometheus. LernAtlas der Anatomie, Georg Thieme Verlag, Stuttgart, 2009. [プロメテウス解剖学アトラス 解剖学総論/連動器系 [第2版] (坂井建雄, 松村讓兒監訳). 医学書院 2011.]
 
3) Moore KL, Dalley AF : Clinically Oriented Anatomy, 5th ed, Lippincott Willialns and Wilkins, Philadelphia, 2006. [臨床のための解剖学 (佐藤達夫, 坂井建雄監訳), メディカル・サイエンス・インターナショナル, 2008. ]
 
4) 松本誠一, ほか : 悪性骨・軟部腫瘍術後の長期的な機能. 日本整形外科学会雑誌 85 : 196-201, 2011.
Medical*Online
P.337 掲載の参考文献
1) Manabe J, et al : Pasteurized autologous bone graft in surgery for bone and soft tissue sarcoma. Clin Orthop Relat Res 419 : 258-266, 2004.
 
2) Lee SY, et al : Are Pasteurized Autografts Durable for Reconstructions After Bone Tumor Resections? Clin Orthop Relat Res 476 : 1728-1737, 2018.
PubMed
3) Rong Y, et al : Effect of elevated temperature on experimental swarm rat chondrosarcoma. Clin Orthop Relat Res 311 : 227-231, 1995.
PubMed
4) Shimizu K, et al : Revascularization and new bone formation in heat-treated bone grafts. Arch Orthop Trauma Surg 119 : 57-61, 1999.
PubMed
5) 中島浩敦, ほか : 加温処理骨を用いた骨盤悪性骨腫瘍切除後の再建とその成績. 整形・災害外科 56 : 97-101, 2013.
 
6) Sugiura H, et al : Evaluation of long-term outcomes of pasteurized autografts in limb salvage surgeries for bone and soft tissue sarcomas. Arch Orthop Trauma Surg 132 : 1685-1695, 2012.
PubMed
7) Eid AS, et al : Can bone scintigraphy predict the final outcome of pasteurized autografts? Skeletal Radiol 39 : 1009-1016, 2010.
PubMed
8) Sugiura H, et al : Remodelling and healing process of moderately heat-treated bone grafts after wide resection of bone and soft-tissue tumors. Arch Orthop Trauma Surg 123 : 514-520, 2003.
PubMed
9) Ehara S, et al : Pasteurized intercalary autogenous bone graft : radiographic and scintigraphic features. Skeletal Radiol 29 : 335-339, 2000.
PubMed
10) Jeon DG, et al : Pasteurized autograft for intercalary reconstruction : an alternative to allograft. Clin Orthop Relat Res 456 : 203-210, 2007.
PubMed
11) Sugiura H, et al : Pasteurized intercalary autogenous bone graft combined with vascularized fibula. Clin Orthop Relat Res 456 : 196-202, 2007.
PubMed
12) Kubo T, et al : Histological findings in a human autogenous pasteurized bone graft. Anticancer Res 24 : 1893-1896, 2004.
 
13) Nishida Y, et al : Vascularized fibular flaps enhance histological repair in pasteurized autogenous bone graft. Ann Plast Surg 67 : 416-420, 2011.
PubMed
14) Ikuta K, et al : Predictors of complications in heat-treated autograft reconstruction after intercalary resection for malignant musculoskeletal tumors of the extremity. J Surg Oncol 117 : 1469-1478, 2018.
PubMed
15) Jeon DG, et al : Pasteurized autograft-prosthesis composite for distal femoral osteosarcoma. J Orthop Sci 12 : 542-549, 2007.
PubMed
P.344 掲載の参考文献
1) Tsuchiya H, et al : Marginal Excision for osteosarcoma with caffeine assisted chemotherapy. Clin Orthop Relat Res (358) : 27-35, 1999.
PubMed
2) Kanazawa Y, et al : Intentional marginal excision of osteosarcoma of the proximal fibula to preserve limb function. J Orthop Sci 8 : 757-761, 2003.
PubMed
3) 山本憲男, ほか : Kotz下肢再建システム使用時の股関節外転筋力温存の工夫. 臨床整形外科 35 : 983-987, 2000.
 
4) 山本憲男 : 液体窒素処理自家腫瘍骨の移植に関する実験的研究. 金沢大学十全医学会雑誌 109 : 193-202, 2000.
Medical*Online
5) Yamamoto N, et al : Effects of liquid nitrogen treatment on the proliferation of osteosarcoma and the biomechanical properties of normal bone. J Orthop Sci 8 : 374-380, 2003.
 
6) Tsuchiya H, et al : Reconstruction using an autograft containing tumour treated by liquid nitrogen. J Bone Joint Surg Br 87 : 218-225, 2005.
PubMed
7) Gede EWI, et al : Outcome of bone recycling using liquid nitrogen as bone reconstruction procedure in malignant and recurrent benign aggressive bone tumour of distal tibia : A report of four cases. J Orthop Surg (Hong Kong) 25 : 2309499017713940, 2017.
 
8) Chen WM, et al : High-grade osteosarcoma treated with hemicortical resection and biological reconstruction. J Surg Oncol 105 : 825-829, 2012.
PubMed
9) 金澤智子, ほか : 液体窒素処理骨による再建を行ったEwing肉腫の1例. 日本整形外科学会雑誌 85 : S914, 2011.
Medical*Online
10) 前原博樹, ほか : 液体窒素処理骨およびVAF flapを用いて膝関節機能を温存し得た多形脂肪肉腫の1例. 整形外科と災害外科 59 (Suppl 1) : 75, 2010.
 
11) 木谷彰岐, ほか : 膝関節周囲悪性骨・軟部腫瘍切除後に液体窒素処理骨のcomposite graftを用いて再建した2症例. 日本整形外科学会雑誌 83 : S907, 2009.
Medical*Online
12) Sakayama K, et al : Pathological findings of an autograft containing osteosarcoma treated by liquid nitrogen retrieved 2 years after implantation. J Orthop Sci 11 : 655-656, 2006.
PubMed
13) Tanzawa Y, et al : Histological examination of frozen autograft treated by liquid nitrogen removed after implantation. J Orthop Sci 14 : 761-768, 2009.
PubMed
14) Yamamoto N, et al : Histological study on liquid nitrogen-treated tumor-bearing bone of the proximal femur excised eight years after transplantation. Low Temp Med 38 : 5-8, 2012.
 
15) 荒木麗博, ほか : 移植後2年半で摘出した高齢者の大腿骨近位液体窒素処理骨の組織学的検討. 整形外科と災害外科 66 : 877-881, 2017.
Medical*Online
16) Tsuchiya H, et al : Pedicle frozen autograft reconstruction in malignant bone tumors. J Orthop Sci 15 : 340-349, 2010.
PubMed
17) Li J, et al : Extracorporeally frozen tumour-bearing bone combined with free vascularised fibula for the intercalary reconstruction of femoral defect after resection of bony sarcoma. J Plast Reconstr Aesthet Surg 69 : 856-863, 2016.
PubMed
P.350 掲載の参考文献
1) 全国骨腫瘍登録一覧表 [平成27年度] (日本整形外科学会骨軟部腫瘍委員会編), 国立がん研究センター, 2015.
 
2) Iwamoto Y, et al : Multiinstitutional phase II study of neoadjuvant chemotherapy for osteosarcoma (NECO study) in Japan : NECO-93J and NECO-95J. J Orthop Sci 14 : 397-404, 2009.
PubMed
3) Weber KL : What's new in musculoskeletal oncology. J Bone Joint Surg Am 87 : 1400-1410, 2005.
 
4) Panagopoulos GN, et al : Intercalary reconstructions after bone tumor resections : a review of treatments. Eur J Orthop Surg Traumatol 27 : 737-746, 2017.
PubMed
5) 畠野宏史, ほか : 過去50年間の骨肉腫治療の検討. 県立がんセンター新潟病院医誌 50 : 80-84, 2011.
Medical*Online
6) 占部憲 : 日本の骨バンクの現状と課題. 整形・災害外科 61 : 1545-1551, 2018.
 
7) 松村崇, ほか : 血管柄付き遊離腓骨と加温処理骨を併用した脛骨悪性骨腫瘍の再建術. 日本形成外科学会会誌 28 : 641-647, 2008.
 
8) 吉村康夫 : 悪性軟部腫瘍の診断と治療. 信州医学雑誌 60 : 67-77, 2012.
Medical*Online
9) 中川雅裕, ほか : 四肢悪性腫瘍における再建の戦略. 日本マイクロサージャリー学会会誌 24 : 367-376, 2011.
 
10) 鳥山和宏, ほか : 四肢悪性骨軟部腫瘍切除後の皮弁による再建術の経験-遊離皮弁の適応について-. 創傷 5 : 181-188, 2014.
 
11) Weiland AJ, et al : Application of the free vascularized bone graft in the treatment of malignant or aggressive bone tumors. Johns Hopkins Med J 140 : 85-96, 1977.
 
12) Moreira-Gonzalez A, et al : Considerations surrounding reconstruction after resection of musculoskeletal sarcomas. Cleve Clin J Med 77 (Suppl 1) : S18-22, 2010.
 
13) Onoda S, et al : Use of vascularized free fibular head grafts for upper limb oncologic reconstruction. Plast Reconstr Surg 127 : 1244-1253, 2011.
PubMed
14) Miyamoto S, et al : Comparative study of different combinations of microvascular anastomoses in a rat model : end-to-end, end-to-side, and flow-through anastomosis. Plast Reconstr Surg 122 : 449-455, 2008.
 
15) Stokke J, et al : Systematic review and meta-analysis of objective and subjective quality of life among pediatric, adolescent, and young adult bone tumor survivors. Pediatr Blood Cancer 62 : 1616-1629, 2015.
 
P.356 掲載の参考文献
1) Matsubara H, Tsuchiya H : Management of juxtaphyseal malignanat bone tumors around the knee joint : New concepts in limb-sparing surgery. In : Pediatric Lower Limb Deformities : Principles and Techniques of Management (ed by Sabharwal S), p349-358, Springer International Publishing, Cham, 2016.
 
2) Matsubara H, Tsuchiya H : Biological reconstruction for extremity osteosarcoma : Distraction osteogenesis technique. In : Osteosarcoma (ed by Ueda T, Kawai A), p209-218, Springer Japan, Tokyo, 2016.
 
3) Watanabe K, et al : Over 10-year follow-up of functional outcome in patients with bone tumors reconstructed using distraction osteogenesis. J Orthop Sci 18 : 101-109, 2013.
PubMed
4) Tsuchiya H, et al : Osteosarcoma around the knee : Intraepiphyseal excision and biological reconstruction with distraction osteogenesis. J Bone Joint Surg Br 84 : 1162-1166, 2002.
PubMed
P.360 掲載の参考文献
1) Borggreve J : Kniegelenksersatz durch das in der Beinlangsachse um 180°gedrehte Fuβgelenk. Arch Orthop Unfall Chir 28 : 175-178, 1930.
 
2) Van Nes CP : Rotation-plasty for congenital defects of the femur : Making use of the ankle of the shortened limb to control the knee joint of a prosthesis. J Bone Joint Surg 32-B : 12-16, 1950.
 
3) Kotz R, et al : Rotation-plasty for childhood osteosarcoma of the distal part of the femur. J Bone Joint Surg Am 64 : 959-969, 1982.
PubMed
4) Winkelmann WW : Hip rotationplasty for malignant tumors of the proximal part of the femur. J Bone Joint Surg Am 68 : 362-369, 1986.
PubMed
5) 米本司, ほか : 骨腫瘍切除後の人工関節によらない下肢機能の再建 : rotationplastyについて. 別冊整形外科 43 : 124-129, 2003.
 
6) Yonemoto T, et al : Knee rotation-plasty for malignant musculoskeletal tumors occurring around the knee joint. Anticancer Res 21 : 717-722, 2001.
PubMed
7) Perez-Garcia A, et al : Free microvascular rotationplasty with nerve repair for rhabdomyosarcoma in a 18-month-old patient. Microsurgery 37 : 344-347, 2017.
 
8) Morri M, Forni C : Rotationplasty in adult cancer patients : what is the rehab strategy and what results can be expected? A case study. Prosthet Orthot Int 41 : 517-521, 2017.
PubMed
9) 嶋田洋平, ほか : 脛骨骨肉腫の人工関節感染に対して膝回転形成術を施行した1例. 日本整形外科学会雑誌 92 : S1494, 2018.
Medical*Online
P.365 掲載の参考文献
1) Tomita K, et al : Total en bloc spondylectomy for solitary spinal metastases, Int Orthop 18 : 291-298, 1994.
PubMed
2) Tomita K, et al : Total en bloc spondylectomy and circumspinal decompression for solitary spinal metastasis. Paraplegia 32 : 36-46, 1994.
PubMed
3) Tomita K, Kawahara N : The threadwire saw : a new device for cutting bone. J Bone Joint Surg Am 78 : 1915-1917, 1996.
 
4) Kawahara N, et al : Total en bloc spondylectomy for spinal tumors : surgical techniques and related basic background. Orthop Clin North Am 40 : 47-63, vi, 2009.
PubMed
5) Tomita K, et al : Total en bloc spondylectomy for spinal tumors : improvement of the technique and its associated basic background. J Orthop Sci 11 : 3-12, 2006.
PubMed
6) 村上英樹 : 凍結免疫療法を併用した新しい脊椎腫瘍根治手術の開発. 金沢大学十全医学会雑誌 120 : 67-71, 2011.
Medical*Online
7) Tsuchiya H, et al : Reconstruction using an autograft containing tumour treated by liquid nitrogen. J Bone Joint Surg Br 87 : 218-225, 2005.
PubMed
8) Kawano M, et al : Cryoimmunologic antitumor effects enhanced by dendritic cells in osteosarcoma. Clin Orthop Relat Res 468 : 1373-1383, 2010.
PubMed
9) Nishida H, et al : Re-implantation of tumour tissue treated by cryotreatment with liquid nitrogen induces anti-tumour activity against murine osteosarcoma. J Bone Joint Surg Br 90 : 1249-1255, 2008.
PubMed
10) Nishida H, et al : Cryoimmunology for malignant bone and soft-tissue tumors. Int J Clin Oncol 16 : 109-117, 2011.
PubMed
11) Tsuchiya H, et al : Pedicle frozen autograft reconstruction in malignant bone tumors. J Orthop Sci 15 : 340-349, 2010.
PubMed
12) Alblin RJ, et al : Prospects for cryo-immunotherapy in cases of metastasizing carcinoma of the prostate. Cryobiology 8 : 271-279, 1971.
PubMed
13) Osada S, et al : Serum cytokine levels in response to hepatic cryoablation. J Surg Oncol 95 : 491-498, 2007.
PubMed
14) Sabel MS, et al : Immunologic response to cryoablation of breast cancer. Breast Cancer Res Treat 90 : 97-104, 2005.
PubMed
P.376 掲載の参考文献
1) 局所皮弁LOCAL FLAPS [第1巻] 顔面・頸部・体幹 (小川令, ほか編), 克誠堂出版, 2017.
 
2) 小野慎平, ほか : 皮膚欠損の修復法-局所皮弁法. アトラス形成外科手術手技 (百束比古編), p46-55, 中外医学社, 2011.
 
3) 中嶋英雄, ほか : 皮弁の概念と分類. 皮弁・筋皮弁実践マニュアル (波利井清紀編), p16-25, 全日本病院出版会, 2002.
 
4) 平林慎一, ほか : 形成手術手技-組織移植術. 標準形成外科学 [第6版] (平林慎一, 鈴木茂彦編), p34-46, 医学書院, 2011.
 
5) 秋元正宇, ほか : Z形成術とそのバリエーション. PEPARS No. 58 (Local flap method), p1-10, 全日本病院出版会, 2011.
 
6) 百束比古, ほか : 顔面頸部の穿通枝皮弁. PEPARS No. 37 (穿通枝皮弁マニュアル), p20-30, 全日本病院出版会, 2010.
 
7) 佐武俊彦, ほか : 下腹部の動脈皮弁・鼠径部の穿通枝至便の挙上法と臨床応用. PEPARS No. 37 (穿通枝皮弁マニュアル), p49-59, 全日本病院出版会, 2010.
 
8) 市田正成 : 皮弁作成術の基本・瘢痕形成術の基本. スキル外来手術アトラス [改題第3版], p57-84, 文光堂, 2006.
 
9) 柴田実, ほか : 手部再建における皮弁の選択. 皮弁・筋皮弁実践マニュアル (波利井清紀編), p182-198, 全日本病院出版会, 2002.
 
10) 光嶋勲, ほか : 大腿部の皮弁. 形成外科ADVANCE SERIES I-4 皮弁移植法 : 最近の進歩 (鳥居修平編), p172-182, 克誠堂出版, 1994.
 
11) 林裕司, ほか : 下腿における皮弁・筋膜皮弁. 形成外科ADVANCE SERIES I-4 皮弁移植法 : 最近の進歩 (鳥居修平編), p194-203, 克誠堂出版, 1994.
 
12) Kiyokawa K, et al : A method that preserves circulation during preparation of the pectoralis major myocutaneous flap in head and neck reconstruction. Plast Reconstr Surg 102 : 2336-2345, 1998.
PubMed
13) Limberg AA : The Planning of Local Plastic Operations on the Body Surface, Collamore Press, Lexington, 1984.
 
P.383 掲載の参考文献
1) 桜井裕之, ほか : 日本・形成外科学会「2004皮弁分類」について. 形成外科 48 : 717-728, 2005.
 
2) Clark MA, et al : Soft-tissue sarcomas in adults. N Engl J Med 353 : 701-711, 2005.
PubMed
3) Tansini I : Sopra il mio nuovo processo di amputazione della mammela. Gaz Med Ital 57 : 141, 1906.
 
4) Angrigiani C, et al : Latissimus dorsi musculocutaneous flap without muscle. Plast Reconstr Surg 96 : 1608-1614, 1995.
PubMed
5) Ariyan S : The pectoralis major myocutaneous flap. A versatiie flap for reconstruction in the head and neck. Plast Reconstr Surg 63 : 73-81, 1979.
PubMed
6) Rikimaru H, et al : New method of preparing a pectoralis major myocutaneous flap with a skin paddle that includes the third intercostal perforating branch of the internal thoracic artery. Plast Reconstr Surg 123 : 1220-1228, 2009.
PubMed
7) Koshima I, Soeda S : Inferior epigastric artery skin flaps without rectus abdominis muscle. Br J Plast Surg 42 : 645-648, 1989.
PubMed
8) 田中克己 : 鼠径皮弁の基礎と応用. PEPARS (118) : 46-56, 2016.
 
9) Song R, et al : The forearm flap. Clin Plast Surg 9 : 21-26, 1982.
PubMed
10) Song YG, et al : The free thigh flap : a new free flap concept based on the septocutaneous artery. Br J Plast Surg 37 : 149-159, 1984.
PubMed
11) Mavrogenis AF, et al : Proximal tibial resections and reconstructions : clinical outcome of 225 patients. J Surg Oncol 107 : 335-342, 2013.
PubMed
P.388 掲載の参考文献
1) 軟部肉腫の手術. 軟部腫瘍診療ガイドライン 2012 (日本整形外科学会診療ガイドライン委員会, 軟部腫瘍診療ガイドライン策定委員会編), p80-82, 南江堂, 2012.
 
2) 柏克彦, ほか : 肩甲下動脈皮弁-肩甲皮弁, 広背筋皮弁, 肩甲骨弁, 肋骨弁-. 使える皮弁術 [下巻] (百束比古, 中島龍夫編), p26-37, 全日本病院出版会, 2010.
 
3) Kimata Y, et al : Anterolateral thigh flap donor-site complications and morbidity. Plast Reconstr Surg 106 : 584-589, 2000.
PubMed
4) 木股敬裕, ほか : 腹壁全層欠損の再建術-遊離皮弁・筋皮弁 (前外側大腿皮弁の利用) -形成外科 41 (増刊号) : S169-175, 1998.
 
5) 酒井成身 : 拡大広背筋皮弁による乳房再建. 形成外科 53 : 1339-1348, 2010.
 
6) 武石明精 : 術中ICG (インドシアニングリーン) 造影による遊離腹直筋皮弁生着領域の検討. 乳癌の臨床 25 : 716-717, 2011.
 
7) 武石明精, 石田勝大 : 腹直筋皮弁. 使える皮弁術 [下巻] (百束比古, 中島龍夫編), p43-48, 全日本病院出版会, 2010.
 
8) 矢野健二 : DIEP flap. 使える皮弁術 [下巻] (百束比古, 中島龍夫編), p49-56, 全日本病院出版会, 2010.
 
9) Wettstein R, et al : Laser scanning evaluation of atrophy after autologous free muscle transfer. Ann Plast Surg 72 : 680-684, 2014.
PubMed
10) 土屋沙緒, ほか : 広背筋皮弁を用いた悪性腫瘍切除後の肘屈筋機能再建の2例. 形成外科 50 : 557-564, 2007.
 
11) 服部泰典, 土井一輝 : 【整形外科手術に役立つ皮弁とそのコツ】遊離皮弁 筋弁・筋皮弁 薄筋皮弁. Orthopaedics 21 : 129-133, 2008.
 
12) Miyamoto S, et al : Free flow-through anterolateral thigh flap for complex knee defect including the popliteal artery. Microsurgery 35 : 485-488, 2015.
PubMed
13) Fujiki M, et al : Flow-through anastomosis for both the artery and vein in leg free flap transfer. Microsurgery 35 : 536-540, 2015.
PubMed
14) Maricevich M, et al : Interposition Vein Grafting in Head and Neck Free Flap Reconstruction. Plast Reconstr Surg 142 : 1025-1034, 2018.
PubMed
P.394 掲載の参考文献
1) 今井智浩, ほか : 上肢軟部悪性腫瘍広範切除後の再建. PEPARS 46 : 69-79, 2010.
 
2) 伊原公一郎, ほか : 整形外科領域における有茎広背筋皮弁の有用性. 臨床整形外科 34 : 1479-1485, 1999.
 
3) Hamdi M, et al : Surgical technique in pedicled thoracodorsal artery perforator flaps : a clinical experience with 99 patients. Plast Reconstr Surg 121 : 1632-1641, 2008.
PubMed
4) Sasaki K, et al : Reconstruction of a large abdominal wall defect using combined free tensor fasciae latae musculocutaneous flap and anterolateral thigh flap. Plast Reconstr Surg 102 : 2244-2252, 1998.
PubMed
5) Choudry UH, et al : Soft-tissue coverage of the elbow : an outcome analysis and reconstructive algorithm. Plast Reconstr Surg 119 : 1852-1857, 2007.
PubMed
6) Miyamoto S, et al : Early Mobilization after Free-flap Transfer to the Lower Extremities : Preferential Use of Flow-through Anastomosis. Plast Reconstr Surg Glob Open 2 : e127, 2014.
 
7) Fujiki M, et al : Flow-through anastomosis for both the artery and vein in leg free flap transfer. Microsurgery 35 : 536-540, 2015.
PubMed
8) 安楽邦明, ほか : 下肢軟部組織腫瘍切除後の再建. PEPARS 57 : 8-14, 2011.
 
9) Miyamoto S, et al : Accompanying artery of sciatic nerve as recipient vessel for free-flap transfer : a computed tomographic angiography study and case reports. Microsurgery 35 : 284-289, 2015.
PubMed
10) 苅部大輔, 上村哲司 : 下肢のlocal flap method. PEPARS 58 : 89-94, 2011.
 
11) Louer CR, et al : Free flap reconstruction of the knee : an outcome study of 34 cases. Ann Plast Surg 74 : 57-63, 2015.
PubMed
12) Park S, Eom JS : Selection of the recipient vessel in the free flap around the knee : the superior medial genicular vessels and the descending genicular vessels. Plast Reconstr Surg 107 : 1177-1182, 2001.
PubMed
13) Mahmoud WH : Foot and Ankle Reconstruction Using the Distally Based Sural Artery Flap Versus the Medlal Plantar Flap : A Comparative Study. J Foot Ankle Surg 56 : 514-518, 2017.
PubMed
14) 関堂充, ほか : 各種遊離組織移植を用いた足底荷重部再建の経験. 日本形成外科学会会誌 25 : 715-723, 2005.
 
15) Jeon BJ, et al : Plantar reconstruction with free thoracodorsal artery perforator flaps. J Plast Reconstr Aesthet Surg 66 : 406-413, 2013.
PubMed
P.400 掲載の参考文献
1) 長谷川健二郎, 木股敬裕 : 特集 : 胸壁・腹壁欠損の再建 硬組織に人工材料を用いた胸壁全層欠損の再建. PEPARS 53 : 10-16, 2011.
 
2) Miyamoto S, et al : Anterolateral thigh flap for axillary reconstruction after sarcoma resection. Microsurgery 36 : 378-383, 2016.
PubMed
3) Nahai F, et al : Experiences with the tensor fascia lata flap. Plast Reconstr Surg 63 : 788-799, 1979.
PubMed
4) Kimata Y, et al : Anterolateral thigh flap for abdominal wall reconstruction. Plast Reconstr Surg 103 :1191-1197, 1999.
PubMed
5) Kayano S, et al : Comparison of pedicled and free anterolateral thigh flaps for reconstruction of complex defects of the abdominal wall : review of 20 consecutive cases. J PIast Reconstr Aesthet Surg 65 : 1525-1529, 2012.
 
6) Miyamoto S, et al : Combined Use of an Anterolateral Thigh Flap and Superficial Inferior Epigastric Artery Flap for Reconstruction of an Extensive Abdominal Wall Defect. Plast Reconstr Surg Glob Open 4 : e1121, 2016.
PubMed
7) Kagaya Y, et al : Successful Pregnancy and Delivery after Autologous Abdominal Wall Reconstruction using Anterolateral-Thigh and Iliotibial-Tract Flap. Plast Reconstr Surg Glob Open 6 : e1819, 2018.
PubMed
8) 宮本慎平, 櫻庭実 : 特集 : 胸壁・腹壁欠損の再建 悪性腫瘍切除後の腹壁再建. PEPARS 53 : 47-54, 2011.
 
9) Miyamoto S, et al : Large-to-Small End-to-Side Venous Anastomosis in Free Flap Transfer. J Surg Res 245 : 377-382, 2019.
PubMed
10) Diener MK, et al : Elective midline laparotomy closure : the INLINE systematic review and meta-analysis. Ann Surg 251 : 843-856, 2010.
PubMed
11) Muysoms FE, et al : European Hernia Society guidelines on the closure of abdominal wall incisions. Hernia 19 : 1-24, 2015.
 
P.406 掲載の参考文献
1) Muramatsu K, et al : Clinical outcome of limb-salvage surgery after wide resection of sarcoma and femoral vessel reconstruction. Ann Vasc Surg 25 : 1070-1077, 2011.
PubMed
2) Nambisan RN, Karakousis CP : Vascular reconstruction for limb salvage in soft tissue sarcomas. Surgery 101 : 668-677, 1987.
PubMed
3) Kawai A, et al : Vascular reconstruction in limb salvage operations for soft tissue tumors of the extremities. Clin Orthop Relat Res (332) : 215-222, 1996.
PubMed
4) Schwarzbach MH, et al : Results of limb-sparing surgery with vascular replacement for soft tissue sarcoma in the lower extremity. J Vasc Surg 42 : 88-97, 2005.
PubMed
5) Alamanda VK, et al : Amputation for extremity soft tissue sarcoma does not increase overall survival : a retrospective cohort study. Eur J Surg Oncol 38 : 1178-1183, 2012.
 
6) Nishinari K, et al : Surgical outcomes of vascular reconstruction in soft tissue sarcomas of the lower extremities. J Vasc Surg 62 : 143-149, 2015.
PubMed
7) Park D, et al : Outcomes after Arterial or Venous Reconstructions in Limb Salvage Surgery for Extremity Soft Tissue Sarcoma. J Korean Med Sci 33 : e265, 2018.
 
8) Adelani MA, et al : Revascularization after segmental resection of lower extremity soft tissue sarcomas. J Surg Oncol 95 : 455-460, 2007.
PubMed
9) Sasajima T, et al : Comparison of reversed and in situ saphenous vein grafts for infragenicular bypass : experience of two surgeons. Cardiovasc Surg 1 : 38-43, 1993.
PubMed
10) Davidovic LB, et al : Femoro-popliteal reconstructions : 'in situ' versus 'reversed' technique. Cardiovasc Surg 9 : 356-361, 2001.
PubMed
11) Umezawa H, et al : Analysis of immediate vascular reconstruction for lower-limb salvage in patients with lower-limb bone and soft-tissue sarcoma. J Plast Reconstr Aesthet Surg 66 : 608-616, 2013.
PubMed
12) Tsukushi S, et al : Results of limb-salvage surgery with vascular reconstruction for soft tissue sarcoma in the lower extremity : comparison between only arterial and arterovenous reconstruction. J Surg Oncol 97 : 216-220, 2008.
PubMed
13) Peat BG, et al : Wound-healing complications after soft-tissue sarcoma surgery. Plast Reconstr Surg 93 : 980-987, 1994.
PubMed
P.413 掲載の参考文献
1) 伊藤聰一郎 : 神経損傷の診断と治療の基本方針. 手の外科の要点と盲点 (金谷文則編), p126-131, 文光堂 2007.
 
2) Millesi H : Techniques for nerve grafting. Hand Clin 16 : 73-91, viii. 2000.
PubMed
3) 橋川和信 : 神経修復に関わる手術手技 末梢神経縫合 : 端々縫合と端側縫合. PEPARS (78) : 16-22, 2013.
 
4) 平沢泰介 : 神経移行術. 末梢神経損傷, 整形外科MOOK 19 : 127-143, 1981.
 
5) 野村進 : 末梢神経外科治療の進歩. 外科治療 24 : 323-333, 1971.
 
6) Koshima I, Harii K : Experimental study of vascularized nerve grafts : morphometric study of axonal regeneration of nerves transplanted into silicone tubes. Ann Plast Surg 14 : 235-243, 1985.
PubMed
7) Weber RA, et al : A randomized prospective study of polyglycolic acid conduits for digital nerve reconstruction in humans. Plast Reconstr Surg 106 : 1036-1045 ; discussion 1046-1048, 2000.
 
8) Mahakkanukrauh P, Chomsung R : Anatomical variations of the sural nerve. Clin Anat 15 : 263-266, 2002.
PubMed
9) 坂本相哲, 土井一輝 : 血管柄付き腓腹神経移植-腓骨動脈皮枝・後脛骨動脈筋内貫通枝を茎とする場合-. PEPARS (78) : 62-67, 2013.
 
10) 山田潔, 木股敬裕 : 血管付き大腿神経移植術. PEPARS (78) : 56-61, 2013.
 
11) Iida T, et al : Supermicrosurgical free sensate superficial circumflex iliac artery perforator flap for reconstruction of a soft tissue defect of the ankle in a 1-year-old child. Microsurgery 36 : 254-258, 2016.
 
12) 大成和寛, ほか : 手指外傷における前腕内側皮神経を用いた血管柄付き神経皮膚移植術. 中国・四国整形外科学会雑誌 16 : 205-209, 2004.
Medical*Online
P.419 掲載の参考文献
1) Shehadeh A, et al : Standardization of rehabilitation after limb salvage surgery for sarcomas improves patients' outcome. Hematol Oncol Stem Cell Ther 6 : 105-111, 2013.
PubMed
2) Enneking WF, et al : Resection and reconstruction for primary neoplasms involving the innominate bone. J Bone Joint Surg Am 60 : 731-746, 1978.
PubMed
3) Wilson RJ, et al : Surgical Outcomes After Limb-Sparing Resection and Reconstruction for Pelvic Sarcoma : A Systematic Review. JBJS Rev 6 : e10, 2018.
PubMed
4) Gebert C, et al : Hip transposition as a universal surgical procedure for periacetabular tumors of the pelvis. J Surg Oncol 99 : 169-172, 2009.
PubMed
5) Kunisada T, et al : Temporary External Fixation Can Stabilize Hip Transposition Arthroplasty After Resection of Malignant Periacetabular Bone Tumors. Clin Orthop Relat Res 477 : 1892-1901, 2019.
PubMed
6) 国定俊之, ほか : 腫瘍型人工関節置換術とそのリハビリテーション. The Japanese Journal of Rehabilitation Medicine 54 : 209-213, 2017.
Medical*Online
7) Winkelmann WW : [Clavicula pro humero-a new surgical method for malignant tumors of the proximal humerus]. Z Orthop Ihre Grenzgeb 130 : 197-201, 1992.
PubMed
8) Mayilvahanan N, et al : Custom mega-prosthetic replacement for proximal humeral tumours. Int Orthop 30 : 158-162, 2006.
PubMed
9) 陳隆明 : 切断者に対するリハビリテーション. 義肢装具のチェックポイント [第8版] (日本整形外科学会, 日本リハビリテーション医学会監), p75-89, 医学書院, 2014.
 
10) Enneking WF, et al : A system for the functional evaluation of reconstructive procedures after surgical treatment of tumors of the musculoskeletal system. Clin Orthop Relat Res (286) : 241-246, 1993.
PubMed
11) Davis AM, et al : Development of a measure of physical function for patients with bone and soft tissue sarcoma. Qual Life Res 5 : 508-516, 1996.
PubMed
12) 小倉浩一 : 骨軟部腫瘍領域の患者立脚型アウトカム評価. Bone Joint Nerve 7 : 491-499, 2017.
Medical*Online
13) Ware JE, et al : The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30 : 473-483, 1992.
PubMed
14) Aaronson NK, et al : The European Organization for Research and Treatment of Cancer QLQ-C30 : a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85 : 365-376, 1993.
 
P.426 掲載の参考文献
1) Link MP, et al : The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med 314 : 1600-1606, 1986.
PubMed
2) Rosen G, et al : Chemotherapy, en bloc resection, and prosthetic bone replacement in the treatment of osteogenic sarcoma. Cancer 37 : 1-11, 1976.
PubMed
3) Rosen G, et al : Preoperative chemotherapy for osteogenic sarcoma : selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer 49 : 1221-1230, 1982.
PubMed
4) Meyers PA, et al : Chemotherapy for nonmetastatic osteogenic sarcoma : the Memorial Sloan-Kettering experience. J Clin Oncol 10 : 5-15, 1992.
PubMed
5) Meyers PA, et al : Osteosarcoma : the addition of muramyl tripeptide to chemotherapy improves overall survival-a report from the Children's Oncology Group. J Clin Oncol 26 : 633-638, 2008.
 
6) Smeland S, et al : Survival and prognosis with osteosarcoma : outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort. Eur J Cancer 109 : 36-50, 2019.
PubMed
7) Fuchs N, et al : Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study group's protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs. Ann Oncol 9 : 893-899, 1998.
 
8) Iwamoto Y, et al : Multiinstitutional phase II study of neoadjuvant chemotherapy for osteosarcoma (NECO study) in Japan : NECO-93J and NECO-95J. J Orthop Sci 14 : 397-404, 2009.
PubMed
9) Souhami RL, et al : Randomised trial of two regimens of chemotherapy in operable osteosarcoma : a study of the European Osteosarcoma Intergroup. Lancet 350 : 911-917, 1997.
PubMed
10) Ferrari S, et al : Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity : a joint study by the Italian and Scandinavian Sarcoma Groups. J Clin Oncol 23 : 8845-8852, 2005.
PubMed
11) Anninga JK, et al : Chemotherapeutic adjuvant treatment for osteosarcoma : where do we stand? Eur J Cancer 47 : 2431-2445, 2011.
PubMed
12) Berrak SG, et al : Doxorubicin cardiotoxicity in children : reduced incidence of cardiac dysfunction associated with continuous-infusion schedules. Oncol Rep 8 : 611-614, 2001.
PubMed
13) Jaffe N, Gorlick R : High-dose methotrexate in osteosarcoma : let the questions surcease-time for final acceptance. J Clin Oncol 26 : 4365-4366, 2008.
PubMed
14) Zelcer S, et al : The Memorial Sloan Kettering Cancer Center experience with outpatient administration of high dose methotrexate with leucovorin rescue. Pediatr Blood Cancer 50 : 1176-1180, 2008.
PubMed
15) Kakunaga S, et al : Neoadjuvant chemotherapy : Osaka University Osteosarcoma (OOS) regimen. In : Osteosarcoma : A Multidisciplinary Approach to Treatment (ed by Ueda T, Kawai A), p97-106, Springer Japan, Tokyo, 2016.
 
P.430 掲載の参考文献
1) Marina NM, et al : Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1) : an open-label, international, randomised controlled trial. Lancet Oncol 17 : 1396-1408, 2016.
PubMed
2) Iwamoto Y, et al : Multiinstitutional phase II study of neoadjuvant chemotherapy for osteosarcoma (NECO study) in Japan : NECO-93J and NECO-95J. J Orthop Sci 14 : 397-404, 2009.
PubMed
3) Casali PG, et al : Bone sarcomas : ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 29 : iv79-iv95, 2018.
PubMed
4) Ferrari S, et al : Postrelapse survival in osteosarcoma of the extremities : prognostic factors for long-term survival. J Clin Oncol 21 : 710-715, 2003.
PubMed
5) Bacci G, et al : Treatment and outcome of recurrent osteosarcoma : experience at Rizzoli in 235 patients initially treated with neoadjuvant chemotherapy. Acta Oncol 44 : 748-755, 2005.
PubMed
6) Navid F, et al : Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma. Cancer 113 : 419-425, 2008.
 
7) Palmerini E, et al : Gemcitabine and docetaxel in relapsed and unresectable high-grade osteosarcoma and spindle cell sarcoma of bone. BMC Cancer 16 : 280, 2016.
PubMed
8) Grignani G, et al : A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy : an Italian Sarcoma Group study. Ann Oncol 23 : 508-516, 2012.
 
9) Grignani G, et al : Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment : a non-randomised phase 2 clinical trial. Lancet Oncol 16 : 98-107, 2015.
PubMed
10) Duffaud F, et al : Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma : a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study. Lancet Oncol 20 : 120-133, 2019.
PubMed
11) Stacchiotti S, et al : Best practices for the management of local-regional recurrent chordoma : a position paper by the Chordoma Global Consensus Group. Ann Oncol 28 : 1230-1242, 2017.
 
12) Stacchiotti S, et al : Phase II study of imatinib in advanced chordoma. J Clin Oncol 30 : 914-920, 2012.
PubMed
13) Bompas E, et al : Sorafenib in patients with locally advanced and metastatic chordomas : a phase II trial of the French Sarcoma Group (GSF/GETO). Ann Oncol 26 : 2168-2173, 2015.
PubMed
14) Lebellec L, et al : Advanced chordoma treated by first-line molecular targeted therapies : Outcomes and prognostic factors. A retrospective study of the French Sarcoma Group (GSF/GETO) and the Association des Neuro-Oncologues d'Expression Francaise (ANOCEF). Eur J Cancer 79 : 119-128, 2017.
PubMed
15) Tawbi HA, et al : Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028) : a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol 18 : 1493-1501, 2017.
PubMed
P.436 掲載の参考文献
1) Lagmay Jp, et al : Outcome of Patients With Recurrent Osteosarcoma Enrolled in Seven Phase II Trials Through Children's Cancer Group, Pediatric Oncology Group, and Children's Oncology Group : Learning From the Past to Move Forward. J Clin Oncol 34 : 3031-3038, 2016.
 
2) Ebb D, et al : Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 20verexpression : a report from the children's oncology group. J Clin Oncol 30 : 2545-2551, 2012.
 
3) Weigel B, et al : Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors : a report from the Children's Oncology Group. Pediatr Blood Cancer 61 : 452-456, 2014.
 
4) Miwa S, et al : Phase 1/2 study of immunotherapy with dendritic cells pulsed with autologous tumor lysate in patients with refractory bone and soft tissue sarcoma. Cancer 123 : 1576-1584, 2017.
PubMed
5) Meyers PA, et al : Osteosarcoma : the addition of muramyl tripeptide to chemotherapy improves overall survival-a report from the Children's Oncology Group. J Clin Oncol 26 : 633-638, 2008.
 
6) Ahmed N, et al : Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma. J Clin Oncol 33 : 1688-1696, 2015.
PubMed
7) Merchant MS, et al : Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid Tumors. Clin Cancer Res 22 : 1364-1370, 2016.
PubMed
8) Grignani G, et al : A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy : an Italian Sarcoma Group study. Ann Oncol 23 : 508-516, 2012.
 
9) Grignani G, et al : Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment : a non-randomised phase 2 clinical trial. Lancet Oncol 16 : 98-107, 2015.
PubMed
10) Duffaud F, et al : Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma : a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study. Lancet Oncol 20 : 120-133, 2019.
PubMed
11) Davis LE, et al : Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma. J Clin Oncol 37 : 1424-1431, 2019.
PubMed
12) Xie L, et al : Apatinib for Advanced Osteosarcoma after Failure of Standard Multimodal Therapy : An Open Label Phase II Clinical Trial. Oncologist 24 : e542-e550, 2019.
PubMed
P.442 掲載の参考文献
1) WHO Classification of Tumours, 5th ed, Vol 3, Soft Tissue and Bone Tumours (ed by WHO Classification of Tumours Editorial Board), IARC, Lyon, 2020.
 
2) Endo M, Lin PP : Surgical margins in the management of extremity soft tissue sarcoma. Chin Clin Oncol 7 : 37, 2018.
PubMed
3) Ravaud A, et al : Prognostic variables for the selection of patients with operable soft tissue sarcomas to be considered in adjuvant chemotherapy trials. Br J Cancer 66 : 961-969, 1992.
PubMed
4) Tanaka K, et al : Perioperative chemotherapy with ifosfamide and doxorubicin for high-grade soft tissue sarcomas in the extremities (JCOG0304). Jpn J Clin Oncol 45 : 555-561, 2015.
PubMed
5) AJCC Cancer Staging Manual, 8th ed (ed by Amin MB. et al), Springer, New York, 2017.
 
6) Grier HE, et al : Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med 348 : 694-701, 2003.
 
7) Paulussen M, et al : Localized Ewing tumor of bone : final results of the cooperative Ewing's Sarcoma Study CESS 86. J Clin Oncol 19 : 1818-1829, 2001.
 
8) Womer RB, et al : Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma : a report from the Children's Oncology Group. J Clin Oncol 30 : 4148-4154, 2012.
 
9) Raney RB, et al : The Intergroup Rhabdomyosarcoma Study Group (IRSG) : Major Lessons From the IRS-1 Through IRS-IV Studies as Background for the Current IRS-V Treatment Protocols. Sarcoma 5 : 9-15, 2001.
 
10) Tanaka K, et al : Ten-year follow-up results of perioperative chemotherapy with doxorubicin and ifosfamide for high-grade soft-tissue sarcoma of the extremities : Japan Clinical Oncology Group study JCOG0304. BMC Cancer 19 : 890, 2019.
 
11) Kataoka K, et al : A randomized phase II/III trial of perioperative chemotherapy with adriamycin plus ifosfamide versus gemcitabine plus docetaxel for high-grade soft tissue sarcoma : Japan Clinical Oncology Group Study JCOG1306. Jpn J Clin Oncol 44 : 765-769, 2014.
 
12) Frustaci S, et al : Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles : results of the Italian randomized cooperative trial. J Clin Oncol 19 : 1238-1247, 2001.
 
13) Petrioli R, et al : Adjuvant epirubicin with or without Ifosfamide for adult soft-tissue sarcoma. Am J Clin Oncol 25 : 468-473, 2002.
 
14) Woll PJ, et al : Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931) : a multicentre randomised controlled trial. Lancet Oncol 13 : 1045-1054, 2012.
PubMed
15) Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults : meta-analysis of individual data. Sarcoma Meta-analysis Collaboration. Lancet 350 : 1647-1654, 1997.
PubMed
16) Pervaiz N, et al : A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer 113 : 573-581, 2008.
PubMed
P.448 掲載の参考文献
1) Crist W, et al : The Third Intergroup Rhabdomyosarcoma Study. J Clin Oncol 13 : 610-630, 1995.
PubMed
2) Crist WM, et al : Intergroup rhabdomyosarcoma study-IV : results for patients with nonmetastatic disease. J Clin Oncol 19 : 3091-3102, 2001.
 
3) Breneman JC, et al : Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma-a report from the Intergroup Rhabdomyosarcoma Study IV. J Clin Oncol 21 : 78-84, 2003.
 
4) Weigel BJ, et al : Intensive Multiagent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide and Vincristine/Doxorubicin/Cyclophosphamide, Irinotecan, and Radiation, in Patients With High-Risk Rhabdomyosarcoma : A Report From the Children's Oncology Group. J Clin Oncol 34 : 117-122, 2016.
 
5) Bisogno G, et al : Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005) : a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 20 : 1566-1575, 2019.
PubMed
6) Van Winkle P, et al : Ifosfamide, carboplatin, and etoposide (ICE) reinduction chemotherapy in a large cohort of children and adolescents with recurrent/refractory sarcoma : the Children's Cancer Group (CCG) experience. Pediatr Blood Cancer 44 : 338-347, 2005.
 
7) Grier HE, et al : Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med 348 : 694-701, 2003.
 
8) Paulussen M, et al : Results of the EICESS-92 Study : two randomized trials of Ewing's sarcoma treatment-cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients. J Clin Oncol 26 : 4385-4393, 2008.
PubMed
9) Ladenstein R, et al : Primary disseminated multifocal Ewing sarcoma : results of the Euro-EWING 99 trial. J Clin Oncol 28 : 3284-3291, 2010.
 
10) Hunold A, et al : Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors. Pediatr Blood Cancer 47 : 795-800, 2006.
PubMed
11) Bramwell VH, et al : Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft-tissue sarcoma : a meta-analysis and clinical practice guideline. Sarcoma 4 : 103-112, 2000.
 
12) Tap WD, et al : Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma : an open-label phase 1b and randomised phase 2 trial. Lancet 388 : 488-497, 2016.
PubMed
13) Tap WD, et al : Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas : The ANNOUNCE Randomized Clinical Triai. JAMA 323 : 1266-1276, 2020.
 
14) van der Graaf WT, et al : Pazopanib for metastatic soft-tissue sarcoma (PALETTE) : a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 379 : 1879-1886, 2012.
PubMed
15) Blay JY, et al : Randomised phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomas. Eur J Cancer 50 : 1137-1147, 2014.
PubMed
16) Demetri GD, et al : Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy : Results of a Phase III Randomized Multicenter Clinical Trial. J Clin Oncol 34 : 786-793, 2016.
 
17) Schoffski P, et al : Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma : a randomised, open-label, multicentre, phase 3 trial. Lancet 387 : 1629-1637, 2016.
 
18) Samuels BL, et al : Results of a prospective phase 2 study of pazopanib in patients with advanced intermediate-grade or high-grade liposarcoma. Cancer 123 : 4640-4647, 2017.
PubMed
19) Seddon B, et al : Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS) : a randomised controlled phase 3 trial. Lancet Oncol 18 : 1397-1410, 2017.
PubMed
20) Rosen G, et al : Synovial sarcoma. Uniform response of metastases to high dose ifosfamide. Cancer 73 : 2506-2511, 1994.
PubMed
21) Penel N, et al : Phase II trial of weekly paclitaxel for unresectable angiosarcoma : the ANGIOTAX Study. J Clin Oncol 26 : 5269-5274, 2008.
PubMed
22) Stacchiotti S, et al : Response to sunitinib malate in advanced alveolar soft part sarcoma. Clin Cancer Res 15 : 1096-1104, 2009.
PubMed
23) Chi Y, et al : Anlotinib for metastasis soft tissue sarcoma : A randomized, double-biind, placebocontrolled and multi-centered clinical trial. J Clin Oncol 36 (15 Suppl) : 11503, 2018.
 
24) Butrynski JE, et al : Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N Engl J Med 363 : 1727-1733, 2010.
PubMed
25) Schoffski P, et al : Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE) : a multicentre, single-drug, prospective, non-randomised phase 2 trial. Lancet Respir Med 6 : 431-441, 2018.
PubMed
26) Stacchiotti S, et al : Sunitinib malate in solitary fibrous tumor (SFT). Ann Oncol 23 : 3171-3179, 2012.
PubMed
27) Valentin T, et al : Sorafenib in patients with progressive malignant solitary fibrous tumors : a subgroup analysis from a phase II study of the French Sarcoma Group (GSF/GETO). Invest New Drugs 31 : 1626-1627, 2013.
PubMed
28) Martin-Broto J, et al : Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour : a multicentre, single-arm, phase 2 trial. Lancet Oncol 20 : 134-144, 2019.
PubMed
29) Dudley JC, et al : Microsatellite Instability as a Biomarker for PD-1 Blockade. Clin Cancer Res 22 : 813-820, 2016.
PubMed
30) Drilon A, et al : Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med 378 : 731-739, 2018.
PubMed
31) Okuma HS, et al : MASTER KEY Project : Powering Clinical Development for Rare Cancers Through a Platform Trial. Clin Pharmacol Ther 2020 Feb 29. doi : 10.1002/cpt.1817.
 
P.454 掲載の参考文献
1) Hanahan D, Weinsberg RA : Hallmarks of cancer : the next generation. Cell 144 : 646-674, 2011.
 
2) Potti A, et al : Determination of vascular endothelial growth factor (VEGF) overexpression in soft tissue sarcomas and the role of overexpression in leiomyosarcoma. J Cancer Res Clin Oncol 130 : 52-56, 2004.
PubMed
3) Yudoh K, et al : Concentration of vascular endothelial growth factor in the tumour tissue as a prognostic factor of soft tissue sarcomas. Br J Cancer 84 : 1610-1615, 2001.
PubMed
4) Wang J, et al : Celi proliferation in human soft tissue tumors correlates with platelet-derived growth factor B chain expression : an immunohistochemical and in situ hybridization study. Cancer Res 54 : 560-564, 1994.
 
5) Sonpavde G, Hutson TE : Pazopanib : a novel multitargeted tyrosine kinase inhibitor. Curr Oncol Rep 9 : 115-119, 2007.
PubMed
6) Kumar R, et al : Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther 6 : 2012-2021, 2007.
PubMed
7) Hurwitz HI, et al : Phase I trial of pazopanib in patients with advanced cancer. Clin Cancer Res 15 : 4220-4227, 2009.
PubMed
8) Verheijen RB, et al : Clinical Pharmacokinetics and Pharmacodynamics of Pazopanib : Towards Optimized Dosing. Clin Pharmacokinet 56 : 987-997, 2017.
PubMed
9) Inada-Inoue M, et al : Phase 1 study of pazopanib alone or combined with lapatinib in Japanese patients with solid tumors. Cancer Chemother Pharmacol 73 : 673-683, 2014.
PubMed
10) van der Graaf WT, et al : Pazopanib for metastatic soft-tissue sarcoma (PALETTE) : a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 379 : 1879-1886, 2012.
PubMed
11) Nakamura T, et al : The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma : A Japanese Musculoskeletal Oncology Group (JMOG) study. Cancer 122 : 1408-1416, 2016.
PubMed
12) Motzer RJ, et al : Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 369 : 722-731, 2013.
PubMed
13) Schutz FA, et al : Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors. J Clin Oncol 30 : 871-877, 2012.
PubMed
14) Ghatalia P, et al : QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors. Br J Cancer 112 : 296-305, 2015.
PubMed
15) Teo YL, et al : Risk of tyrosine kinase inhibitors-induced hepatotoxicity in cancer patients : a meta-analysis. Cancer Treat Rev 39 : 199-206, 2013.
PubMed
16) ヴォトリエント錠200mg適正使用ガイド (悪性軟部腫瘍), ノバルティス ファーマ株式会社, 2018.
 
17) Sleijfer S, et al : Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma : a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol 27 : 3126-3132, 2009.
PubMed
18) Samuels BL, et al : Results of a prospective phase 2 study of pazopanib in patients with advanced intermediate-grade or high-grade liposarcoma. Cancer 123 : 4640-4647, 2017.
PubMed
19) Mir O, et al : Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST) : a randomised, multicentre, open-label phase 2 trial. Lancet Oncol 17 : 632-641, 2016.
PubMed
20) Martin-Broto J, et al : Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour : a multicentre, single-arm, phase 2 trial. Lancet Oncol 20 : 134-144, 2019.
PubMed
21) Choi H, et al : Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate : proposal of new computed tomography response criteria. J Clin Oncol 25 : 1753-1759, 2007.
 
22) Maruzzo M, et al : Pazopanib as first line treatment for solitary fibrous tumours : the Royal Marsden Hospital experience. Clin Sarcoma Res 5 : 5, 2015.
 
23) Sartor O : Adverse Event Reporting in Clinical Trials : Time to Include Duration as Well as Severity. Oncologist 23 : 1, 2018.
PubMed
24) Frezza AM, et al : Anthracycline, Gemcitabine, and Pazopanib in Epithelioid Sarcoma : A Multi-institutional Case Series. JAMA Oncol 4 : e180219, 2018.
PubMed
25) Kollar A, et al : Pazopanib in advanced vascular sarcomas : an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis. Acta Oncol 56 : 88-92, 2017.
PubMed
26) Kim HJ, et al : Pazopanib monotherapy in the treatment of pretreated, metastatic uterine sarcoma : a single-center retrospective study. J Gynecol Oncol 29 : e3, 2018.
PubMed
27) Menegaz BA, et al : Clinical Activity of Pazopanib in Patients with Advanced Desmoplastic Small Round Cell Tumor. Oncologist 23 : 360-366, 2018.
PubMed
28) Kasper B, et al : Long-term responders and survivors on pazopanib for advanced soft tissue sarcomas : subanalysis of two European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62043 and 62072. Ann Oncol 25 : 719-724, 2014.
PubMed
29) Sleijfer S, et al : Cytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in advanced soft-tissue sarcoma : an EORTC-STBSG study. Br J Cancer 107 : 639-645, 2012.
PubMed
30) Nakano K, et al : Relative dose intensity of induction-phase pazopanib treatment of soft tissue sarcoma : its relationship with prognoses of pazopanib responders. J Clin Med 8. pii : E60, 2019.
 
P.460 掲載の参考文献
1) Larsen AK, et al : Unique features of trabectedin mechanism of action. Cancer Chemother Pharmacol 77 : 663-671, 2016.
PubMed
2) Kawai A, et al : Trabectedin monotherapy after standard chemotherapy versus best supportive care in patients with advanced, translocation-related sarcoma : a randomised, open-label, phase 2 study. Lancet Oncol 16 : 406-416, 2015.
PubMed
3) Demetri GD, et al : Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy : Results of a Phase III Randomized Multicenter Clinical Trial. J Clin Oncol 34 : 786-793, 2016.
 
4) Takahashi M, et al : Efficacy of Trabectedin in Patients with Advanced Translocation-Related Sarcomas : Pooled Analysis of Two Phase II Studies. Oncologist 22 : 979-988, 2017.
PubMed
5) Buonadonna A, et al : A noninterventional, multicenter, prospective phase IV study of trabectedin in patients with advanced soft tissue sarcoma. Anticancer Drugs 28 : 1157-1165, 2017.
PubMed
6) Morioka H, et al : Results of sub-analysis of a phase 2 study on trabectedin treatment for extraskeletal myxoid chondrosarcoma and mesenchymal chondrosarcoma. BMC Cancer 16 : 479, 2016.
PubMed
7) Khalifa J, et al : Efficacy of trabectedin in malignant solitary fibrous tumors : aretrospective analysis from the French Sarcoma Group. BMC Cancer 15 : 700, 2015.
 
8) Martin-Broto J, et al : Randomized Phase II Study of Trabectedin and Doxorubicin Compared With Doxorubicin Alone as First-Line Treatment in Patients With Advanced Soft Tissue Sarcomas : A Spanish Group for Research on Sarcoma Study. J Clin Oncol 34 : 2294-2302, 2016.
 
9) Blay JY, et al : Randomised phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomas. Eur J Cancer 50 : 1137-1147, 2014.
PubMed
10) Jones RL, et al : Efficacy and tolerability of trabectedin in elderly patients with sarcoma : subgroup analysis from a phase III, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma. Ann Oncol 29 : 1995-2002, 2018.
 
11) Taieb S, et al : Comparison of response evaluation criteria in solid tumours and Choi criteria for response evaluation in patients with advanced soft tissue sarcoma treated with trabectedin : a retrospective analysis. Eur J Cancer 51 : 202-209, 2015.
PubMed
12) Gronchi A, et al : Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001) : an international, open-label, randomised, controlled, phase 3, multicentre trial. Lancet Oncol 18 : 812-822, 2017.
PubMed
13) Schoffski P, et al : Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin : a retrospective multicentric study. Eur J Cancer 47 : 1006-1012, 2011.
PubMed
14) Laroche A, et al : Activity of trabectedin and the PARP inhibitor rucaparib in soft-tissue sarcomas. J Hematol Oncol 10 : 84, 2017.
PubMed
P.467 掲載の参考文献
1) Jordan MA, Wilson L : Microtubules as a target for anticancer drugs. Nat Rev Cancer 4 : 253-265, 2004.
PubMed
2) Kawano S, et al : Antimitotic and Non-mitotic Effects of Eribulin Mesilate in Soft Tissue Sarcoma. Anticancer Res 36 : 1553-1561, 2016.
PubMed
3) Morgan RJ, et al : Pharmacodynamics (PD) and pharmacokinetics (PK) of E7389 (eribulin, halichondrin B analog) during a phase I trial in patients with advanced solid tumors : a California Cancer Consortium trial. Cancer Chemother Pharmacol 76 : 897-907, 2015.
PubMed
4) Mukohara T, et al : Eribulin mesylate in patients with refractory cancers : a Phase I study. Invest New Drugs 30 : 1926-1933, 2012.
PubMed
5) Schoffski P, et al : Activity of eribulin mesylate in patients with soft-tissue sarcoma : a phase 2 study in four independent histological subtypes. Lancet Oncol 12 : 1045-1052, 2011.
PubMed
6) Kawai A, et al : Phase 2 study of eribulin in patients with previously treated advanced or metastatic soft tissue sarcoma. Jpn J Clin Oncol 47 : 137-144, 2017.
PubMed
7) Schoffski P, et al : Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma : a randomised, open-label, multicentre, phase 3 trial. Lancet 387 : 1629-1637, 2016.
 
8) Demetri GD, et al : Activity of Eribulin in Patients With Advanced Liposarcoma Demonstrated in a Subgroup Analysis From a Randomized Phase III Study of Eribulin Versus Dacarbazine. J Clin Oncol 35 : 3433-3439, 2017.
 
9) Yoshida T, et al : Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states. Br J Cancer 110 : 1497-1505, 2014.
PubMed
10) Funahashi Y, et al : Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models. Cancer Sci 105 : 1334-1342, 2014.
PubMed
11) Kobayashi E, et al : Interim results of a real-world observational study of eribulin in soft tissue sarcoma including rare subtypes. Jpn J Clin Oncol 49 : 938-946, 2019.
PubMed
12) D'Incalci M, et al : Trabectedin, a drug acting on both cancer cells and the tumour microenvironment. Br J Cancer 111 : 646-650, 2014.
PubMed
13) Demetri GD, et al : Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy : Results of a Phase III Randomized Multicenter Clinical Trial. J Clin Oncol 34 : 786-793, 2016.
 
14) Grosso F, et al : Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas : a retrospective study, Lancet Oncol 8 : 595-602, 2007.
PubMed
15) Kawai A, et al : Trabectedin monotherapy after standard chemotherapy versus best supportive care in patients with advanced, translocation-related sarcoma : a randomised, open-label, phase 2 study. Lancet Oncol 16 : 406-416, 2015.
PubMed
16) van der Graaf WT, et al : Pazopanib for metastatic soft-tissue sarcoma (PALETTE) : a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 379 : 1879-1886, 2012.
PubMed
17) Sleijfer S, et al : Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma : a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol 27 : 3126-3132, 2009.
PubMed
18) Nakarnura T, et al : The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma : A Japanese Musculoskeletal Oncology Group (JMOG) study. Cancer 122 : 1408-1416, 2016.
 
19) Nakano K, et al : Differences in the responses to pazopanib and the prognoses of soft tissue sarcomas by their histological eligibility for the PALETTE study. Jpn J Clin Oncol 45 : 449-455, 2015.
PubMed
20) Osgood CL, et al : FDA Approval Summary : Eribulin for Patients with Unresectable or Metastatic Liposarcoma Who Have Received a Prior Anthracycline-Containing Regimen. Clin Cancer Res 23 : 6384-6389, 2017.
PubMed
21) Garcia-Del-Muro X, et al : Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma : a Spanish Group for Research on Sarcomas study. J Clin Oncol 29 : 2528-2533, 2011.
 
22) Takahashi S, et al : One-year follow-up results of eribulin for soft-tissue sarcoma including rare subtypes in a real-world observational study in Japan. Ann Oncol 30 (Suppl 5) : 1269, 2019.
 
P.473 掲載の参考文献
1) Heldin CH et al : Targeting the PDGF signaling pathway in tumor treatment. Cell Commun Signal 11 : 97, 2013.
PubMed
2) Tap WD, et al : Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma : an open-label phase 1b and randomised phase 2 trial. Lancet 388 : 488-497, 2016.
PubMed
3) Tap WD, et al : ANNOUNCE : A randomized, placebo-controlled, double-blind, phase III trial of doxorubicin+olaratumab vs doxorubicin+placebo in patients with advanced soft tissue sarcomas. ASCO Annual meeting 2019.
 
P.478 掲載の参考文献
1) Morgan RA, et al : Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314 : 126-129, 2006.
PubMed
2) Dudley ME, et al : Adoptive cell therapy for patients with metastatic melanoma : evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 26 : 5233-5239, 2008.
PubMed
3) Johnson LA, et al : Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 114 : 535-546, 2009.
 
4) Johnson LA, et al : Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes. J Immunol 177 : 6548-6559, 2006.
PubMed
5) Robbins PF, et al : A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor : long-term follow-up and correlates with response. Clin Cancer Res 21 : 1019-1027, 2015.
 
6) Robbins PF, et al : Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions. J Immunol 180 : 6116-6131, 2008.
PubMed
7) Jungbluth AA, et al : Monophasic and biphasic synovial sarcomas abundantly express cancer/testis antigen NY-ESO-l but not MAGE-A1 or CT7. Int J Cancer 94 : 252-256, 2001.
PubMed
8) D'Angelo SP, et al : Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 c259T Cells in Synovial Sarcoma. Cancer Discov 8 : 944-957, 2018.
PubMed
9) Sch6ffski P, et al : Activity of eribulin mesylate in patients with soft-tissue sarcoma : a phase 2 study in four independent histological subtypes. Lancet Oncol 12 : 1045-1052, 2011.
 
10) Sleijfer S, et al : Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma : a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol 27 : 3126-3132, 2009.
PubMed
11) D'Angelo SP, et al : Pilot study of NY-ESO-1c259 T cells in advanced myxoid/round cell liposarcoma [abstract]. J Clin Oncol 35 (15 Suppl) : 3005, 2017.
 
12) Davis JL, et al : Development of human anti-murine T-cell receptor antibodies in both responding and nonresponding patients enrolled in TCR gene therapy trials. Clin Cancer Res 16 : 5852-5861, 2010.
PubMed
13) Morgan RA, et al : Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother 36 : 133-151, 2013.
PubMed
14) Cameron BJ, et al : Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. Sci Transl Med 5 : 197ra103, 2013.
PubMed
15) Akahori Y, et al : Antitumor activity of CAR-T cells targeting the intracellular oncoprotein WT1 can be enhanced by vaccination. Blood 132 : 1134-1145, 2018.
 
P.484 掲載の参考文献
1) WHO Classification of Tumours, 5th ed, Vol 3, Soft Tissue and Bone Tumours (ed by WHO Classification of Tumours Editorial Board), IARC, Lyon, 2020.
 
2) 軟部腫瘍診療ガイドライン 2012 (日本整形外科学会診療ガイドライン委員会, 軟部腫瘍診療ガイドライン策定委員会編), 南江堂, 2012.
 
3) Tap WD, et al : Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma : an open-label phase 1b and randomised phase 2 trial. Lancet 388 : 488-497, 2016.
PubMed
4) Tap WD, et al : ANNOUNCE : A randomized, placebo (PBO) -controlled, double-blind, phase (Ph) III trial of doxorubicin (dox) +olaratumab versus dox+PBO in patients (pts) with advanced soft tissue sarcomas (STS). J Clin Oncol 37 (18 Suppl) : LBA3 (Abstract), 2019.
 
5) Tap WD, et al : Effect of Doxorubicin Plus Oiaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas : The ANNOUNCE Randomized Clinical Trial. JAMA 323 : 1266-1276, 2020.
PubMed
6) Vaishnavi A, et al : TRKing down an old oncogene in a new era of targeted therapy. Cancer Discov 5 : 25-34, 2015.
 
7) Yoshino T, et al : JSCO-ESMO-ASCO-JSMO-TOS : international expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions. Ann Oncol 31 : 861-872, 2020.
PubMed
8) Naito Y, et al : Japan society of clinical oncology/Japanese society of medical oncology-led clinical recommendations on the diagnosis and use of tropomyosin receptor kinase inhibitors in adult and pediatric patients with neurotrophic receptor tyrosine kinase fusion-positive advanced solid tumors, cooperated by the Japanese society of pediatric hematology/oncology. Int J Clin Oncol 25 : 403-417, 2020.
PubMed
9) Doebele RC, et al : Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours : integrated analysis of three phase 1-2 trials. Lancet Oncol 21 : 271-282, 2020.
 
10) Hong DS, et al : Larotrectinib in patients with TRK fusion-positive solid tumours : a pooled analysis of three phase 1/2 clinical trials. Lancet Oncol 21 : 531-540, 2020.
PubMed
11) Demetri GD, et al : Larotrectinib efficacy and safety in patients with TRK fusion sarcomas. Paper #10, CTOS (Connective Tissue Oncology Society) Annual Meeting : November 13-16, 2019 ; Tokyo, Japan.
 
12) Dickson MA, et al : Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With CDK41nhibitor Palbociclib : A Phase 2 Clinical Trial. JAMA Oncol 2 : 937-940, 2016.
 
13) Dickson MA, et al : Phase 2 study of the CDK4 inhibitor abemaciclib in dedifferentiated liposarcoma. J Clin Oncol 37 (15 Suppl) : 11004 (Abstract), 2019.
 
14) Bauer TM, et al : A phase 1 study of MDM2 inhibitor DS-3032b in patients with well/de-differentiated liposarcoma (WD/DD LPS), solid tumors (ST) and lymphornas (L). J Clin Oncol 36 (15 Suppl) : 11514 (Abstract), 2018.
 
15) Razak AA, et al : Results of a dose-and regimen-finding Phase Ib study of HDM201 in combination with ribociclib in patients with locally advanced or metastatic liposarcoma. Cancer Res 78 (13 Suppl) : CT009 (Abstract), 2018.
 
16) A Study of RO5045337 in Patients With Liposarcomas Prior to Debulking Surgery. ClinicalTrials. gov Identifier : NCT01143740, Last Update Posted : November 2, 2016.
 
17) Chbani L, et al : Epithelioid sarcoma : a clinicopathologic and immunohistochemical analysis of 106 cases from the French sarcoma group. Am J Clin Pathol 131 : 222-227, 2009.
 
18) Stacchiotti S, et al : Safety and efficacy of tazemetostat, a first-in-class EZH2 inhibitor, in patients (pts) with epithelioid sarcoma (ES) (NCT02601950). J Clin Oncol 37 (15 Suppl) : 11003 (Abstract), 2019.
 
19) Movva S, et al : Multi-platform profiling of over 2000 sarcomas : identification of biomarkers and novel therapeutic targets. Oncotarget 6 : 12234-12247, 2015.
PubMed
20) D'Angelo SP, et al : Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment. Hum Pathol 46 : 357-365, 2015.
PubMed
21) Tawbi HA, et al : Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028) : a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol 18 : 1493-1501, 2017.
PubMed
22) Ben-Ami E, et al : Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus : Results of a phase 2 study. Cancer 123 : 3285-3290, 2017.
PubMed
23) D'Angelo SP, et al : Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401) : two open-label, non-comparative, randomised, phase 2 trials. Lancet Oncol 19 : 416-426, 2018.
 
24) Pollack S, et al : A phase I/II study of pembrolizumab (Pem) and doxorubicin (Dox) in treating patients with metastatic/unresectable sarcoma. J Clin Oncol 37 (15 Suppl) : 11009 (Abstract), 2019.
 
25) Gounder MM, et al : Sorafenib for Advanced and Refractory Desmoid Tumors. N Engl J Med 379 : 2417-2428, 2018.
PubMed
26) Toulmonde M, et al : Pazopanib or methotrexate-vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ) : anon-comparative, randomised, open-label, multicentre, phase 2 study. Lancet Oncol 20 : 1263-1272, 2019.
 
27) Jones RL, et al : Results of the TAPPAS trial : an adaptive enrichment phase 3 trial of TRC105 and pazopanib (P) versus pazopanib alone in patients with advanced angiosarcoma (AS). Ann Oncol 30 (Suppl 5) : v683-v709, 2019.
 
28) Wilky BA, et al : Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma : a single-centre, single-arm, phase 2 trial. Lancet Oncol 20 : 837-848, 2019.
PubMed
29) Tap WD, et al : Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN) : a randomised phase 3 trial. Lancet 394 : 478-487, 2019.
PubMed
30) 日本サルコーマ治療研究学会 : 臨床試験 [https://jstar.or.jp/clinical-trials.html]
 
31) 日本医薬情報センター : 臨床試験情報 (Japic Clinical Trials Information). [https://www.clinicaltriais.jp/cti-user/common/Top.jsp]
 
32) 国立保健医療科学院 : 臨床研究情報ポータルサイト. [https://rctportal.niph.go.jp/]
 
33) 大学病院医療情報ネットワーク : UMIN臨床試験登録システム. [https://www.umin.ac.jp/ctr/index-j.htm]
 
34) ClinicalTrials.gov. [https://clinicaltrials.gov/]
 
P.492 掲載の参考文献
1) Okuma HS, Fujiwara Y : Have We Found the Key to Unravel Treatment Development Lags for Rare Cancers? : MASTER KEY Project. Clin Pharmacol Ther 106 : 491-492, 2019.
PubMed
2) Gatta G, et al : Rare cancers are not so rare : the rare cancer burden in Europe. Eur J Cancer 47 : 2493-2511, 2011.
 
3) Fujiwara Y, Ono S : Regulatory Review of New Therapeutic Agents. N Engl J Med 376 : 2598, 2017.
PubMed
4) Yonemori K, et al : The notorious "drug lag" for oncology drugs in Japan. Invest New Drugs 29 : 706-712, 2011.
PubMed
5) Tanabe Y, et al : Comprehensive screening of target molecules by next-generation sequencing in patients with malignant solid tumors : guiding entry into phase I clinical trials. Mol Cancer 15 : 73, 2016.
PubMed
6) JMACCT : 臨床試験登録システム ; ALK遺伝子異常を有する希少がんに対するアレクチニブの医師主導治験. [https://dbcentre3.jmacct.med.or.jp/JMACTR/App/JMACTRE02_04/JMACTRE02_04.aspx?kbn=3&seqno=8259]
 
7) JMACCT : 臨床試験登録システム ; ミスマッチ修復機能異常のある希少がんに対するニボルマブ単剤療法の医師主導治験. [https://dbcentre3.jmacct.med.or.jp/JMACTR/App/JMACTRE02_04/JMACTRE02_04.aspx?kbn=3&seqno=7817]
 
8) UMIN-CTR臨床試験登録情報の閲覧 ; 切除不能かつ化学療法歴を有するHER2 : 1+以上の進行・再発子宮癌肉腫に対するDS-8201aの医師主導治験 [https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000033713]
 
9) JMACCT : 臨床試験登録システム ; MDM2増幅を有する内膜肉腫を対象としたDS-3032b単剤療法の医師主導治験. [https://dbcentre3.jmacct.med.or.jp/JMACTR/App/JMACTRE02_04/JMACTRE02_04.aspx?kbn=3&seqno=8921]
 
10) Redman MW, Allegra CJ : The Master Protocol Concept. Semin Oncol 42 : 724-730, 2015.
PubMed
11) Berry DA : The Brave New World of clinical cancer research : Adaptive biomarker-driven trials integrating clinical practice with clinical research. Mol Oncol 9 : 951-959, 2015.
PubMed
12) Malik SM, et al : Consensus report of a joint NCI thoracic malignancies steering committee : FDA workshop on strategies for integrating biomarkers into clinical development of new therapies for lung cancer leading to the inception of "master protocols" in lung cancer. J Thorac Oncol 9 : 1443-1448, 2014.
 
13) Woodcock J, LaVange LM : Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both. N Engl J Med 377 : 62-70, 2017.
PubMed
14) Hirakawa A, et al : Utility of Bayesian Single-Arm Design in New Drug Application for Rare Cancers in Japan. : A Case Study of Phase 2 Trial for Sarcoma. Ther Innov Regul Sci 52 : 334-338, 2018.
PubMed
P.498 掲載の参考文献
1) Mayer DK, et al : Defining cancer survivors, their needs, and perspectives on survivorship health care in the USA. Larlcet Oncol 18 : e11-e18, 2017.
PubMed
2) Shelburne N, et al : Cancer treatment-related cardiotoxicity : current state of knowledge and future research priorities. J Natl Cancer Inst 106 : dju232, 2014.
PubMed
3) Shelburne N, et al : Changing Hearts and Minds : Improving Outcomes in Cancer Treatment-Related Cardiotoxicity. Curr Oncol Rep 21 : 9, 2019.
PubMed
4) Armstrong GT, et al : Reduction in Late Mortality among 5-Year Survivors of Childhood Cancer. N Engl J Med 374 : 833-842, 2016.
PubMed
5) Abdel-Qadir H, et al : A Population-Based Study of Cardiovascular Mortality Following Early-Stage Breast Cancer. JAMA Cardiol 2 : 88-93, 2017.
PubMed
6) Yeh ET, et al : Oncocardiology-Past, Present, and Future : A Review. JAMA Cardiol 1 : 1066-1072, 2016.
PubMed
7) Moslehi JJ : Cardiovascular Toxic Effects of Targeted Cancer Therapies. N Engl J Med 375 : 1457-1467, 2016.
PubMed
8) Moslehi JJ, et al : Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet 391 : 933, 2018.
PubMed
9) Guha A, et al : Update on cardio-oncology : Novel cancer therapeutics and associated cardiotoxicities. Trends Cardiovasc Med 29 : 29-39, 2019.
PubMed
10) Kenigsberg B, et al : Left Ventricular Dysfunction in Cancer Treatment : Is it Relevant? JACC Heart Fail 6 : 87-95, 2018.
PubMed
11) Zamorano JL, et al : 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines : The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 37 : 2768-2801, 2016.
 
12) Lenneman CG, et al : Cardio-Oncology : An Update on Cardiotoxicity of Cancer-Related Treatment. Circ Res 118 : 1008-1020, 2016.
PubMed
13) Levis BE, et al : Cardiotoxic effects of anthracycline-based therapy : what is the evidence and what are the potential harms? Lancet Oncol 18 : e445-e456, 2017.
PubMed
14) Snipelisky D, et al : How to Develop a Cardio-Oncology Clinic. Heart Fail Clin 13 : 347-359, 2017.
PubMed
15) 佐瀬一洋, ほか : がんサバイバーに対する循環器サポートの必要性. 循環器内科 83 : 495-503, 2018.
 
16) 佐瀬一洋, ほか : Cardio-Oncology (腫瘍循環器学) -最新の診療ガイドラインと今後の課題-腫瘍内科 22 : 181-189, 2018.
 
17) Armenian SH, et al : Recommendations for cardiomyopathy surveillance for survivors of childhood cancer : a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncol 16 : e123-e136, 2015.
PubMed
18) Armenian SH, et al : Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers : American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 35 : 893-911, 2017.
 
19) Clark MA, et al : Soft-tissue sarcomas in adults. N Engl J Med 353 : 701-711, 2005.
PubMed
20) Yonemori K, et al : Prediction of response and prognostic factors for Ewing family of tumors in a low incidence population. J Cancer Res Clin Oncol 134 : 389-395, 2008.
 
21) Taylor BS, et al : Advances in sarcoma genomics and new therapeutic targets. Nat Rev Cancer 11 : 541-557, 2011.
PubMed
22) 小林英介, 川井章 : 軟部肉腫に対するがん薬物療法の新展開 病理組織型からみた薬物療法の選択. 癌と化学療法 44 : 468-472, 2017.
 
23) Simmons CE : Overcoming Inertia to Tame the Red Devil. JACC : CardioOncology 1 : 80-83, 2019.
PubMed
24) Gilchrist SC, et al : Cardio-Oncology Rehabilitation to Manage Cardiovascular Outcomes in Cancer Patients and Survivors : A Scientific Statement From the American Heart Association. Circulation 139 : e997-e1012, 2019.
PubMed
25) Campia U, et al : Cardio-Oncology : Vascular and Metabolic Perspectives : A Scientific Statement From the American Heart Association. Circulation 139 : e579-e602, 2019.
PubMed
P.505 掲載の参考文献
1) 日本放射線腫瘍学会 粒子線治療委員会 : 先進医療会議発表資料-粒子線治療, 2015. [http://www.mhlw.go.jp/file/05-Shingikai-12401000-Hokenkyoku-Soumuka/0000093345.pdf]
 
2) Rosenberg SA, et al : The treatment of soft-tissue sarcomas of the extremities : prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy. Ann Surg 196 : 305-315, 1982.
PubMed
3) Yang JC, et al : Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol 16 : 197-203, 1998.
PubMed
4) Beane JD, et al : Efficacy of adjuvant radiation therapy in the treatment of soft tissue sarcoma of the extremity : 20-year follow-up of a randomized prospective trial. Ann Surg Oncol 21 : 2484-2489, 2014.
PubMed
5) Pisters PW, et al : Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma. J Clin Oncol 14 : 859-868, 1996.
PubMed
6) O'Sullivan B, et al : Five-year results of a randomized phase III trial of pre-operative vs post-operative radiotherapy in extrernity soft tissue sarcoma, ASCO Annual Meeting Proceedings 2004 [abstract]. J Clin Oncol 22 (14 Suppl) : 9007, 2004.
 
7) Al Yami A, et al : Positive surgical margins in soft tissue sarcoma treated with preoperative radiation : is a postoperative boost necessary? Int J Radiat Oncol Biol Phys 77 : 1191-1197, 2010.
PubMed
8) Pisters PW, et al : Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities. J Clin Oncol 14 : 1679-1689, 1996.
PubMed
9) Coindre JM, et al : Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas : a study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group. Cancer 91 : 1914-1926, 2001.
PubMed
10) Suit HD, et al : Treatment of the patient with stage M0 soft tissue sarcoma. J Clin Oncol 6 : 854-862, 1988.
PubMed
11) Koshy M, et al : Improved survival with radiation therapy in high-grade soft tissue sarcomas of the extremities : a SEER analysis. Int J Radiat Oncol Biol Phys 77 : 203-209, 2010.
PubMed
12) O'Sullivan B, et al : Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs : a randomised trial. Lancet 359 : 2235-2241, 2002.
PubMed
13) Davis AM, et al : Late radiation morbidity following randomization to preoperative versus postoperative radiotherapy in extremity soft tissue sarcoma. Radiother Oncol 75 : 48-53, 2005.
PubMed
14) Dickie CI, et al : Bone fractures following external beam radiotherapy and limb-preservation surgery for lower extremity soft tissue sarcoma : relationship to irradiated bone length, volume, tumor location and dose. Int J Radiat Oncol Biol Phys 75 : 1119-1124, 2009.
PubMed
15) Haas RL, et al : Radiotherapy for management of extremity soft tissue sarcomas : why, when, and where? Int J Radiat Oncol Biol Phys 84 : 572-580, 2012.
PubMed
16) Itami J, et al : High-dose rate brachytherapy alone in postoperative soft tissue sarcomas with close or positive margins. Brachytherapy 9 : 349-353, 2010.
PubMed
17) Holloway CL, et al : American Brachytherapy Society (ABS) consensus statement for sarcoma brachytherapy. Brachytherapy 12 : 179-190, 2013.
PubMed
18) Alektiar KM, et al : Impact of intensity-modulated radiation therapy on local control in primary softtissue sarcoma of the extremity. J Clin Oncol 26 : 3440-3444, 2008.
PubMed
P.509 掲載の参考文献
1) 先進医療会議発表資料 : 粒子線治療, 2015. 08. 03. [https://www.mhlw.go.jp/file/05-Shingikai-12401000-Hokenkyoku-Soumuka/0000093345.pdf]
 
2) Imai R, et al : Carbon Ion Radiation Therapy for Unresectable Sacral Chordoma : An Analysis of 188 Cases. Int J Radiat Oncol Biol Phys 95 : 322-327, 2016.
PubMed
3) Matsumoto Y, et al : Evaluation of Risk Factors for Vertebral Compression Fracture after Carbon-Ion Radiotherapy for Primary Spinal and Paraspinal Sarcoma. Biomed Res Int 2017 : 9467402, 2017.
PubMed
4) Matsunobu A, et al : Impact of carbon ion radiotherapy for unresectable osteosarcoma of the trunk. Cancer 118 : 4555-4563, 2012.
PubMed
5) Mohamad O, et al : Carbon ion radiotherapy for inoperable pediatric osteosarcoma. Oncotarget 9 : 22976-22985, 2018.
PubMed
6) Imai R, et al : Clinical Efficacy of Carbon Ion Radiotherapy for Unresectable Chondrosarcomas. Anticancer Res 37 : 6959-6964, 2017.
PubMed
7) Imai R, et al : Carbon ion radiotherapy for unresectable localized axial soft tissue sarcoma. Cancer Med 7 : 4308-4314, 2018.
PubMed
8) Nikoghosyan AV, et al : Randomised trial of proton vs. carbon ion radiation therapy in patients with low and intermediate grade chondrosarcoma of the skull base, clinical phase III study. BMC Cancer 10 : 606, 2010.
PubMed
9) Nikoghosyan AV, et al : Randomised trial of proton vs. carbon ion radiation therapy in patients with chordoma of the skull base, clinical phase III study HIT-1-Study. BMC Cancer 10 : 607, 2010.
PubMed
10) Uhl M, et al : Randomized phase II trial of hypofractionated proton versus carbon ion radiation therapy in patients with sacrococcygeal chordoma-the ISAC trial protocol. Radiat Oncol 9 : 100, 2014.
PubMed
11) Blattmann C, et al : Non-randomized therapy trial to determine the safety and efficacy of heavy ion radiotherapy in patients with non-resectable osteosarcoma. BMC Cancer 10 : 96, 2010.
PubMed
12) Baumann BC, et al : A prospective clinical trial of proton therapy for chordoma and chondrosarcoma : Feasibility assessment. J Surg Oncol 120 : 200-205, 2019.
PubMed
13) Matsumoto K, et al : Treatment Planning Comparison for Carbon Ion Radiotherapy, Proton Therapy and Intensity-modulated Radiotherapy for Spinal Sarcoma. Anticancer Res 35 : 4083-4089, 2015.
PubMed
14) Matsumoto Y, et al : Clinical results of carbon-ion radiotherapy with separation surgery for primary spine/paraspinal sarcomas. Int J Clin Oncol 24 : 1490-1497, 2019.
PubMed
15) Weber DC, et al : Long term outcome of skull-base chondrosarcoma patients treated with high-dose proton therapy with or without conventional radiation therapy. Radiother Oncol 129 : 520-526, 2018.
 
P.517 掲載の参考文献
1) Chung CS, et al : Incidence of second malignancies among patients treated with proton versus photon radiation. Int J Radiat Oncol Biol Phys 87 : 46-52, 2013.
PubMed
2) Ladra MM, et al : Preliminary results of a phase II trial of proton radiotherapy for pediatric rhabdomyosarcoma. J Clin Oncol 32 : 3762-3770, 2014.
PubMed
3) Mizumoto M, et al : Preliminary results of proton radiotherapy for pediatric rhabdomyosarcoma : a multi-institutional study in Japan. Cancer Med 7 : 1870-1874, 2018.
PubMed
4) Leiser D, et al : Tumour control and Quality of Life in children with rhabdomyosarcoma treated with pencil beam scanning proton therapy. Radiother Oncol 120 : 163-168, 2016.
PubMed
5) Weber DC, et al : Pencil Beam Scanning Proton Therapy for Pediatric Parameningeal Rhabdomyosarcomas : Clinical Outcome of Patients Treated at the Paul Scherrer Institute. Pediatr Blood Cancer 63 : 1731-1736, 2016.
PubMed
6) Childs SK, et al : Proton radiotherapy for parameningeal rhabdomyosarcoma : clinical outcomes and late effects. Int J Radiat Oncol Biol Phys 82 : 635-642, 2012.
PubMed
7) Rombi B, et al : Proton radiotherapy for pediatric Ewing's sarcoma : initial clinical outcomes. Int J Radiat Oncol Biol Phys 82 : 1142-1148, 2012.
PubMed
8) Weber DC, et al : Pencil beam scanned protons for the treatment of patients with Ewing sarcoma. Pediatr Blood Cancer 64. doi : 10.1002/pbc.26688, 2017.
 
9) Iwata S, et al : Efficacy of carbon-ion radiotherapy and high-dose chemotherapy for patients with unresectable Ewing's sarcoma family of tumors. Int J Clin Oncol 18 : 1114-1118, 2013.
PubMed
10) Rombi B, et al : Spot-scanning proton radiation therapy for pediatric chordoma and chondrosarcoma : clinical outcome of 26 patients treated at paul scherrer institute. Int J Radiat Oncol Biol Phys 86 : 578-584, 2013.
PubMed
11) McDonald MW, et al : Proton therapy for reirradiation of progressive or recurrent chordoma. Int J Radiat Oncol Biol Phys 87 : 1107-1114, 2013.
 
12) Ares C, et al : Effectiveness and safety of spot scanning proton radiation therapy for chordomas and chondrosarcomas of the skull base : first long-term report. Int J Radiat Oncol Biol Phys 75 : 1111-1118, 2009.
PubMed
13) Rutz HP, et al : Postoperative spot-scanning proton radiation therapy for chordoma and chondrosarcoma in children and adolescents : initial experience at paul scherrer institute. Int J Radiat Oncol Biol Phys 71 : 220-225, 2008.
PubMed
14) Demizu Y, et al : Proton beam therapy for bone sarcomas of the skull base and spine : A retrospective nationwide multicenter study in Japan. Cancer Sci 108 : 972-977, 2017.
PubMed
15) DeLaney TF, Haas RL : Innovative radiotherapy of sarcoma : Proton beam radiation. Eur J Cancer 62 : 112-123, 2016.
PubMed
16) Baldini EH, et al : Treatment Guidelines for Preoperative Radiation Therapy for Retroperitoneal Sarcoma : Preliminary Consensus of an International Expert Panel. Int J Radiat Oncol Biol Phys 92 : 602-612, 2015.
 
17) Frisch S, Timmermann B : The Evolving Role of Proton Beam Therapy for Sarcomas. Clin Oncol (R Coll Radiol) 29 : 500-506, 2017.
PubMed
18) Ciernik IF, et al : Proton-based radiotherapy for unresectable or incompletely resected osteosarcoma. Cancer 117 : 4522-4530, 2011.
PubMed
19) DeLaney TF, et al : Long-term results of Phase II study of high dose photon/proton radiotherapy in the management of spine chordomas, chondrosarcomas, and other sarcomas. J Surg Oncol 110 : 115-122, 2014.
PubMed
20) Demizu Y, et al : Particle Therapy Using Protons or Carbon Ions for Unresectable or Incompletely Resected Bone and Soft Tissue Sarcomas of the Pelvis. Int J Radiat Oncol Biol Phys 98 : 367-374, 2017.
 

II 各論

P.524 掲載の参考文献
1) Ogura K, et al : Statistics of soft-tissue sarcoma in Japan : Report from the Bone and Soft Tissue Tumor Registry in Japan. J Orthop Sci 22 : 755-764, 2017.
PubMed
2) Unni KK, Inwards CY : Introduction and scope of study. In : Dahlin's Bone Turnors, 6th ed, p1-8, Lippincott Williams & Wilkins, Philadelphia, 2010.
 
3) Tsukushi S, et al : Clavicula pro humero reconstruction after wide resection of the proximal humerus. Clin Orthop Relat Res 447 : 132-137, 2006.
PubMed
4) Wada T, et al : Reconstruction and limb salvage after resection for malignant bone tumour of the proximal humerus. A sling procedure using a free vascularised fibular graft. J Bone Joint Surg Br 81 : 808-813, 1999.
 
5) Emori M, et al : Vascularised fibular grafts for reconstruction of extremity bone defects after resection of bone and soft-tissue tumours : a single institutional study of 49 patients. Bone Joint J 99-B : 1237-1243, 2017.
PubMed
6) 白戸力弥, ほか : 小児上腕骨近位部悪性骨腫瘍に対する上腕吊り下げ法術後の2症例-術後の肘関節屈曲拘縮に対するスプリント療法-. 北海道作業療法 29 : 105-110, 2012.
Medical*Online
7) Teunis T, et al : Outcome after reconstruction of the proximal humerus for turnor resection : a systematic review. Clin Orthop Relat Res 472 : 2245-2253, 2014.
 
8) Grosel TW, et al : Reverse total shoulder arthroplasty provides stability and better function than hemiarthroplasty following resection of proximal humerus tumors. J Shoulder Elbow Surg. 28 : 2147-2152, 2019.
PubMed
P.533 掲載の参考文献
1) 日本整形外科学会 骨・軟部腫瘍委員会 (編) : 全国骨腫瘍登録一覧表, 国立がん研究センター, 2014.
 
2) Yilmaz M, et al : Long-term results of the Global Modular Replacement System tumor prosthesis for reconstruction after limb-sparing bone resections in orthopedic oncologic conditions : Results from a national cohort. J Surg Oncol 120 : 183-192, 2019.
PubMed
3) Shimozaki S, et al : Pedicle versus free frozen autograft for reconstruction in malignant bone and soft tissue tumors of the lower extremities. J Orthop Sci 19 : 156-163, 2014.
 
4) Ogura K, et al : Statistics of soft-tissue sarcoma in Japan : Report from the Bone and Soft Tissue Tumor Registry in Japan. J Orthop Sci 22 : 755-764, 2017.
PubMed
5) Mavrogenis AF, et al : Similar survival but better function for patients after limb salvage versus amputation for distal tibia osteosarcoma. Clin Orthop Relat Res 470 : 1735-1748, 2012.
PubMed
6) Kotz R, Salzer M : Rotation-plasty for childhood osteosarcoma of the distal part of the femur. J Bone Joint Surg Am 64 : 959-969, 1982.
PubMed
7) Bernthal NM, et al : How long do endoprosthetic reconstructions for proximal femoral tumors last? Clin Orthop Relat Res 468 : 2867-2874, 2010.
 
8) Watanabe K, et al : Over 10-year follow-up of functional outcome in patients with bone tumors reconstructed using distraction osteogenesis. J Orthop Sci 18 : 101-109, 2013.
PubMed
9) Pala E, et al : Distal femur reconstruction with modular tumour prostheses : a single Institution analysis of implant survival comparing fixed versus rotating hinge knee prostheses. Int Orthop 40 : 2171-2180, 2016.
PubMed
10) Myers GJ, et al : Endoprosthetic replacement of the distal femur for bone tumours : long-term results. J Bone Joint Surg Br 89 : 521-526, 2007.
PubMed
11) Sevelda F, et al : Total Femur Replacement After Tumor Resection : Limb Salvage Usually Achieved But Complications and Failures are Common. Clin Orthop Relat Res 473 : 2079-2087, 2015.
PubMed
12) Medellin MR, et al : Mechanisms of failure and survival of total femoral endoprosthetic replacements. Bone Joint J 101-B : 522-528, 2019.
PubMed
13) Malawer MM, McHale KA : Limb-sparing surgery for high-grade malignant tumors of the proximal tibia. Surgical technique and a method of extensor mechanism reconstruction. Clin Orthop Relat Res (239) : 231-248, 1989.
 
14) Albergo JI, et al : Proximal Tibia Reconstruction After Bone Tumor Resection : Are Survivorship and Outcomes of Endoprosthetic Replacement and Osteoarticular Allograft Similar? Clin Orthop Relat Res 475 : 676-682, 2017.
PubMed
15) Puchner SE, et al : Outcome after Reconstruction of the Proximal Tibia-Complications and Competing Risk Analysis. PLoS ONE 10 : e0135736, 2015.
PubMed
16) 増田秀輔, ほか : 脛骨遠位に発生した淡明細胞型軟骨肉腫の1例. 関東整形災害外科学会雑誌 45 : 129-134, 2014.
 
17) Abdel MP, et al : Malignant proximal fibular tumors : surgical management of 112 cases. J Bone Joint Surg Am 94 : e165, 2012.
 
18) Dieckmann R, et al : Reconstruction after wide resection of the entire distal fibula in malignant bone tumours. Int Orthop 35 : 87-92, 2011.
PubMed
19) 森岡秀夫 : 小児固形悪性腫瘍の外科治療 運動器に発生する小児がん切除後の機能再建 悪性骨腫瘍に対する患肢温存手術を中心として. 日本小児血液・がん学会雑誌 51 : 382-388, 2014.
 
20) Schiller C, et al : Extendable tumour endoprostheses for the leg in children. J Bone Joint Surg Br 77 : 608-614, 1995.
 
21) Schinhan M, et al : Extendible Prostheses for Children After Resection of Primary Malignant Bone Tumor : Twenty-seven Years of Experience. J Bone Joint Surg Am 97 : 1585-1591, 2015.
PubMed
P.540 掲載の参考文献
1) Mendenhall WM, et al : Head and neck osteosarcoma. Am J Otolaryngol 32 : 597-600, 2011.
PubMed
2) Peng KA, et al : Head and neck sarcomas : analysis of the SEER database. Otolaryngol Head Neck Surg 151 : 627-633, 2014.
PubMed
3) Smeele LE, et al : Effect of chemotherapy on survival of craniofacial osteosarcoma : a systematic review of 201 patients. J Clin Oncol 15 : 363-367, 1997.
PubMed
4) Guadagnolo BA, et al : Osteosarcoma of the jaw/craniofacial region : outcomes after multimodality treatrnent. Cancer 115 : 3262-3270, 2009.
 
5) Ellis MA, et al : Head and neck chondrosarcomas : Analysis of the Surveillance, Epidemiology, and End Results database. Head Neck 38 : 1359-1366, 2016.
PubMed
6) Wasserman JK, et al : Chordoma of the Head and Neck : A Review. Head Neck Pathol 12 : 261-268, 2018.
PubMed
7) Unni KK, Inwards CY : Dahlin's Bone Tumors : General Aspects and Data on 10,165 Cases, 6th ed, Lippincott Williams & Wilkins, Philadelphia, 2010.
 
8) Boon E, et al : Impact of chemotherapy on the outcome of osteosarcoma of the head and neck in adults. Head Neck 39 : 140-146, 2017.
PubMed
9) Liang L, et al : An individual patient data meta-analysis on the effect of chemotherapy on survival in patients with craniofacial osteosarcoma. Head Neck 41 : 2016-2023, 2019.
 
10) Bouaoud J, et al : Lack of efficacy of neoadjuvant chemotherapy in adult patients with maxillo-facial high-grade osteosarcomas : A French experience in two reference centers. Oral Oncol 95 : 79-86, 2019.
PubMed
11) Vogel J, et al : Proton therapy for pediatric head and neck malignancies. Pediatr Blood Cancer 65. doi : 10.1002/pbc.26858, 2018.
 
12) Rombi B, et al : Proton radiotherapy for pediatric tumors : review of first clinical results. Ital J Pediatr 40 : 74, 2014.
PubMed
P.549 掲載の参考文献
1) Ciftdemir M, et al : Tumors of the spine. World J Orthop 7 : 109-116, 2016.
PubMed
2) Shankar GM, et al : The role of revision surgery and adjuvant therapy following subtotal resection of osteosarcoma of the spine : a systematic review with meta-analysis. J Neurosurg Spine 27 : 97-104, 2017.
PubMed
3) Berger GK, et al : Outcomes in different age groups with primary Ewing sarcoma of the spine : a systematic review of the literature. J Neurosurg Spine 30 : 664-673, 2019.
 
4) Arshi A, et al : Chondrosarcoma of the Osseous Spine : An Analysis of Epidemiology, Patient Outcomes, and Prognostic Factors Using the SEER Registry From 1973 to 2012. Spine 42 : 644-652, 2017.
PubMed
5) Yang Y, et al : Primary leiomyosarcomti of the spine : A case report and literature review. Medicine (Baltimore) 96 : e6227, 2017.
PubMed
6) Yang M, et al : Surgical management and outcome of synovial sarcoma in the spine. World J Surg Oncol 16 : 175, 2018.
PubMed
7) Tenny S, Varacallo M : Chordoma. StatPearls [Internet], 2019.
 
P.555 掲載の参考文献
1) Jawad MU, et al : Malignant sarcoma of the pelvic bones : treatment outcomes and prognostic factors vary by histopathology. Cancer 117 : 1529-1541, 2011.
PubMed
2) Song K, et al : Prognostic nomograms for predicting overall and cancer-specific survival of highgrade osteosarcoma patients. J Bone Oncol 13 : 106-113, 2018.
PubMed
3) Kawai A, et al : Osteosarcoma of the pelvis. Oncologic results of 40 patients. Clin Orthop Relat Res (348) : 196-207, 1998.
PubMed
4) Ham SJ, et al : Osteosarcoma of the pelvis-oncological results of 40 patients registered by The Netherlands Committee on Bone Tumours. Eur J Surg Oncol 26 : 53-60, 2000.
 
5) Ozaki T, et al : Osteosarcoma of the pelvis : experience of the Cooperative Osteosarcoma Study Group. J Clin Oncol 21 : 334-341, 2003.
 
6) Donati D, et al : Osteosarcoma of the pelvis. Eur J Surg Oncol 30 : 332-340, 2004.
PubMed
7) Fuchs B, et al : Osteosarcoma of the pelvis : outcome analysis of surgical treatment. Clin Orthop Relat Res 467 : 510-518, 2009.
PubMed
8) Parry MC, et al : Osteosarcoma of the pelvis. Bone Joint J 98-B : 555-563, 2016.
 
9) Song WS, et al : Pelvis and extremity osteosarcoma with similar tumor volume have an equivalent survival. J Surg Oncol 101 : 611-617, 2010.
PubMed
10) Tsagozis P, et al : Treatment outcome of patients with chondroblastic osteosarcoma of the limbs and pelvis. Bone Joint J 101-B : 739-744, 2019.
PubMed
11) Xu J, et al : Neoadjuvant Chemotherapy Followed by Delayed Surgery : Is it Necessary for All Patients With Nonmetastatic High-Grade Pelvic Osteosarcoma? Clin Orthop Relat Res 476 : 2177-2186, 2018.
PubMed
12) Liang H, et al : Radiological characteristics and predisposing factors of venous tumor thrombus in pelvic osteosarcoma : A mono-institutional retrospective study of 115 cases. Cancer Med 7 : 4903-4913, 2018.
PubMed
13) Chen L, et al : Prognostic nomograms to predict overall survival and cancer-specific survival in patients with pelvic chondrosarcoma. Cancer Med 8 : 5438-5449, 2019.
PubMed
14) Bus MPA, et al : Conventional Primary Central Chondrosarcoma of the pelvis : Prognostic Factors and Outcome of Surgical Treatment in 162 Patients. J Bone Joint Surg Am 100 : 316-325, 2018.
PubMed
15) Donati D, et al : Surgical treatment and outcome of conventional pelvic chondrosarcoma. J Bone Joint Surg Br 87 : 1527-1530, 2005.
PubMed
16) Stevenson JD, et al : The role of surgical margins in chondrosarcoma. Eur J Surg Oncol 44 : 1412-1418, 2018.
PubMed
17) Yock TI, et al : Local control in pelvic Ewing sarcoma : analysis from INT-0091-a report from the Children's Oncology Group. J Clin Oncol 24 : 3838-3843, 2006.
 
18) Ahmed SK, et al : Pelvis Ewing sarcoma : Local control and survival in the modern era. Pediatr Blood Cancer 64. doi : 10.1002/pbc.26504, 2017.
 
19) Zhu C, et al : Provider views on the management of Ewing sarcoma of the spine and pelvis. J Surg Oncol 117 : 417-424, 2018.
PubMed
20) Fujiwara T, et al : Surgical treatment for pelvic Ewing sarcoma : What is a safe and functional acetabular reconstruction when combined with modern multidisciplinary treatments? J Surg Oncol 120 : 985-993, 2019.
PubMed
21) Kunisada T, et al : Temporary External Fixation Can Stabilize Hip Transposition Arthroplasty After Resection of Malignant Periacetabular Bone Tumors. Clin Orthop Relat Res 477 : 1892-1901, 2019.
PubMed
P.562 掲載の参考文献
1) 日本整形外科学会骨軟部腫瘍委員会 : 平成27年度全国軟部腫瘍登録一覧表, 2015.
 
2) Kawaguchi N, et al : The concept of curative margin in surgery for bone and soft tissue sarcoma. Clin Orthop Relat Res (419) : 165-172, 2004.
 
3) Talbert ML, et al : Conservative surgery and radiation therapy for soft tissue sarcoma of the wrist, hand, ankle, and foot. Cancer 66 : 2482-2491, 1990.
PubMed
4) Muramatsu K, et al : Musculoskeletal sarcomas in the forearm and hand : standard treatment and microsurgical reconstruction for limb salvage. Anticancer Res 33 : 4175-4182, 2013.
PubMed
5) Clarkson PW, et al : Epineural dissection is a safe technique that facilitates limb salvage surgery. Clin Orthop Relat Res 438 : 92-96, 2005.
PubMed
6) Popov P, et al : Soft-tissue sarcomas of the upper extremity : surgical treatment and outcome. Plast Reconstr Surg 113 : 222-230 ; discussion 231-232, 2004.
 
7) Puhaindran ME, Athanasian EA : Double ray amputation for tumors of the hand. Clin Orthop Relat Res 468 : 2976-2979, 2010.
PubMed
8) Megerle K, Sauerbier M : Reconstructive treatment of soft tissue sarcoma of the upper extremity. J Hand Surg Am 36 : 1241-1247, 2011.
PubMed
9) Radaelli S, et al : Vascular resection en-bloc with tumor removal and graft reconstruction is safe and effective in soft tissue sarcoma (STS) of the extremities and retroperitoneum. Surg Oncol 25 : 125-131, 2016.
PubMed
10) Tanaka K et al : Perioperative chemotherapy with ifosfamide and doxorubicin for high-grade soft tissue sarcomas in the extremities (JCOG0304). Jpn J Clin Oncol 45 : 555-561, 2015.
PubMed
11) O'Sullivan B, et al : Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs : a randomised trial. Lancet 359 : 2235-2241, 2002.
PubMed
12) Alektiar KM, et al : Influence of site on the therapeutic ratio of adjuvant radiotherapy in soft-tissue sarcoma of the extremity. Int J Radiat Oncol Biol Phys 63 : 202-208, 2005.
PubMed
13) Matsubara T, et al : Clinical outcomes of minimally invasive surgery using acridine orange for musculoskeletal sarcomas around the forearm, compared with conventional limb salvage surgery after wide resection. J Surg Oncol 102 : 271-275, 2010.
PubMed
14) Gustafson P, Arner M : Soft tissue sarcoma of the upper extremity : descriptive data and outcome in a population-based series of 108 adult patients. J Hand Surg Am 24 : 668-674, 1999.
 
15) Yamada Y, et al : Oncologic and functional outcomes of soft tissue sarcomas of the distal upper extremity : comparison with those of the proximal upper extremity. Int Surg 95 : 33-39, 2010.
PubMed
P.567 掲載の参考文献
1) 日本整形外科学会骨軟部腫瘍委員会 : 登録診断名・発生部位 (平成18年～27年) (2006-2015). 全国軟部腫瘍登録一覧表 (国立がん研究センター編), p46-49, 2015.
 
2) Gerrand CH, et al : The infiuence of anatomic location on functional outcome in lower-extremity soft-tissue sarcoma. Ann Surg Oncol 11 : 476-482, 2004.
 
3) Moore J, et al : Major wound complication risk factors following soft tissue sarcoma resection. Eur J Surg Oncol 40 : 1671-1676, 2014.
PubMed
4) Tanaka A, et al : Knee extension strength and post-operative functional prediction in quadriceps resection for soft-tissue sarcoma of the thigh. Bone Joint Res 5 : 232-238, 2016.
PubMed
5) Tanaka A, et al : Prediction of muscle strength and postoperative function after knee flexor muscle resection for soft tissue sarcoma of the lower limbs. Orthop Traumatol Surg Res 103 : 1081-1085, 2017.
PubMed
6) Nakamura T, et al : Soft tissue sarcoma at the adductor compartment of the thigh may have a greater risk of tumor-associated events and wound complications. J Orthop Surg (Hong Kong) 27 : 2309499019840813, 2019.
PubMed
7) Kito M, et al : Risk factor for wound complications following wide resection of soft tissue sarcoma in the adductor compartment of the thigh. Jpn J Clin Oncol, 2019. [Epub ahead of print]
 
8) Tsukushi S, et al : Results of limb-salvage surgery with vascular reconstruction for soft tissue sarcoma in the lower extremity : comparison between only arterial and arterovenous reconstruction. J Surg Oncol 97 : 216-220, 2008.
PubMed
9) Turcotte RE, et al : Outcomes in patients with popliteal sarcomas. Can J Surg 52 : 51-55, 2009.
PubMed
10) Pritsch T, et al : Popliteal sarcomas : presentation, prognosis, and limb salvage. Clin Orthop Relat Res 455 : 225-233, 2007.
PubMed
11) Huh WW, et al : Soft tissue sarcomas of the popliteal fossa : a single-institution retrospective review. Cancer 117 : 2728-2734, 2011.
 
12) Harati K, et al : Soft tissue sarcomas of the distal lower extremities : A single-institutional analysis of the prognostic significance of surgical margins in 120 patients. Oncol Rep 36 : 863-870, 2016.
PubMed
13) Niimi R, et al : Usefulness of limb salvage surgery for bone and soft tissue sarcomas of the distal lower leg. J Cancer Res Clin Oncol 134 : 1087-1095, 2008.
PubMed
14) Cribb GL, et al : Limb salvage for soft-tissue sarcomas of the foot and ankle. J Bone Joint Surg Br 92 : 424-429, 2010.
PubMed
15) Kozawa E, et al : Foot sarcomas : Factors affecting oncological and functional outcomes. Oncol Lett 3 : 82-88, 2012.
PubMed
P.573 掲載の参考文献
1) Mullinax JE, et al : Management of Truncal Sarcoma. Surg Clin North Am 96 : 1003-1013, 2016.
PubMed
2) 日本整形外科学会骨軟部腫瘍委員会 : 全国軟部腫瘍登録一覧表, p46-49. 国立がん研究センター, 2015.
 
3) Brennan MF, et al : Lessons learned from the study of 10,000 patients with soft tissue sarcoma. Ann Surg 260 : 416-421 ; discussion 421-422, 2014.
 
4) Trovik C, et al : The Scandinavian Sarcoma Group Central Register : 6,000 patients after 25 years of monitoring of referral and treatment of extremity and trunk wall soft-tissue sarcoma. Acta Orthop 88 : 341-347, 2017.
PubMed
5) Tsukushi S, et al : Soft tissue sarcomas of the chest wall. J Thorac Oncol 4 : 834-837, 2009.
PubMed
6) Wilder F, et al : Soft tissue tumors of the trunk : management of local disease in the breast and chest and abdominal walls. J Surg Oncol 111 : 546-552, 2015.
 
7) Maretty-Nielsen K, et al : Prognostic factors for local recurrence and mortality in adult soft tissue sarcoma of the extremities and trunk wall : a cohort study of 922 consecutive patients. Acta Orthop 85 : 323-332, 2014.
 
8) Yu PY, et al : Perioperative chemotherapy is not associated with improved survival in high-grade truncal sarcoma. J Surg Res 231 : 248-256, 2018.
 
9) Pasquali S, et al : The impact of chemotherapy on survival of patients with extremity and trunk wall soft tissue sarcoma : revisiting the results of the EORTC-STBSG 62931 randomised trial. Eur J Cancer 109 : 51-60, 2019.
PubMed
10) Biau DJ, et al : Adverse effect of older age on the recurrence of soft tissue sarcoma of the extremities and trunk. J Clin Oncol 29 : 4029-4035, 2011.
 
11) 田中達也, ほか : 腹壁再建を施行した腹壁軟部腫瘍の治療経験. 整形外科 69 : 213-218, 2018.
 
12) 樋口恒司, ほか : 胸壁悪性軟部肉腫に対する肋骨合併切除・胸郭再建術. 小児外科 46 : 120-124, 2014.
Medical*Online
13) Riad S, et al : The clinical and functional outcome for patients with radiation-induced soft tissue sarcoma. Cancer 118 : 2682-2692, 2012.
PubMed
P.579 掲載の参考文献
1) Raut CP, et al : Retroperitoneal sarcomas : Combined-modality treatment approaches. J Surg Oncol 94 : 81-87, 2006.
PubMed
2) NCCN Clinical Practice Guidelines in Oncology, Soft Tissue Sarcoma, Ver 4.2019-September 12, 2019. [https://www.nccn.org/professionals/physician_gls/default.aspx]
 
3) Tan MC, et al : Surgical management of retroperitoneal and pelvic sarcomas. J Surg Oncol 111 : 553-561, 2015.
PubMed
4) Trans-Atlantic RPS Working Group : Management of primary retroperitoneal sarcoma (RPS) in the adult : a consensus approach from the Trans-Atlantic RPS Working Group. Ann Surg Oncol 22 : 256-263, 2015.
 
5) 込山元清 : 後腹膜原発のサルコーマ 手術療法. 外科 80 : 344-349, 2018.
 
6) MacNeill AJ, et al : Post-relapse outcomes after primary extended resection of retroperitoneal sarcoma : A report from the Trans-Atlantic RPS Working Group. Cancer 123 : 1971-1978, 2017.
 
7) Datta J, et al : Contemporary reappraisal of the efficacy of adjuvant chemotherapy in resected retroperitoneal sarcoma : Evidence from a nationwide clinical oncology database and review of the literature. Surg Oncol 26 : 117-124, 2017.
PubMed
8) Le Pechoux C, et al : Should adjuvant radiotherapy be administered in addition to front-line aggressive surgery (FAS) in patients with primary retroperitoneal sarcoma? Ann Oncol 24 : 832-837, 2013.
PubMed
9) Antman K, et al : An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol 11 : 1276-1285, 1993.
PubMed
10) Italiano A, et al : Advanced well-differentiated/dedifferentiated liposarcomas : role of chemotherapy and survival. Ann Oncol 23 : 1601-1607, 2012.
PubMed
11) Judson I, et al : Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma : a randomised controlled phase 3 trial. Lancet Oncol 15 : 415-423, 2014.
PubMed
12) Seddon B, et al : Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS) : a randomised controlled phase 3 trial. Lancet Oncol 18 : 1397-1410, 2017.
PubMed
13) Schoffski P, et al : Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma : a randomised, open-label, multicentre, phase 3 trial. Lancet 387 : 1629-1637, 2016.
 
14) Demetri GD, et al : Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy : Results of a Phase III Randomized Multicenter Clinical Trial. J Clin Oncol 34 : 786-793, 2016.
 
15) van der Graaf WT, et al : Pazopanib for metastatic soft-tissue sarcoma (PALETTE) : a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 379 : 1879-1886, 2012.
PubMed
16) Sleijfer S, et al : Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma : a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol 27 : 3126-3132, 2009.
PubMed
17) Dickson MA, et al : Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With CDK4 Inhibitor Palbociclib : A Phase 2 Clinical Trial. JAMA Oncol 2 : 937-940, 2016.
 
18) Pawlik TM, et al : Long-term results of two prospective trials of preoperative external beam radiotherapy for localized intermediate-or high-grade retroperitoneal soft tissue sarcoma. Ann Surg Oncol 13 : 508-517, 2006.
PubMed
19) Sylvie B, et al : STRASS (EORTC 62092) : A phase III randomized study of preoperative radiotherapy plus surgery versus surgery alone for patients with retroperitoneal sarcoma [abstract]. J Clin Oncol 37 (15 Suppl) : 11001, 2019.
 
20) Sampath S, et al : Radiotherapy and extent of surgical resection in retroperitoneal soft-tissue sarcoma : multi-institutional analysis of 261 patients. J Surg Oncol 101 : 345-350, 2010.
PubMed
P.590 掲載の参考文献
1) Lazar AJ et al : Mesenchymal tumours of the digestive system : Introduction. In : Digestive System Tumours, WHO Classification of Tumours, 5th ed (ed by the WHO Classification of Tumours Editorial Board), p436-438, International Agency for Research on Cancer, Lyon, 2019.
 
2) von Mehren M, Joensuu H : Gastrointestinal Stromal Tumors. J Clin Oncol 36 : 136-143, 2018.
PubMed
3) GIST診療ガイドライン [第3版] 2014年4月改訂 (日本癌治療学会, ほか編), 金原出版, 2014.
 
4) Aisu Y, et al : Laparoscopic and endoscopic cooperative surgery for gastric tumors : Perspective for actual practice and oncological benefits. World J Gastrointest Oncol 10 : 381-397, 2018.
PubMed
5) Joensuu H, et al : Adjuvant Imatinib for High-Risk GI Stromal Tumor : Analysis of a Randomized Trial. J Clin Oncol 34 : 244-250, 2016.
 
6) Kurokawa Y, et al : Phase II study of neoadjuvant imatinib in large gastrointestinal stromal tumours of the stomach. Br J Cancer 117 : 25-32, 2017.
PubMed
7) Young RJ, et al : Angiosarcoma. Lancet Oncol 11 : 983-991, 2010.
PubMed
8) Li DB, et al : A pooled analysis of treatment and prognosis of hepatic angiosarcoma in adults. Hepatobiliary Pancreat Dis Int 17 : 198-203, 2018.
PubMed
9) Lenze F, et al : Undifferentiated embryonal sarcoma of the liver in adults. Cancer 112 : 2274-2282, 2008.
PubMed
10) 守正浩, ほか : 手術症例報告 若年成人に発症した肝原発未分化肉腫の1例. 手術 65 : 625-630, 2011.
 
11) Green C, et al : Clear cell sarcoma of the gastrointestinal tract and malignant gastrointestinal neuroectodermal tumour : distinct or related entities? A review. Pathology 50 : 490-498, 2018.
PubMed
12) Dry SM, Kumarasinghe MP : Rhabdomyosarcoma. In : Digestive System Tumours, WHO Classification of Tumours, 5th ed (ed by the WHO Classification of Tumours Editorial Board), p460-461, International Agency for Research on Cancer, Lyon, 2019.
 
13) Gootee J, et al : Important prognostic factors in leiomyosarcoma survival : a National Cancer Database (NCDB) analysis. Clin Transl Oncol, 2019. [Epub ahead of print]
 
14) 横紋筋肉腫. 小児がん診療ガイドライン [2016年版] (日本小児血液・がん学会編), p251-299, 金原出版, 2016.
 
15) Makhlouf HR, et al : Synovial sarcoma of the stomach : a clinicopathologic, immunohistochemical, and molecular genetic study of 10 cases. Am J Surg Pathol 32 : 275-281, 2008.
PubMed
P.596 掲載の参考文献
1) 子宮体がん治療ガイドライン [2018年版] (第4版), 金原出版, 2018.
 
2) McMeekin DS, et al : A phase II trial of thalidomide in patients with refractory uterine carcinosarcoma and correlation with biomarkers of angiogenesis : a Gynecologic Oncology Group study. Gynecol Oncol 127 : 356-361, 2012.
 
3) Campos SM, et al : A phase II evaluation of pazopanib in the treatment of recurrent or persistent carcinosarcoma of the uterus : a gynecologic oncology group study. Gynecol Oncol 133 : 537-541, 2014.
PubMed
4) Powell MA, et al : Phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of the uterus : a Gynecologic Oncology Group study. J Clin Oncol 28 : 2727-2731, 2010.
 
5) Sutton G, et al : A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus : A Gynecologic Oncology Group Study. Gynecol Oncol 79 : 147-153, 2000.
 
6) Homesley HD, et al : Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma : a Gynecologic Oncology Group Study. J Clin Oncol 25 : 526-531, 2007.
 
7) Cancer Genome Atlas Research Network. Electronic address : elizabeth.demicco@sinaihealthsystem.ca, Cancer Genome Atlas Research Network : Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas. Cell 171 : 950-965. e28, 2017.
 
8) Tsuyoshi H, Yoshida Y : Molecular biomarkers for uterine leiomyosarcoma and endometrial stromal sarcoma. Cancer Sci 109 : 1743-1752, 2018.
PubMed
9) Hensley ML, et al : Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma : results of a phase II trial. J Clin Oncol 20 : 2824-2831, 2002.
PubMed
10) Hensley ML, et al : Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma : a Gynecologic Oncology Group phase II trial. Gynecol Oncol 109 : 329-334, 2008.
PubMed
11) Hensley ML, et al : Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma : a Gynecologic Oncology Group phase II study. Gynecol Oncol 109 : 323-328, 2008.
PubMed
12) Takano T, et al : Feasibility study of gemcitabine plus docetaxel in advanced or recurrent uterine leiomyosarcoma and undifferentiated endometrial sarcoma in Japan. Int J Clin Oncol 19 : 897-905, 2014.
PubMed
13) Seddon B, et al : Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advaneed unresectable or metastatic soft-tissue sarcomas (GeDDiS) : a randomised controlled phase 3 trial. Lancet Oncol 18 : 1397-1410, 2017.
 
14) Ben-Ami E, et al : Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus : Results of a phase 2 study. Cancer 123 : 3285-3290, 2017.
PubMed
15) Tawbi HA, et al : Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARCO28) : a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol 18 : 1493-1501, 2017.
PubMed
16) van der Graaf WT, et al : Pazopanib for metastatic soft-tissue sarcoma (PALETTE) : a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 379 : 1879-1886, 2012.
PubMed
17) Tap WD, et al : Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma : an open-label phase 1b and randomised phase 2 trial. Lancet 388 : 488-497, 2016.
PubMed
18) Schoffski P, et al : Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma : a randomised, open-label, multicentre, phase 3 trial. Lancet 387 : 1629-1637, 2016.
 
19) Demetri GD, et al : Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy : Results of a Phase III Randomized Multicenter Clinical Trial. J Clin Oncol 34 : 786-793, 2016.
 
20) Amant F, et al : Gynecologic Cancer InterGroup (GCIG) consensus review for endometrial stromal sarcoma. Int J Gynecol Cancer 24 : S67-72, 2014.
PubMed
21) Altman AD, et al : Uterine sarcoma and aromatase inhibitors : Tom Baker Cancer Centre experience and review of the literature. Int J Gynecol Cancer 22 : 1006-1012, 2012.
 
22) Pink D, et al : Harm or benefit of hormonal treatment in metastatic low-grade endometrial stromal sarcoma : single center experience with 10 cases and review of the literature. Gynecol Oncol 101 : 464-469, 2006.
PubMed
23) Wade K, et al : Uterine sarcoma : steroid receptors and response to hormonal therapy. Gynecol Oncol 39 : 364-367, 1990.
PubMed
24) Sutton G, et al : Ifosfamide treatment of recurrent or metastatic endometrial stromal sarcomas previously unexposed to chemotherapy : a study of the Gynecologic Oncology Group. Obstet Gynecol 87 (5pt 1) : 747-750, 1996.
 
P.603 掲載の参考文献
1) Colwell B : Angiosarcoma [http://www.parkhurstexchange.com/oncology/2012-03-09], 2012.
 
2) 増澤幹男, ほか : 北里大学病院皮膚科脈管肉腫の集計と解析. 皮膚病診療 32 : 476-482, 2010.
 
3) Pawlik TM, et al : Cutaneous angiosarcoma of the scalp : a multidisciplinary approach. Cancer 98 : 1716-1726, 2003.
PubMed
4) Abraham JA, et al : Treatment and outcome of 82 patients with angiosarcoma. Ann Surg Oncol 14 : 1953-1967, 2007,
PubMed
5) 山崎直也 : 血管肉腫に対する国立がんセンターの治療戦略. Skin Cancer 24 : 385-391, 2009.
 
6) Mark RJ, et al : Angiosarcoma. A report of 67 patients and a review of the literature. Cancer 77 : 2400-2406, 1996.
 
7) Penel N, et al : Phase II trial of weekly paclitaxel for unresectable angiosarcoma : the ANGIOTAX Study. J Clin Oncol 26 : 5269-5274, 2008.
PubMed
8) Fujisawa Y, et al : Chemoradiotherapy with taxane is superior to conventional surgery and radiotherapy in the management of cutaneous angiosarcoma : a multicentre, retrospective study. Br J Dermatol 171 : 1493-1500, 2014.
PubMed
9) Bowne WB, et al : Dermatofibrosarcoma protuberans : A clinicopathologic analysis of patients treated and followed at a single institution. Cancer 88 : 2711-2720, 2000.
 
10) Mendenhall WM, et al : Dermatofibrosarcoma protuberans. Cancer 101 : 2503-2508, 2004.
PubMed
11) Ugurel S, et al : Short German guidelines : Dermatofibrosarcoma protuberans. J Dtsch Dermatol Ges 6 (Suppl 1) : S17-18, 2008.
 
12) Lemm D, et al : Current treatment options in dermatofibrosarcoma protuberans. J Cancer Res Clin Oncol 135 : 653-665, 2009.
PubMed
13) Snow SN, et al : Dermatofibrosarcoma protuberans : a report on 29 patients treated by Mohs micrographic surgery with long-term follow-up and review of the literature. Cancer 101 : 28-38, 2004.
PubMed
14) Rutgers EJ, et al : Dermatofibrosarcoma protuberans : treatment and prognosis. Eur J Surg Oncol 18 : 241-248, 1992.
PubMed
15) Chase DR, Enzinger FM : Epithelioid sarcoma. Diagnosis, prognostic indicators, and treatment. Am J Surg Pathol 9 : 241-263, 1985.
PubMed
P.608 掲載の参考文献
1) Rosen G, et al : Primary osteogenic sarcoma : the rationale for preoperative chemotherapy and delayed surgery. Cancer 43 : 2163-2177, 1979.
PubMed
2) Iwamoto Y, et al : Multiinstitutional phase II study of neoadjuvant chemotherapy for osteosarcoma (NECO study) in Japan : NECO-93J and NECO-95J. J Orthop Sci 14 : 397-404, 2009.
PubMed
3) Bielack SS, et al : Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP : First Results of the EURAMOS-1 Good Response Randomized Controlled Trial. J Clin Oncol 33 : 2279-2287, 2015.
PubMed
4) Marina NM, et al : Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1) : an open-label, international, randomised controlled trial. Lancet Oncol 17 : 1396-1408, 2016.
PubMed
5) Bacci G, et al : Neoadjuvant chemotherapy for osteosarcoma of the extremities with synchronous lung metastases : treatment with cisplatin, adriamycin and high dose of methotrexate and ifosfamide. Oncol Rep 7 : 339-346, 2000.
PubMed
6) Smeland S, et al : Survival and prognosis with osteosarcoma : outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort. Eur J Cancer 109 : 36-50, 2019.
PubMed
7) Ferrari S, et al : EURO-B. O. S. S. : A European study on chemotherapy in bone-sarcoma patients aged over 40 : Outcome in primary high-grade osteosarcoma. Tumori 104 : 30-36, 2018.
 
8) Weiss A, et al : Telangiectatic osteosarcoma : the St. Jude Children's Research Hospital's experience. Cancer 109 : 1627-1637, 2007.
 
9) Nakajima H, et al : Small cell osteosarcoma of bone. Review of 72 cases. Cancer 79 : 2095-2106, 1997.
PubMed
10) Choong PF, et al : Low grade central osteogenic sarcoma. A long-term followup of 20 patients. Clin Orthop Relat Res (322) : 198-206, 1996.
PubMed
11) Okada K, et al : Parosteal osteosarcoma. A clinicopathological study. J Bone Joint Surg Am 76 : 366-378, 1994.
PubMed
12) Grimer RJ, et al : Periosteal osteo sarcoma-a European review of outcome. Eur J Cancer 41 : 2806-2811, 2005.
 
13) Staals EL, et al : High-grade surface osteosarcoma : a review of 25 cases from the Rizzoli Institute. Cancer 112 : 1592-1599, 2008.
PubMed
P.612 掲載の参考文献
1) Delattre O, et al : Gene fusion with an ETS DNA-binding dornain caused by chromosome translocation in human tumours. Nature 359 : 162-165, 1992.
PubMed
2) Delattre O, et al : The Ewing family of tumors-a subgroup of small-round-cell tumors defined by specific chimeric transcripts. N Engl J Med 331 : 294-299, 1994.
PubMed
3) Sankar S, Lessnick SL : Promiscuous partnerships in Ewing's sarcoma. Cancer Genet 204 : 351-365, 2011.
PubMed
4) Hawkins DS, et al : [18F] Fluorodeoxyglucose positron emission tomography predicts outcome for Ewing sarcoma family of tumors. J Clin Oncol 23 : 8828-8834, 2005.
PubMed
5) Schleiermacher G, et al : Increased risk of systemic relapses associated with bone marrow micrometastasis and circulating tumor cells in localized ewing tumor. J Clin Oncol 21 : 85-91, 2003.
PubMed
6) Grier HE, et al : Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med 348 : 694-701, 2003.
 
7) Granowetter L, et al : Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors : a Children's Oncology Group Study. J Clin Oncol 27 : 2536-2541, 2009.
 
8) Womer RB, et al : Randomized controlled trial of Interval-compressed chemotherapy for the treatment of localized Ewing sarcoma : a report from the Children's Oncology Group. J Clin Oncol 30 : 4148-4154, 2012.
 
9) Paulussen M, et al : Localized Ewing tumor of bone : final results of the cooperative Ewing's Sarcoma Study CESS 86. J Clin Oncol 19 : 1818-1829, 2001.
 
10) Jurgens H, et al : Multidisciplinary treatment of primary Ewing's sarcoma of bone. A 6-year experience of a European Cooperative Trial. Cancer 61 : 23-32, 1988.
 
11) Le Deley MC, et al : Cyclophosphamide compared with ifosfamide in consolidation treatment of standard-risk Ewing sarcoma : results of the randomized noninferiority Euro-EWING99-R1 trial. J Clin Oncol 32 : 2440-2448, 2014.
 
12) Schuck A, et al : Local therapy in localized Ewing tumors : results of 1058 patients treated in the CESS 81, CESS 86, and EICESS 92 trials. Int J Radiat Oncol Biol Phys 55 : 168-177, 2003.
PubMed
13) Ozaki T, et al : Significance of surgical margin on the prognosis of patients with Ewing's sarcoma. A report from the Cooperative Ewing's Sarcoma Study. Cancer 78 : 892-900, 1996.
PubMed
14) Bacci G, et al : Prognostic factors in non-metastatic Ewing's sarcoma tumor of bone : an analysis of 579 patients treated at a single institution with adjuvant or neoadjuvant chemotherapy between 1972 and 1998. Acta Oncol 45 : 469-475, 2006.
PubMed
15) Picci P, et al : Chemotherapy-induced tumor necrosis as a prognostic factor in localized Ewing's sarcoma of the extremities. J Clin Oncol 15 : 1553-1559, 1997.
PubMed
P.620 掲載の参考文献
1) Stevenson JD, et al : The role of surgical margins in chondrosarcoma. Eur J Surg Oncol 44 : 1412-1418, 2018.
PubMed
2) 川井章, ほか : 低悪性度軟骨肉腫に対する凍結手術の試み. 臨床整形外科 37 : 585-592, 2002.
 
3) Shemesh SS, et al : Treatment strategies for central low-grade chondrosarcoma of long bones : a systematic review of the literature and meta-analysis. Musculoskelet Surg 102 : 95-109, 2018.
 
4) Skeletal Lesions Interobserver Correlation among Expert Diagnosticians (SLICED) Study Group : Reliability of histopathologic and radiologic grading of cartilaginous neoplasms in long bones. J Bone Joint Surg Am 89 : 2113-2123, 2007.
 
5) Konishi E, et al : Primary central chondrosarcoma of long bone, limb girdle and trunk : Analysis of 174 cases by numerical scoring on histology. Pathol Int 65 : 468-475, 2015.
PubMed
6) Roitman PD, et al : Is Needle Biopsy Clinically Useful in Preoperative Grading of Central Chondrosarcoma of the Pelvis and Long Bones? Clin Orthop Relat Res 475 : 808-814, 2017.
PubMed
7) Bus MPA, et al : Conventional Primary Central Chondrosarcoma of the Pelvis : Prognostic Factors and Outcome of Surgical Treatment in 162 Patients. J Bone Joint Surg Am 100 : 316-325, 2018.
PubMed
8) Outani H, et al : Comparison of clinical and functional outcome between surgical treatment and carbon ion radiotherapy for pelvic chondrosarcoma. Int J Clin Oncol 21 : 186-193, 2016.
PubMed
9) Imai R, et al : Clinical Efficacy of Carbon Ion Radiotherapy for Unresectable Chondrosarcomas. Anticancer Res 37 : 6959-6964, 2017.
PubMed
10) Staals EL, et al : Dedifferentiated central chondrosarcoma. Cancer 106 : 2682-2691, 2006.
PubMed
11) Grimer RJ, et al : Dedifferentiated chondrosarcoma : prognostic factors and outcome from a European group. Eur J Cancer 43 : 2060-2065, 2007.
 
12) Italiano A, et al : Advanced chondrosarcomas : role of chemotherapy and survival. Ann Oncol 24 : 2916-2922, 2013.
PubMed
13) Frezza AM, et al : Mesenchymal chondrosarcorna : prognostic factors and outcome in 113 patients. A European Musculoskeletal Oncology Society study. Eur J Cancer 51 : 374-381, 2015.
 
14) Tsuda Y, et al : Mesenchymal chondrosarcoma : A Japanese Musculoskeletal Oncology Group (JMOG) study on 57 patients. J Surg Oncol 115 : 760-767, 2017.
 
15) Itala A, et al : An institutional review of clear cell chondrosarcoma. Clin Orthop Relat Res 440 : 209-212, 2005.
PubMed
P.627 掲載の参考文献
1) D'Amore T, et al : Chordoma of the mobile spine and sacrum : clinical management and prognosis. J Spine Surg 4 : 546-552, 2018.
PubMed
2) Baratti D, et al : Chordoma : natural history and results in 28 patients treated at a single institution. Ann Surg Oncol 10 : 291-296, 2003.
 
3) Yamaguchi T, et al : Incipient chordoma : a report of two cases of early-stage chordoma arising from benign notochordal cell tumors. Mod Pathol 18 : 1005-1010, 2005.
PubMed
4) Rich TA, et al : Clinical and pathologic review of 48 cases of chordoma. Cancer 56 : 182-187, 1985.
PubMed
5) Bjornsson J, et al : Chordoma of the mobile spine. A clinicopathologic analysis of 40 patients. Cancer 71 : 735-740, 1993.
PubMed
6) Ahmed R, et al : Disease outcomes for skull base and spinal chordomas : a single center experience. Clin Neurol Neurosurg 130 : 67-73, 2015,
PubMed
7) Erazo IS, et al : Clival Chondroid Chordoma : A Case Report and Review of the Literature. Cureus 10 : e3381, 2018.
PubMed
8) 全国骨腫瘍登録一覧表 (日本整形外科学会骨軟部腫瘍委員会編) 平成27年度, p46-47, 国立がんセンター, 2015.
 
9) Steven PM : Chordoma. In : MRI of Bone and Soft Tissue Tumors and Tumorlike Lesions : Differential Diagnosis and Atlas, p379-p382, Thieme, New York, 2008.
 
10) 町並陸生, 牛込新一郎 : 取扱い規約に沿った腫瘍鑑別診断アトラス 骨, p148-151, 文光堂, 1992
 
11) Nachwalter RN, et al : Treatment of dedifferentiated chordoma : a retrospective study from a large volume cancer center. J Neurooncol 144 : 369-376, 2019.
 
12) Hindi N, et al : Imatinib in advanced chordoma : A retrospective case series analysis. Eur J Cancer 51 : 2609-2614, 2015.
PubMed
13) Ishii K, et al : Local recurrence after S2-3 sacrectomy in sacral chordoma. Report of four cases. J Neurosurg 97 : 98-101, 2002.
 
14) Shah AA, et al : Modified En Bloc Spondylectomy for Tumors of the Thoracic and Lumbar Spine : Surgical Technique and Outcomes. J Bone Joint Surg Am 99 : 1476-1484, 2017.
PubMed
15) Mizoe JE : Review of carbon ion radiotherapy for skull base tumors (especially chordomas). Rep Pract Oncol Radiother 21 : 356-360, 2016.
PubMed
16) Pennicooke B, et al : Safety and Local Control of Radiation Therapy for Chordoma of the Spine and Sacrum : A Systematic Review, Spine 41 (Suppl 20) : S186-S192, 2016.
 
17) Jung EW, et al : Single-Fraction Spine Stereotactic Body Radiation Therapy for the Treatment of Chordoma. Technol Cancer Res Treat 16 : 302-309, 2017.
PubMed
18) Aibe N, et al : Outcomes of Patients With Primary Sacral Chordoma Treated With Definitive Proton Beam Therapy. Int J Radiat Oncol Biol Phys 100 : 972-979, 2018.
PubMed
19) Alahmari M, Temel Y : Skull base chordoma treated with proton therapy : A systematic review. Surg Neurol Int 10 : 96, 2019.
PubMed
20) Imai R, et al ; Working Group for Bone and Soft Tissue Sarcomas : Carbon ion radiation therapy for unresectable sacral chordoma : an analysis of 188 cases. Int J Radiat Oncol Biol Phys 95 : 322-327, 2016
 
21) 土井浩, ほか : 原発性脊椎腫瘍の治療における最近の進歩. 臨床整形外科 51 : 593-599, 2016
 
22) Dea N, et al : Current treatment strategy for newly diagnosed chordoma of the mobile spine and sacrum : results of an international survey. J Neurosurg. Spine 30 : 119-125, 2018.
PubMed
P.632 掲載の参考文献
1) Rosenberg AE, et al : Epithelioid haemangioendothelioma. In : WHO Classification of Tumours of Soft Tissue and Bone, 4th ed (ed by Fletcher CDM, et al), p335-336, IARC Press, Lyon, 2013.
 
2) Bovee JVMG, Rosenberg AE : Angiosarcoma. In : WHO Classification of Tumours of Soft Tissue and Bone, 4th ed (ed by Fletcher CDM, et al), p337-338, IARC Press, Lyon, 2013.
 
3) Kleer CG, et al : Epithelioid hemangioendothelioma of bone. Am J Surg Pathol 20 : 1301-1311, 1996.
PubMed
4) Palmerini E, et al : Primary angiosarcoma of bone : a retrospective analysis of 60 patients from 2 institutions. Am J Clin Oncol 37 : 528-534, 2014.
 
5) Florou V, Wilky BA : Current and Future Directions for Angiosarcoma Therapy. Curr Treat Options Oncol 19 : 14, 2018.
 
6) Sindhu S, et al : Angiosarcoma treated successfully with anti-PD-1 therapy-a case report. J Immunother Cancer 5 : 58, 2017.
PubMed
7) Hogendoorn PCW, Kanamori M : Adamantinoma. In : WHO Classification of Tumours of Soft Tissue and Bone, 4th ed (ed by Fletcher CDM, et al), p343-345, IARC Press, Lyon, 2013.
 
8) Puchner SE, et al : Long-term outcome following treatment of Adamantinoma and Osteofibrous dysplasia of long bones. Orthop Traumatol Surg Res 102 : 925-932, 2016.
PubMed
9) McKeown D, Boland PJ : Miscellaneous Malignant Primary Bone Tumors. In : Orthopaedic Knowledge Update. Musculoskeletal Tumors 3, 3rd ed (ed by Biermann JS), p195-201, AAOS, Rosemont, 2014.
 
10) Rekhi B, et al : Clinicopathologic Features of Two Rare Cases of Dedifferentiated Adamantinomas, Including Diagnostic Implications. Int J Surg Pathol 27 : 193-202, 2019.
PubMed
11) Unni KK, Inwards CY : Malignancy in Giant Cell Tumor of Bone. In : Dahlin's Bone Tumors, 6th ed, p243-247, Lippincott Williams & Wilkins, Philadelphia, 2010.
 
12) Palmerini E, et al : Malignancy in Giant Cell Tumor of Bone : A Review of the Literature. Technol Cancer Res Treat 18 : 1-9, 2019.
PubMed
13) Beebe-Dimmer JL, et al : The epidemiology of malignant giant cell tumors of bone : an analysis of data from the Surveillance, Epidemiology and End Results Program (1975-2004). Rare Tumors 1 : e52, 2009.
 
14) Joo MW, et al : Post-radiation sarcoma : A study by the Eastern Asian Musculoskeletal Oncology Group. PLoS One 13 : e0204927, 2018.
PubMed
15) Mavrogenis AF, et al : Post-radiation sarcomas. Clinical outcome of 52 Patients. J Surg Oncol 105 : 570-576, 2012.
PubMed
P.638 掲載の参考文献
1) Ducimetiere F, et al : Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing. PLoS ONE 6 : e20294, 2011.
 
2) Lucas DR, et al : Well-differentiated liposarcoma. The Mayo Clinic experience with 58 cases. Am J Clin Pathol 102 : 677-683, 1994.
 
3) Fletcher CDM, et al : WHO Classification of Tumours of Soft Tissue and Bone, 4th ed, IARC Press, Lyon, 2013.
 
4) Weiss SW, Rao VK : Well-differentiated liposarcoma (atypical lipoma) of deep soft tissue of the extremities, retroperitoneum, and miscellaneous sites. A follow-up study of 92 cag. es with analysis of the incidence of "dedifferentiation". Am J Surg Pathol 16 : 1051-1058, 1992.
 
5) Cassier PA, et al : Adjuvant radiotherapy for extremity and trunk wall atypical lipomatous tumor/well-differentiated LPS (ALT/WD-LPS) : a French Sarcoma Group (GSF-GETO) study. Ann Oncol 25 : 1854-1860, 2014.
PubMed
6) Hoshi M, et al : Surgery for dedifferentiated liposarcoma, presenting two radiologically and pathologically distinctive patterns. Jpn J Clin Oncol 36 : 462-467, 2006.
PubMed
7) Kito M, et al : Clinical outcome of dedifferentiated liposarcoma in the extremities : A retrospective case series of 7 patients. J Orthop Sci 21 : 673-677, 2016,
PubMed
8) Henricks WH, et al : Dedifferentiated liposarcoma : a clinicopathological analysis of 155 cases with a proposal for an expanded definition of dedifferentiation. Am J Surg Pathol 21 : 271-281, 1997.
PubMed
9) Okada K, et al : Primary (de novo) dedifferentiated liposarcoma in the extremities : a multi-institution Tohoku Musculoskeletal Tumor Society study of 18 cases in northern Japan. Jpn J Clin Oncol 41 : 1094-1100, 2011.
PubMed
10) Kilpatrick SE, et al : The clinicopathologic spectrum of myxoid and round cell liposarcoma. A study of 95 cases. Cancer 77 : 1450-1458, 1996.
PubMed
11) Smith TA, et al : Myxoid/round cell liposarcoma of the extremities. A clinicopathologic study of 29 cases with particular attention to extent of round cell liposarcoma. Am J Surg Pathol 20 : 171-180, 1996.
PubMed
12) Durr HR, et al : Myxoid liposarcoma : local relapse and metastatic pattern in 43 patients. BMC Cancer 18 : 304, 2018.
PubMed
13) Asano N, et al : Metastatic patterns of myxoid/round cell liposarcoma : a review of a 25-year experience. Sarcoma 2012 : 345161, 2012.
PubMed
14) Chowdhry V, et al : Myxoid Liposarcoma : Treatment Outcomes from Chemotherapy and Radiation Therapy. Sarcoma 2018 : 8029157, 2018.
PubMed
15) Forni C, et al : Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors. Mol Cancer Ther 8 : 449-457, 2009.
PubMed
16) Di Giandomenico S, et al : Mode of action of trabectedin in myxoid liposarcomas. Oncogene 33 : 5201-5210, 2014.
PubMed
17) Gronchi A, et al : Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma. Ann Oncol 23 : 771-776, 2012.
PubMed
18) Gronchi A, et al : Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001) : an international, open-label, randomised, controlled, phase 3, multicentre trial. Lancet Oncol 18 : 812-822, 2017.
PubMed
19) Chapman TR, et al : Myxoid Liposarcomas Demonstrate a Profound Response to Neoadjuvant Radiation Therapy : An MRI-Based Volumetric Analysis and Pathological Correlation. Int J Radiat Oncol Biol Phys 90 (Suppl) : S756-S757, 2014.
 
20) Wilke CT, et al : Radiologic and Pathologic Response After Neoadjuvant Radiation Therapy for Myxoid Liposarcoma of the Extremities. Int J Radiat Oncol Biol Phys 90 : S765, 2014.
 
21) Chung PW, et al : Radiosensitivity translates into excellent local control in extremity myxoid liposarcoma : a comparison with other soft tissue sarcomas. Cancer 115 : 3254-3261, 2009.
PubMed
22) Guadagnolo BA, et al : Excellent local control rates and distinctive patterns of failure in myxoid liposarcoma treated with conservation surgery and radiotherapy. Int J Radiat Oncol Biol Phys 70 : 760-765, 2008.
PubMed
23) Pitson G, et al : Radiation response : an additional unique signature of myxoid liposarcoma. Int J Radiat Oncol Biol Phys 60 : 522-526, 2004.
PubMed
24) Stevenson JD, et al : Whole-body magnetic resonance imaging in myxoid liposarcoma : A useful adjunct for the detection of extra-pulmonary metastatic disease. Eur J Surg Oncol 42 : 574-580, 2016.
PubMed
25) von Mehren M, et al : Soft Tissue Sarcoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 16 : 536-563, 2018.
 
26) Anderson WJ, Jo VY : Pleomorphic liposarcoma : Updates and current differential diagnosis. Semin Diagn Pathol 36 : 122-128, 2019.
PubMed
27) Gebhard S, et al : Pleomorphic liposarcoma : clinicopathologic, immunohistochemical, and follow-up analysis of 63 cases : a study from the French Federation of Cancer Centers Sarcoma Group. Am J Surg Pathol 26 : 601-616, 2002.
 
28) Hornick JL, et al : Pleomorphic liposarcoma : clinicopathologic analysis of 57 cases. Am J Surg Pathol 28 : 1257-1267, 2004.
PubMed
29) Pirayesh A, et al : The management of retroperitoneal soft tissue sarcoma : a single institution experience with a review of the literature. Eur J Surg Oncol 27 : 49. 1-497, 2001.
 
30) Lewis JJ, et al : Retroperitoneal soft-tissue sarcoma : analysis of 500 patients treated and followed at a single institution. Ann Surg 228 : 355-365, 1998.
 
31) Vijay A, Ram L : Retroperitoneal liposarcoma : a comprehensive review. Am J Clin Oncol 38 : 213-219, 2015.
PubMed
32) Nussbaum DP, et al : Preoperative or postoperative radiotherapy versus surgery alone for retroperitoneal sarcoma : a case-control, propensity score-matched analysis of a nationwide clinical oncology database. Lancet Oncol 17 : 966-975, 2016.
 
33) Datta J, et al : Contemporary reappraisal of the efficacy of adjuvant chemotherapy in resected retroperitoneal sarcoma : Evidence from a nationwide clinical oncology database and review of the literature. Surg Oncol 26 : 117-124, 2017.
PubMed
34) Dickson MA, et al : Phase 2 study of the CDK4 inhibitor abemaciclib in dedifferentiated liposarcoma. J Clin Oncol 37 : 11004, 2019.
 
35) Judson I, et al : Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma : a randomised controlled phase 3 trial. Lancet Oncol 15 : 415-423, 2014.
PubMed
36) Demetri GD, et al : Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy : Results of a Phase III Randomized Multicenter Clinical Trial. J Clin Oncol 34 : 786-793, 2016.
 
37) Schoffski P, et al : Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma : a randomised, open-label, multicentre, phase 3 trial. Lancet 387 : 1629-1637, 2016.
 
38) Sleijfer S, et al : Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma : a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol 27 : 3126-3132, 2009.
PubMed
39) Nakamura T, et al : The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma : A Japanese Musculoskeletal Oncology Group (JMOG) study. Cancer 122 : 1408-1416, 2016.
PubMed
40) Tawbi HA, et al : Pembrolizumab in advanced soft-tissue sarcoma and bone sarcorna (SARC028) : a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol 18 : 1493-1501, 2017.
 
41) Middha S, et al : Reliable Pan-Cancer Microsatellite Instability Assessment by Using Targeted Next-Generation Sequencing Data. JCO Precis Oncol 2017. doi : 10, 1200, 2017.
 
42) Dickson MA, et al : Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With CDK4 Inhibitor Palbociclib : A Phase 2 Clinical Trial. JAMA Oncol 2 : 937-940, 2016.
 
P.645 掲載の参考文献
1) Kikuta K, et al : Global protein-expression profiling for reclassification of malignant fibrous histiocytoma. Biochim Biophys Acta 1854 : 696-701, 2015.
PubMed
2) 沼本邦彦, 尾崎敏文 : 3章 軟部腫瘍各論 悪性軟部腫瘍 悪性線維性組織球腫. 最新整形外科学大系 20 骨軟部腫瘍および関連疾患 (吉川秀樹編), p377-382, 中山書店, 2007.
 
3) Mentzel T, et al : Myxofibrosarcoma. In : WHO Classification of Tumours of Soft Tissue and Bone, 4th ed (ed by Fletcher CDM, et al), p93-94, IARC Press, Lyon, 2013.
 
4) Kikuta K, et al : An analysis of factors related to the tail-like pattern of myxofibrosarcoma seen on MRI. Skeletal Radiol 44 : 55-62, 2015.
 
5) Kikuta K, et al : An analysis of factors related to recurrence of myxofibrosarcoma. Jpn J Clin Oncol 43 : 1093-1104, 2013.
PubMed
6) Kikuta K, et al : Wide-spread ignorance on the treatment of subcutaneous malignant tumors ; a questionnaire-based study. Jpn J Clin Oncol 48 : 130-134, 2018.
PubMed
7) Kikuta K, et al : A histological positive margin after surgery is correlated with high local re-recurrence rate in patients with recurrent myxofibrosarcoma. Jpn J Clin Oncol 47 : 334-341, 2017.
PubMed
8) Oguro S, et al : Preoperatively determining the margins of subcutaneous malignant soft tissue tumours using contrast-enhanced ultrasonography. J Med Ultrason (2001) 45 : 385-388, 2018.
PubMed
9) Kikuta K, et al : Discoidin, CUB and LCCL domain-containing protein 2 (DCBLD2) is a novel biomarker of myxofibrosarcoma invasion identified by global protein expression profiling. Biochim Biophys Acta Proteins Proteom 1865 : 1160-1166, 2017.
PubMed
P.651 掲載の参考文献
1) Dry SM, Frohling S : Leiomyosarcoma. In : WHO Classification of Tumours, 5th ed, Vol 3, Soft Tissue and Bone Tumours (ed by WHO Classification of Tumours Editorial Board), p195-197, IARC, Lyon, 2020.
 
2) 日本整形外科学会骨・軟部腫瘍委員会 : 全国骨・軟部腫瘍登録一覧表. 国立がん研究センター, 2015.
 
3) Goldblum JR, et al : Leiomyosarcoma. In : Enzinger and Weiss's Soft Tissue Tumors, 6th ed, p549-568, Mosby/Elsevier, Philadelphia, 2013.
 
4) Coindre JM, et al : Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas : a study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group. Cancer 91 : 1914-1926, 2001.
PubMed
5) Malinka T, et al : Analysis of outcomes and predictors of long-term survival following resection for retroperitoneal sarcoma. BMC Surg 19 : 61, 2019.
 
6) Davidson B, et al : Progesterone Receptor Expression Is an Independent Prognosticator in FIGO Stage I Uterine Leiomyosarcoma. Am J Clin Pathol 145 : 449-458, 2016.
 
7) George S, et al : Soft Tissue and Uterine Leiomyosarcoma. J Clin Oncol 36 : 144-150, 2018.
PubMed
8) Nussbaum DP, et al : Preoperative or postoperative radiotherapy versus surgery alone for retroperitoneal sarcoma : a case-control, propensity score-matched analysis of a nationwide clinical oncology database. Lancet Oncol 17 : 966-975, 2016.
 
9) Trovik LH, et al : Adjuvant radiotherapy in retroperitoneal sarcomas. A Scandinavian Sarcoma Group study of 97 patients. Acta Oncol 53 : 1165-1172, 2014.
 
10) Reed NS, et al : Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II : an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). Eur J Cancer 44 : 808-818, 2008.
 
11) Tanaka K, et al : Ten-year follow-up results of perioperative chemotherapy with doxorubicin and ifosfamide for high-grade soft-tissue sarcoma of the extremities : Japan Clinical Oncology Group study JCOG0304. BMC Cancer 19 : 890, 2019.
 
12) Hensley ML, et al : Adjuvant gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine leiomyosarcoma : Results of a prospective study. Gynecol Oncol 112 : 563-567, 2009.
PubMed
13) Seddon B, et al : A phase II trial to assess the activity of gemcitabine and docetaxel as first line chemotherapy treatment in patients with unresectable leiomyosarcoma. Clin Sarcoma Res 5 : 13, 2015.
PubMed
14) Demetri GD, et al : Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy : Results of a Phase III Randomized Multicenter Clinical Trial. J Clin Oncol 34 : 786-793, 2016.
 
15) Kawai A, et al : Phase 2 study of eribulin in patients with previously treated advanced or metastatic soft tissue sarcoma. Jpn J Clin Oncol 47 : 137-144, 2017.
PubMed
16) Kobayashi E, et al : Interim results of a real-world observational study of eribulin in soft tissue sarcoma including rare subtypes. Jpn J Clin Oncol, 2019. [Epub ahead of print]
 
17) Schoffski P, et al : Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma : a randomised, open-label, multicentre, phase 3 trial. Lancet 387 : 1629-1637, 2016.
 
18) Blay JY, et al : Eribulin versus dacarbazine in patients with leiomyosarcoma : subgroup analysis from a phase 3, 0pen-label, randomised study. Br J Cancer 120 : 1026-1032, 2019.
PubMed
19) van der Graaf WT, et al : Pazopanib for metastatic soft-tissue sarcoma (PALETTE) : a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 379 : 1879-1886, 2012.
PubMed
20) Benson C, et al : Outcome of uterine sarcoma patients treated with pazopanib : A retrospective analysis based on two European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG) clinical trials 62043 and 62072. Gynecol Oncol 142 : 89-94, 2016.
PubMed
21) Kawai A, et al : Systemic Therapy for Soft Tissue Sarcoma : Proposals for the Optimal Use of Pazopanib, Trabectedin, and Eribulin. Adv Ther 34 : 1556-1571, 2017.
PubMed
22) George S, et al : Phase 2 trial of aromatase inhibition with letrozole in patients with uterine leiomyosarcomas expressing estrogen and/or progesterone receptors. Cancer 120 : 738-743, 2014.
 
23) Slomovitz BM, et al : A randomized phase II study of letrozole vs. observation in patients with newly diagnosed uterine leiomyosarcoma (uLMS). Gynecol Oncol Rep 27 : 1-4, 2019.
PubMed
24) Paoluzzi L, et al : Response to anti-PD1 therapy with nivolumab in metastatic sarcomas. Clin Sarcoma Res 6 : 24, 2016.
PubMed
25) Ben-Ami E, et al : Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus : Results of a phase 2 study. Cancer 123 : 3285-3290, 2017.
PubMed
26) Beck AH, et al : Discovery of molecular subtypes in leiomyosarcoma through integrative molecular profiling. Oncogene 29 : 845-854, 2010.
PubMed
P.659 掲載の参考文献
1) 全国軟部腫瘍登録一覧表 (平成26年度) (日本整形外科学会骨軟部腫瘍委員会編), 国立がん研究センター, 2014.
 
2) Suurmeijer AJH, et al : Synovial sarcoma. In : WHO Classification of Tumours of Soft Tissue and Bone, 4th ed (ed by Fletcher CDM, et al), p213-215, IARC Press, Lyon, 2013.
 
3) Trassard M, et al : Prognostic factors in localized primary synovial sarcoma : a multicenter study of 128 adult patients. J Clin Oncol 19 : 525-534, 2001.
 
4) Guadagnolo BA, et al : Long-term outcomes for synovial sarcoma treated with conservation surgery and radiotherapy. Int J Radiat Oncol Biol Phys 69 : 1173-1180, 2007.
PubMed
5) Canter RJ, et al : A synovial sarcoma-specific preoperative nomogram supports a survival benefit to ifosfamide-based chemotherapy and improves risk stratification for patients. Clin Cancer Res 14 : 8191-8197, 2008.
PubMed
6) Takenaka S, et al : Prognostic implication of SYT-SSX fusion type in synovial sarcorna : a multi-institutional retrospective analysis in Japan. Oncol Rep 19 : 467-476, 2008.
 
7) Palmerini E, et al : Synovial sarcoma : retrospective analysis of 250 patients treated at a single institution. Cancer 115 : 2988-2998, 2009.
 
8) Al-Hussaini H, et al : Clinical features, treatment, and outcome in 102 adult and pediatric patients with localized high-grade synovial sarcoma. Sarcoma 2011 : 231789, 2011.
PubMed
9) Vlenterie M, et al : Age as an independent prognostic factor for survival of localised synovial sarcoma patients. Br J Cancer 113 : 1602-1606, 2015.
PubMed
10) Naing KW, et al : Perioperative radiotherapy is associated with improved survival among patients with synovial sarcoma : ASEER analysis. J Surg Oncol 111 : 158-164, 2015.
 
11) Ferrari A, et al : Synovial sarcoma in children and adolescents : the European Pediatric Soft Tissue Sarcoma Study Group prospective trial (EpSSG NRSTS 2005). Ann Oncol 26 : 567-572, 2015.
 
12) Gronchi A, et al : Histotype-tailored neoadjuvant chemotherapy versus standard chelnotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001) : an international, open-label, randomised, controlled, phase 3, multicentre trial. Lancet Oncol 18 : 812-822, 2017.
PubMed
13) Ferrari A, et al : Surgery alone is sufficient therapy for children and adolescents with low-risk synovial sarcoma : A joint analysis from the European paediatric soft tissue sarcoma Study Group and the Children's Oncology Group. Eur J Cancer 78 : 1-6, 2017.
 
14) Casali PG, et al ; ESMO Guidelines Committee and EURACAN : Soft tissue and visceral sarcomas : ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 29 (Suppl 4) : iv268-iv269, 2018.
 
15) Rosen G, et al : Synovial sarcoma. Uniform response of metastases to high dose ifosfamide. Cancer 73 : 2506-2511, 1994.
PubMed
16) Kubo T, et al : Prognostic value of SS18-SSX fusion type in synovial sarcoma ; systematic review and meta-analysis. Springerplus 4 : 375, 2015.
PubMed
17) Spurrell EL, et al : Prognostic factors in advanced synovial sarcoma : an analysis of 104 patients treated at the Royal Marsden Hospital. Ann Oncol 16 : 437-444, 2005.
 
18) Salah S, et al : Factors influencing survival in metastatic synovial sarcoma : importance of patterns of metastases and the first-line chemotherapy regimen. Med Oncol 30 : 639, 2013.
PubMed
19) Vlenterie M, et al : Outcome of chemotherapy in advanced synovial sarcoma patients : Review of 15 clinical trials from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group ; setting a new landmark for studies in this entity. Eur J Cancer 58 : 62-72, 2016.
PubMed
20) Lindner LH, et al : Prognostic factors for soft tissue sarcoma patients with lung metastases only who are receiving first-line chemotherapy : An exploratory, retrospective analysis of the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTCSTBSG). Int J Cancer 142 : 2610-2620, 2018.
PubMed
21) Seddon B, et al : Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS) : a randomised controlled phase 3 trial. Lancet Oncol 18 : 1397-1410, 2017.
PubMed
22) Pender A, et al : Poor treatment outcomes with palliative gemcitabine and docetaxel chemotherapy in advanced and metastatic synovial sarcoma. Med Oncol 35 : 131, 2018.
PubMed
23) Kawai A, et al : Trabectedin monotherapy after standard chemotherapy versus best supportive care in patients with advanced, translocation-related sarcoma : a randomised, open-label, phase 2 study. Lancet Oncol 16 : 406-416, 2015.
PubMed
24) Araki N, et al : Retrospective inter-and intra-patient evaluation of trabectedin after best supportive care for patients with advanced translocation-related sarcoma after failure of standard chemotherapy. Eur J Cancer 56 : 122-130, 2016.
PubMed
25) Takahashi M, et al : Efficacy of Trabectedin in Patients with Advanced Translocation-Related Sarcomas : Pooled Analysis of Two Phase II Studies. Oncologist 22 : 979-988, 2017.
PubMed
26) Sanfilippo R, et al : Trabectedin in advanced synovial sarcomas : a multicenter retrospective study from four European institutions and the Italian Rare Cancer Network. Anticancer Drugs 26 : 678-681, 2015.
PubMed
27) van der Graaf WT, et al : Pazopanib for metastatic soft-tissue sarcoma (PALETTE) : a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 379 : 1879-1886, 2012.
PubMed
28) Nakamura T, et al : The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma : A Japanese Musculoskeletal Oncology Group (JMOG) study. Cancer 122 : 1408-1416, 2016.
PubMed
29) Gelderblom H, et al : Treatment patterns and clinical outcomes with pazopanib in patients with advanced soft tissue sarcomas in a compassionate use setting : results of the SPIRE study. Acta Oncol 56 : 1769-1775, 2017.
 
30) Schoffski P, et al : Activity of eribulin mesylate in patients with soft-tissue sarcoma : a phase 2 study in four independent histological subtypes. Lancet Oncol 12 : 1045-1052, 2011.
PubMed
31) Kobayashi E, et al : Interim results of a real-world observational study of eribulin in soft tissue sarcoma including rare subtypes. Jpn J Clin Oncol, 2019. [Epub ahead of print]
 
32) Kawai A, et al : Systemic Therapy for Soft Tissue Sarcoma : Proposals for the Optimal Use of Pazopanib, Trabectedin, and Eribulin. Adv Ther 34 : 1556-1571, 2017.
PubMed
33) Desar IME, et al : Systemic Treatment for Adults with Synovial Sarcoma. Curr Treat Options Oncol 19 : 13, 2018.
 
P.663 掲載の参考文献
1) Farid M, et al : Malignant peripheral nerve sheath tumors. Oncologist 19 : 193-201, 2014.
 
2) Thway K, Fisher C : Malignant peripheral nerve sheath tumor : pathology and genetics. Ann Diagn Pathol 18 : 109-116, 2014.
PubMed
3) Kahn J, et al : Radiation therapy in management of sporadic and neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors. Front Oncol 4 : 324, 2014.
PubMed
4) Watson KL, et al : Patterns of recurrence and survival in sporadic, neurofibromatosis Type 1-associated, and radiation-associated malignant peripheral nerve sheath tumors. J Neurosurg 126 : 319-329, 2017.
PubMed
5) Karpinsky G, et al : Tumor expression of survivin, p53, cyclin D1, osteopontin and fibronectin in predicting the response to neo-adjuvant chemotherapy in children with advanced malignant peripheral nerve sheath tumor. J Cancer Res Clin Oncol 144 : 519-529, 2018.
PubMed
6) Wong WW, et al : Malignant peripheral nerve sheath tumor : analysis of treatment outcome. Int J Radiat Oncol Biol Phys 42 : 351-360, 1998.
PubMed
7) Kolberg M, et al : Survival meta-analyses for > 1800 malignant peripheral nerve sheath tumor patients with and without neurofibromatosis type 1. Neuro-oncology 15 : 135-147, 2013.
PubMed
8) Bernthal NM, et al : The effect of surgical margins on outcomes for low grade MPNSTs and atypical neurofibroma. J Surg Oncol 110 : 813-816, 2014.
PubMed
9) James AW, et al : Malignant Peripheral Nerve Sheath Tumor. Surg Oncol Clin N Am 25 : 789-802, 2016.
PubMed
10) Lin AL, Gutmann DH : Advances in the treatment of neurofibromatosis-associated tumours. Nat Rev Clin Oncol 10 : 616-624, 2013.
PubMed
11) van Noesel MM, et al : Outcome and prognostic factors in pediatric malignant peripheral nerve sheath tumors : An analysis of the European Pediatric Soft Tissue Sarcoma Group (EpSSG) NRSTS-2005 prospective study. Pediatr Blood Cancer 66 : e27833, 2019.
PubMed
12) Kroep JR, et al : First-line chemotherapy for malignant peripheral nerve sheath tumor (MPNST) versus other histological soft tissue sarcoma subtypes and as a prognostic factor for MPNST : an EORTC soft tissue and bone sarcoma group study. Ann Oncol 22 : 207-214, 2011.
 
13) Higham CS, et al : SARC006 : Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated Chemotherapy-Naive Malignant Peripheral Nerve Sheath Tumors. Sarcoma 2017 : 8685638, 2017.
PubMed
14) Moretti VM, et al : Early outcomes for malignant peripheral nerve sheath tumor treated with chemotherapy. Am J Clin Oncol 34 : 417-421, 2011.
PubMed
15) D'Adamo DR, et al : A Phase II Trial of Sorafenib and Dacarbazine for Leiomyosarcoma, Synovial Sarcoma, and Malignant Peripheral Nerve Sheath Tumors. Oncologist 24 : 857-863, 2019.
PubMed
16) Kar M, et al : Malignant peripheral nerve sheath tumors (MPNST) -clinicopathological study and treatment outcome of twenty-four cases. World J Surg Oncol 4 : 55, 2006.
PubMed
P.668 掲載の参考文献
1) Young RJ, et al : Angiosarcoma. Lancet Oncol 11 : 983-991, 2010.
PubMed
2) Guadagnolo BA, et al : Outcomes after definitive treatment for cutaneous angiosarcoma of the face and scalp. Head Neck 33 : 661-667, 2011.
PubMed
3) Oashi K, et al : Surgery with curative intent is associated with prolonged survival in patients with cutaneous angiosarcoma of the scalp and face-a retrospective study of 38 untreated cases in the Japanese population. Eur J Surg Oncol 44 : 823-829, 2018.
 
4) Patel SH, et al : Angiosarcoma of the scalp and face : the Mayo Clinic experience. JAMA Otolaryngol Head Neck Surg 141 : 335-340, 2015.
 
5) Shin JY, et al : Predisposing factors for poor prognosis of angiosarcoma of the scalp and face : Systematic review and meta-analysis. Head Neck 39 : 380-386, 2017.
PubMed
6) Fujisawa Y, et al : Chemoradiotherapy with taxane is superior to conventional surgery and radiotherapy in the management of cutaneous angiosarcoma : a multicentre, retrospective study. Br J Dermatol 171 : 1493-1500, 2014.
PubMed
7) Miki Y, et al : Single institutional experience of the treatment of angiosarcoma of the face and scalp. Br J Radiol 86 : 20130439, 2013.
PubMed
8) Namikawa K, Yamazaki N : A case of scalp angiosarcoma with lung metastases presenting as multiple thin-walled cysts. Jpn J Clin Oncol 43 : 101, 2013.
PubMed
9) Van Glabbeke M, et al : Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma : an analysis of 2,185 patients treated with anthracycline-containing first-line regimens-a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol 17 : 150-157, 1999.
 
10) Schlemmer M, et al : Paclitaxel in patients with advanced angiosarcomas of soft tissue : a retrospective study of the EORTC soft tissue and bone sarcoma group. Eur J Cancer 44 : 2433-2436, 2008.
 
11) Penel N, et al : Phase II trial of weekly paclitaxel for unresectable angiosarcoma : the ANGIOTAX Study. J Clin Oncol 26 : 5269-5274, 2008.
PubMed
12) Hirata T, et al : Efficacy of taxane regimens in patients with metastatic angiosarcoma. Eur J Dermatol 21 : 539-545, 2011.
PubMed
13) Italiano A, et al : Comparison of doxorubicin and weekly paclitaxel efficacy in metastatic angiosarcomas. Cancer 118 : 3330-3336, 2012.
PubMed
14) Schoffski P, et al : Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma : a randomised, open-label, multicentre, phase 3 trial. Lancet 387 : 1629-1637, 2016.
 
15) Fujisawa Y, et al : The efficacy of eribulin mesylate for patients with cutaneous angiosarcoma previously treated with taxane : a multicentre prospective observational study. Br J Dermatol 2020.
PubMed
16) Agulnik M, et al : An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas. Ann Oncol 24 : 257-263, 2013.
PubMed
17) Ray-Coquard IL, et al : Paclitaxel Given Once Per Week With or Without Bevacizumab in Patients With Advanced Angiosarcoma : A Randomized Phase II Trial. J Clin Oncol 33 : 2797-2802, 2015.
PubMed
18) Ray-Coquard I, et al : Sorafenib for patients with advanced angiosarcoma : a phase II Trial from the French Sarcoma Group (GSF/GETO). Oncologist 17 : 260-266, 2012.
PubMed
19) van der Graaf WT, et al : Pazopanib for metastatic soft-tissue sarcoma (PALETTE) : a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 379 : 1879-1886, 2012.
PubMed
20) Mehta CR, et al : An adaptive population enrichment phase III trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma (TAPPAS trial). Ann Oncol 30 : 103-108, 2019.
PubMed
21) Jones RL, et al : Results of the TAPPAS trial : An adaptive enrichment phase III trial of TRC105 and pazopanib (P) versus pazopanib alone in patients with advanced angiosarcoma (AS). Ann Oncol 30 (Suppl 5) : v683, 2019.
 
22) D'Angelo SP, et al : Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401) : two open-label, non-comparative, randomised, phase 2 trials. Lancet Oncol 19 : 416-426, 2018.
 
23) Florou V, et al : Angiosarcoma patients treated with immune checkpoint inhibitors : a case series of seven patients from a single institution. J Immunother Cancer 7 : 213, 2019.
PubMed
P.675 掲載の参考文献
1) Archer NM, et al : An Increased Risk of Second Malignant Neoplasms After Rhabdomyosarcoma : Population-Based Evidence for a Cancer Predisposition Syndrome? Pediatr Blood Cancer 63 : 196-201, 2016.
PubMed
2) Vaarwerk B, et al : Indeterminate Pulmonary Nodules at Diagnosis in Rhabdomyosarcoma : Are They Clinically Significant? A Report From the European Paediatric Soft Tissue Sarcoma Study Group. J Clin Oncol 37 : 723-730, 2019.
 
3) Miyachi M, et al : Circulating muscle-specific microRNA, miR-206, as a potential diagnostic marker for rhabdomyosarcoma. Biochem Biophys Res Commun 400 : 89-93, 2010.
PubMed
4) Hosoi H, et al : A review of 331 rhabdomyosarcoma cases in patients treated between 1991 and 2002 in Japan. Int J Clin Oncol 12 : 137-145, 2007.
PubMed
5) Skapek SX, et al : PAX-FOXO1 fusion status drives unfavorable outcome for children with rhabdomyosarcoma : a children's oncology group report. Pediatr Blood Cancer 60 : 1411-1417, 2013.
 
6) Missiaglia E, et al : PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification. J Clin Oncol 30 : 1670-1677, 2012.
PubMed
7) Walterhouse DO, et al : Shorter-duration therapy using vincristine, dactinomycin, and lower-dose cyclophosphamide with or without radiotherapy for patients with newly diagnosed low-risk rhabdomyosarcoma : a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. J Clin Oncol 32 : 3547-3552, 2014.
PubMed
8) Raney RB, et al : Results of the Intergroup Rhabdomyosarcoma Study Group D9602 protocol, using vincristine and dactinomycin with or without cyclophosphamide and radiation therapy, for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma : a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. J Clin Oncol 29 : 1312-1318, 2011.
 
9) Walterhouse DO, et al : Reduction of cyclophosphamide dose for patients with subset 2 low-risk rhabdomyosarcoma is associated with an increased risk of recurrence : A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. Cancer 123 : 2368-2375, 2017.
 
10) Hawkins DS, et al : Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk Rhabdomyosarcoma : A Report From the Children's Oncology Group. J Clin Oncol 36 : 2770-2777, 2018.
 
11) Weigel BJ, et al : Intensive Multiagent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide and Vincristine/Doxorubicin/Cyclophosphamide, Irinotecan, and Radiation, in Patients With High-Risk Rhabdomyosarcoma : A Report From the Children's Oncology Group. J Clin Oncol 34 : 117-122, 2016.
 
12) Hosoi H, et al : Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells. Cancer Res 59 : 886-894, 1999.
PubMed
13) Mascarenhas L, et al : Randomized Phase II Trial of Bevacizumab or Temsirolimus in Combination With Chemotherapy for First Relapse Rhabdomyosarcoma : A Report From the Children's Oncology Group. J Clin Oncol 37 : 2866-2874, 2019.
PubMed
14) Casanova M, et al : Vinorelbine and low-dose cyclophosphamide in the treatment of pediatric sarcomas : pilot study for the upcoming European Rhabdomyosarcoma Protocol. Cancer 101 : 1664-1671, 2004.
PubMed
15) Bisogno G, et al : Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS 2005) : a multicentre, open-label, randomised controlled, phase 3 trial. Lancet Oncol 19 : 1061-1071, 2018.
 
16) Bisogno G, et al : Maintenance low-dose chemotherapy in patients with high-risk (HR) rhabdomyosarcoma (RMS) : A report from the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG). J Clin Oncol 36 (18 Suppl) : LBA2, 2018.
 
P.681 掲載の参考文献
1) World Health Organization Classification of Tumours of Soft Tissue and Bone (ed by Fletcher CDM, et al), JARC Press, Lyon, 2013.
 
2) Weiss SW, Goldblum JR : Enzinger & Weiss's Soft Tissue Tumors, 5th ed, Mosby, Philadelphia, 2008.
 
3) Guillou L, et al : "Proximal-type" epithelioid sarcoma, a distinctive aggressive neoplasm showing rhabdoid features. Clinicopathologic, immunohistochemical, and ultrastructural study of a series. Am J Surg Pathol 21 : 130-146, 1997.
PubMed
4) Hornick JL, et al : Loss of INI1 expression is characteristic of both conventional and proximal-type epithelioid sarcoma. Am J Surg Pathol 33 : 542-550, 2009.
PubMed
5) Asano N, et al : Prognostic Value of Relevant Clinicopathologic Variables in Epithelioid Sarcoma : A Multi-Institutional Retrospective Study of 44 Patients. Ann Surg Oncol 22 : 2624-2632, 2015.
PubMed
6) Frezza AM, et al : Anthracycline, Gemcitabine, and Pazopanib in Epithelioid Sarcoma : A Multi-institutional Case Series. JAMA Oncol 4 : e180219, 2018.
PubMed
P.686 掲載の参考文献
1) Gronchi A, et al : Sporadic desmoid-type fibromatosis : a stepwise approach to a non-metastasising neoplasm-a position paper from the Italian and the French Sarcoma Group. Ann Oncol 25 : 578-583, 2014.
PubMed
2) Briand S, et al : Wait-and-see policy as a first-line management for extra-abdominal desmoid tumors. J Bone Joint Surg Am 96 : 631-638, 2014.
PubMed
3) Orbach D, et al : The EpSSG NRSTS 2005 treatment protocol for desmoid-type fibromatosis in children : an international prospective case series. Lancet Child Adolesc Health 1 : 284-292, 2017.
PubMed
4) Penel N, et al : Surgical versus non-surgical approach in primary desmoid-type fibromatosis patients : A nationwide prospective cohort from the French Sarcoma Group. Eur J Cancer 83 : 125-131, 2017.
PubMed
5) Ballo MT, et al : Desmoid tumor : prognostic factors and outcome after surgery, radiation therapy, or combined surgery and radiation therapy. J Clin Oncol 17 : 158-167, 1999.
 
6) Shido Y, et al : Surgical treatment for local control of extremity and trunk desmoid tumors. Arch Orthop Trauma Surg 129 : 929-933, 2009.
PubMed
7) Salas S, et al : Prognostic factors influencing progression-free survival determined from a series of sporadic desmoid tumors : a wait-and-see policy according to tumor presentation. J Clin Oncol 29 : 3553-3558, 2011.
PubMed
8) Colombo C, et al : CTNNB1 45F mutation is a molecular prognosticator of increased postoperative primary desmoid tumor recurrence : an independent, multicenter validation study. Cancer 119 : 3696-3702, 2013.
PubMed
9) Schoffski P, et al : Assessment of Physician's Systemic Treatment Preferences for Patients with Advanced Desmoid-Type Fibromatosis : Experience-Based Medicine in the Absence of High-Levei Evidence. Oncol Res Treat 41 : 214-219, 2018.
 
10) Quast DR, et al : Long-term outcome of sporadic and FAP-associated desmoid tumors treated with high-dose selective estrogen receptor modulators and sulindac : a single-center long-term observational study in 134 patients. Fam Cancer 15 : 31-40, 2016.
PubMed
11) Nishida Y, et al : Successful treatment with meloxicam, a cyclooxygenase-2 inhibitor, of patients with extra-abdominal desmoid tumors : a pilot study. J Clin Oncol 28 : elO7-109, 2010.
 
12) Azzarelli A, et al : Low-dose chemotherapy with methotrexate and vinblastine for patients with advanced aggressive fibromatosis. Cancer 92 : 1259-1264, 2001.
PubMed
13) Nishida Y, et al : Low-dose chemotherapy with methotrexate and vinblastine for patients with desmoid tumors : relationship to CTNNB1 mutation status. Int J Clin Oncol 20 : 1211-1217, 2015.
PubMed
14) Gounder MM, et al : Sorafenib for Advanced and Refractory Desmoid Tumors. N Engl J Med 379 : 2417-2428, 2018.
PubMed
15) Toulmonde M, et al : Pazopanib or methotrexate-vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ) : a non-comparative, randomised, openlabel, multicentre, phase 2 study. Lancet Oncol 20 : 1263-1272, 2019.
 
16) Eastley N, et al : Extra-abdominal desmoid fibromatosis : A review of management, current guidance and unanswered questions. Eur J Surg Oncol 42 : 1071-1083, 2016.
PubMed
17) Nuyttens JJ, et al : Surgery versus radiation therapy for patients with aggressive fibromatosis or desmoid tumors : A comparative review of 22 articles. Cancer 88 : 1517-1523, 2000.
PubMed
P.692 掲載の参考文献
1) Hornick JL : Subclassification of pleomorphic sarcomas : How and why should we care? Ann Diagn Pathol 37 : 118-124, 2018.
PubMed
2) Fletcher CD, et al : Clinicopathologic re-evaluation of 100 malignant fibrous histiocytomas : prognostic relevance of subclassification. J Clin Oncol 19 : 3045-3050, 2001.
 
3) Dineen SP, et al : Radiation-Associated Undifferentiated Pleomorphic Sarcoma is Associated with Worse Clinical Outcomes than Sporadic Lesions. Ann Surg Oncol 22 : 3913-3920, 2015.
PubMed
4) Sheng WQ, et al : Expression of COL1A1-PDGFB fusion transcripts in superficial adult fibrosarcoma suggests a close relationship to dermatofibrosarcoma protuberans. J Pathol 194 : 88-94, 2001.
PubMed
5) Orbach D, et al : Conservative strategy in infantile fibrosarcoma is possible : The European paediatric Soft tissue sarcoma Study Group experience. Eur J Cancer 57 : 1-9, 2016.
 
6) Navarrete-Dechent C, et al : Imatinib Treatment for Locally Advanced or Metastatic Dermatofibrosarcoma Protuberans : A Systematic Review. JAMA Dermatol 155 : 361-369, 2019.
PubMed
7) Bahrami A, Folpe AL : Adult-type fibrosarcoma : A reevaluation of 163 putative cases diagnosed at a single institution over a 48-year period. Am J Surg Pathol 34 : 1504-1513, 2010.
 
8) Setsu N, et al : Histological analysis suggests an invasion-independent metastatic mechanism in alveolar soft part sarcoma. Hum Pathol 45 : 137-142, 2014.
PubMed
9) Paoluzzi L, Maki RG : Diagnosis, Prognosis, and Treatment of Alveolar Soft-Part Sarcoma : A Review. JAMA Oncol 5 : 254-260, 2019.
PubMed
10) Vander Jagt TA, et al : Pseudoprogression of CNS metastatic disease of alveolar soft part sarcoma during anti-PDL1 treatment. Radiol Case Rep 13 : 882-885, 2018.
PubMed
11) Ogose A, et al ; Japanese Musculoskeletal Oncology Group : Alveolar soft part sarcoma in Japan : multi-institutional study of 57 patients from the Japanese Musculoskeletal Oncology Group. Oncology 65 : 7-13, 2003.
PubMed
12) Stacchiotti S, et al : Activity of sunitinib in extraskeletal myxoid chondrosarcoma. Eur J Cancer 50 : 1657-1664, 2014.
PubMed
13) Kemmerer EJ, et al : Benefit of Radiotherapy in Extraskeletal Myxoid Chondrosarcoma : A Propensity Score Weighted Population-based Analysis of the SEER Database. Am J Clin Oncol 41 : 674-680, 2018.
PubMed
14) Ogura K, et al : Extraskeletal myxoid chondrosarcoma : a review of 23 patients treated at a single referral center with long-term follow-up. Arch Orthop Trauma Surg 132 : 1379-1386, 2012.
 

書評

最近チェックした商品履歴

Loading...